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Abstract 
 
Neurosteroids are important endogenous modulators of the major inhibitory 
neurotransmitter receptor in the brain, the γ-amino-butyric acid type A (GABAA) 
receptor. They are involved in numerous physiological processes, and are linked to 
several central nervous system disorders, including depression and anxiety.  The 
neurosteroids allopregnanolone and allo-tetrahydro-deoxy-corticosterone (THDOC) 
have many effects in animal models (anxiolysis, analgesia, sedation, anticonvulsion, 
antidepressive), suggesting they could be useful therapeutic agents, for example in 
anxiety, stress and mood disorders. 
 
Neurosteroids potentiate GABA-activated currents by binding to a conserved site within 
α subunits. Potentiation can be eliminated by hydrophobic substitution of the α1Q241 
residue (or equivalent in other α isoforms). Previous studies suggest that α2 subunits 
are key components in neural circuits affecting anxiety and depression, and that 
neurosteroids are endogenous anxiolytics. It is therefore possible that this anxiolysis 
occurs via potentiation at α2 subunit-containing receptors. To examine this hypothesis, 
α2Q241M knock-in mice were generated, and used to define the roles of α2 subunits in 
mediating effects of endogenous and injected neurosteroids.  
 
Biochemical and imaging analyses indicated that relative expression levels and 
localization of GABAA receptor α1-α5 subunits were unaffected, suggesting the knock-
in had not caused any compensatory effects. Electrophysiological characterization of 
cells in hippocampal and nucleus accumbens brain slices revealed faster-decaying 
inhibitory synaptic transmission in α2Q241M mice. Furthermore, the response to applied 
THDOC was markedly reduced compared to wild-type cells. α2 subunits therefore 
formed a major component of synaptic GABAA receptors in these areas.  
 
The α2Q241M knock-ins showed greater anxiety levels in two classical rodent anxiety 
paradigms (light-dark box and elevated plus maze), consistent with endogenous 
neurosteroids mediating anxiolysis via α2-type GABAA receptors. In addition, the 
anxiolytic response to injected THDOC is impaired by the α2Q241M mutation, which 
would identify the α2 isoform as an appropriate target for generating receptor subtype-
selective neurosteroid therapeutics for anxiety disorders. 
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Chapter 1: Introduction 
 
Neurosteroid modulation of GABAergic neurotransmission in physiology 
and pathophysiology  
 
 
1.1. GABAA receptors 
 
Gamma-aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the 
mammalian central nervous system (CNS), playing a central role in regulating 
neuronal excitability. GABA fulfils this role by activating two classes of receptor: 
ionotropic type-A receptors (GABAA receptors) and metabotropic type-B 
(GABAB) receptors. The focus of this study is the GABAA receptor family, which 
encompasses Cl- and bicarbonate-permeable channels of the Cys-loop-
containing ligand-gated ion channel family (of which the nicotinic acetylcholine 
receptor is the founding member) (Barnard et al., 1998), now known as the 
pentameric ligand-gated ion channels (Miller & Smart, 2010; Corringer et al., 
2012). 
 
Excitatory and inhibitory neurotransmission are finely balanced processes, and 
any disruption of this balance can be detrimental to brain function. Improper 
GABAergic signalling is seen in neurodegenerative diseases such as 
Huntington’s, after ischemic episodes, and also in epilepsy, anxiety disorders, 
depression and schizophrenia (Fritschy & Brunig, 2003; Mohler, 2006b). It is 
therefore unsurprising that GABAA receptors represent a major pharmacological 
target for the treatment of these disorders. This thesis will focus on the roles of 
GABAA receptors in anxiety and depression, with particular attention paid to 
neurosteroids as players in the disease process, as well as assessing their 
potential as therapeutic agents for these disorders. 
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1.1.1. GABAA receptor composition and function 
 
The GABAA-receptor gene family encompasses several subunits, some of 
which are present in multiple isoforms (α1-6, β1-3, γ1-3, δ, ε, π and ρ1-3 
(Barnard et al., 1998; Korpi et al., 2002)), with further diversity imparted by 
alternative splicing (e.g. γ2 is expressed as short and long splice forms – γ2S 
and γ2L, respectively (Whiting et al., 1990; Kofuji et al., 1991; Glencorse et al., 
1992)). When studied in recombinant expression systems, functional receptors 
may assemble from a single subunit (e.g. β or ρ), or two subunits (e.g. α with β). 
However, the majority of native receptors in vivo are thought to be pentamers of 
2α, 2β and 1x subunit (Fig. 1.1), where x is typically a γ subunit in synaptic 
receptors, but could be δ in receptors outside the synapse (Brickley et al., 1999; 
Mody, 2001; Moss & Smart, 2001; Sieghart & Sperk, 2002; Mohler, 2006a). 
These rules are not strict, however, since typically synaptic subunits are found 
outside of synapses too (e.g. α1 and γ2 in electron micrographs of cerebellar 
granule cells (Nusser et al., 1998)), and αβ receptors (i.e. without γ or δ 
subunits) have been observed in hippocampal neurons (Mortensen & Smart, 
2006). The γ subunit in αβγ receptors may be replaced by ε or π, whilst θ 
subunits are thought to take the place of β subunits (Sieghart & Sperk, 2002). 
Expression of subunits ρ1-3 is mostly restricted to the retina, where they exist 
as homo- or hetero-oligomers with properties distinct from αβx assemblies, 
leading to their separate classification as GABAC receptors (Sieghart & Sperk, 
2002). 
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Figure 1.1 – GABAA receptor subunit assembly and modulator binding sites 
Each GABAA receptor subunit has the depicted topology (A) of a large extracellular 
amino-terminal (NH2) domain, four transmembrane helices (M1-4), and a short 
extracellular carboxy-terminus (COOH) (Korpi et al., 2002). The large intracellular loop 
between M3 and M4 helices is a key site for protein-protein interactions and 
phosphorylation, both of which are means for regulating receptor location and function 
(see main text). Subunits are thought to assemble as pentamers of stoichiometry 
2α:2β:1x subunits (Chang et al., 1996; Tretter et al., 1997; Farrar et al., 1999). The 
proposed arrangement of subunits is depicted as viewed from the extracellular surface 
(B) or in the plane of the membrane (C). The locations of binding sites for GABA, 
benzodiazepines (BDZ, note that this site depends on x being a γ subunit) and 
neurosteroid activation (Nster (a)) and neurosteroid potentiation (Nster (p)) are 
indicated (Korpi et al., 2002; Hosie et al., 2006; Hosie et al., 2009). 
 
Given the large number of subunit isoforms, there are theoretically many 
permutations of αβx assemblies. However, far fewer combinations are actually 
found in vivo, depending on which subunits are co-expressed within a neuron 
(McKernan & Whiting, 1996; Sieghart & Sperk, 2002; Mohler, 2006a). Distinct 
expression profiles are observed for each subunit across brain areas, which 
alter with development (Laurie et al., 1992a; Laurie et al., 1992b; Wisden et al., 
1992; Pirker et al., 2000). Furthermore, within a particular brain region and/or 
cell type, there can be cell-to-cell variations in receptor expression (e.g. using 
single-cell polymerase chain reaction (PCR) measurements of messenger 
ribonucleic acid (mRNA) levels, some cerebellar granule cells appear to 
express only α1, others only α6, and a third subset express both (Santi et al., 
1994)). The likely receptor subunit combinations formed in vivo have been 
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defined by examining protein co-distribution with immunostaining and mRNA 
co-distribution by in situ hybridisation (Somogyi et al., 1989; Fritschy et al., 
1992; Wisden & Seeburg, 1992), and co-immunoprecipitation of subunits from 
brain tissue (Benke et al., 1991; McKernan & Whiting, 1996). The two most 
abundant receptor combinations in rat brain are thought to be α1β2γ2 (40-60%) 
and α2β2/3γ2 (15-20%); other less common combinations include α3βnγ2 (10-
15%), α4βnγ2/α4βnδ (<5%), α5βnγ2 (<5%) and α6βnγ2/α6βnδ (<5%) 
(McKernan & Whiting, 1996; Sieghart & Sperk, 2002; Mohler, 2006a). It is also 
possible that the two copies of α or β subunits within a receptor can be different 
isoforms – e.g. α1α3β2/3γ2 receptors (Fritschy et al., 1992).  
 
The agonist-gated pore of GABAA receptors allows transmembrane passage of 
Cl- and HCO3
- ions; the direction of the ion flow is determined by their 
transmembrane electrochemical gradients, which can be developmentally 
regulated (switching from excitatory to inhibitory during brain development (Ben-
Ari, 2002)). Depending on their properties and subcellular location, GABAA 
receptors can carry two types of current: ‘phasic’ and ‘tonic’ (Mody, 2001; 
Semyanov et al., 2004; Farrant & Nusser, 2005). Phasic events, or inhibitory 
post synaptic currents (IPSCs), involve action-potential stimulated release of 
GABA at the synaptic cleft, which stimulates opening of synaptically-located 
GABAA receptors; events are short-lived, due to rapid GABA clearance from the 
cleft. In contrast, tonic currents result from more persistent activation of GABAA 
receptors, which are responding to the low ambient GABA levels outside the 
synapse (Mody, 2001; Semyanov et al., 2004; Farrant & Nusser, 2005). Both 
types of inhibition can be considered a means to counter excessive neuronal 
network excitation; phasic currents are also involved in generating rhythmic 
network activities, whilst tonic inhibition can modulate the input-output 
relationship for excitatory signalling onto a particular cell (Semyanov et al., 
2004; Farrant & Nusser, 2005). 
 
The source of ambient GABA responsible for tonic currents varies, but can 
involve spillover of synaptically released GABA, reverse transport at synapses 
and non-synaptic sources of GABA (including release from astrocytes) 
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(Richerson, 2004; Semyanov et al., 2004; Farrant & Nusser, 2005). The 
importance of vesicular release is supported by the reduction in extracellular 
GABA concentrations after blocking action potentials with tetrodotoxin (Bianchi 
et al., 2003; Xi et al., 2003) and also by the strong positive correlation between 
phasic and tonic current amplitudes recorded from brain slices under a range of 
conditions (Glykys & Mody, 2007). Nevertheless, the residual measures of 
extracellular GABA after tetrodotoxin treatment of the hippocampus (Bianchi et 
al., 2003) or nucleus accumbens (Xi et al., 2003) indicate that as much as 75% 
of extracellular GABA in these regions is of non-vesicular origin. 
 
In order to pass current during prolonged exposure to low ambient GABA 
concentrations, tonic-carrying receptors must have a higher GABA affinity and 
slower desensitisation kinetics than those involved in phasic currents (Farrant & 
Nusser, 2005). Approaches to determine the identity of tonic vs. phasic 
receptors include imaging (to demonstrate appropriate subcellular localisation), 
pharmacology (demonstrating current sensitivity to subunit-selective 
compounds) and subunit knock-outs (loss of current when subunit x is ablated). 
The results of these experiments are not always unequivocal, probably because 
the identity of receptors passing each type of current varies across cell types, 
and within a particular cell type according to the recording conditions employed. 
This is perhaps best illustrated by considering the reports for tonic currents in 
hippocampal pyramidal cells (PCs), particularly those in the cornu ammonis 1 
(CA1) region. Semyanov et al. (2003) found no detectable tonic current in PCs 
from guinea pig hippocampi at baseline, and required inhibition of GABA uptake 
to reveal a tonic current. In contrast, Prenosil et al. (2006) observe a clear tonic 
current in CA1 PCs without manipulating extracellular GABA levels. Where a 
tonic current has been detected in wild-type CA1 PCs, pharmacological profiling 
pointed to roles for α5, β2/3 and γ2, whilst suggesting no involvement of α4, α6, 
ε or δ subunits (Caraiscos et al., 2004). In addition, knock-out of α5 subunits 
diminished tonic current recorded from CA1 (Caraiscos et al., 2004). However, 
a role for α5 subunits is not universally supported: for example, Prenosil et al. 
(2006) find their tonic current to be insensitive to L655-708, an α5-selective 
benzodiazepine-site inverse agonist. A role for δ subunits in tonic currents 
seemed unlikely on the basis of several observations: δ subunit knock-out mice 
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(δ-/- mice) have undiminished tonic currents in hippocampal pyramidal cells in 
culture (Caraiscos et al., 2004) and brain slice tissue (Stell et al., 2003; Glykys 
et al., 2008), and the tonic current of wild-type cells is insensitive to the 
neurosteroid THDOC (allo-tetrahydro-deoxy-corticosterone) (Stell et al., 2003). 
However, they cannot rule out compensatory alterations in response to losing 
the δ subunit, nor does THDOC insensitivity necessarily imply a lack of δ 
subunit contribution. Indeed, a role for δ subunits has more recently been 
acknowledged, because the residual tonic current in CA1 PCs of α5-/- mice is 
lost in double knockout α5-/-δ-/- mice (Glykys et al., 2008). Interestingly, 
treatment of slices from δ-/- mice with L-655,708 does not abolish the tonic 
current (Glykys et al., 2008), suggesting yet more subunits could contribute to 
tonic currents in CA1 PCs. Indeed, there is evidence for a contribution of αnβn 
combinations to tonic currents of cultured hippocampal pyramidal cells 
(Mortensen & Smart, 2006). Data therefore predict a dominant role for α5β2/3γ2 
receptors in determining CA1 PC tonic current, but do not rule out contributions 
from other subunit combinations. On the basis of results from similar 
experimental approaches, cerebellar granule cell tonic current is believed to be 
mostly mediated by α6βnδ receptors (Brickley et al., 2001), and that in dentate 
gyrus granule cells (DG GC) by α4βnδ (Nusser & Mody, 2002; Stell et al., 
2003). 
 
Regardless of the identity of receptors passing GABAergic currents, it is 
appreciated that this neurotransmission is highly plastic, and is modulated by a 
number of physiological and pharmacological processes (Luscher & Keller, 
2004). Mechanisms exist to alter the density of receptors in a given membrane 
region, as well as the amount of current that flows through these receptors in 
response to GABA binding. Some of these mechanisms are described in the 
following sections (1.1.2 and 1.1.3). 
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1.1.2. GABAA receptor modulation: trafficking 
 
The regulation of synaptic GABAA receptor trafficking and the roles of its many 
receptor-associated partners in these processes has been extensively reviewed 
elsewhere (Kittler & Moss, 2001; Moss & Smart, 2001; Fritschy & Brunig, 2003; 
Kittler & Moss, 2003; Luscher & Keller, 2004; Arancibia-Carcamo & Kittler, 
2009; Luscher et al., 2011b). A full discussion of these mechanisms is beyond 
the scope of this thesis, but some of the key components (shown in Fig. 1.2) will 
be described below. The majority of the GABAA receptor binding partners 
associate with the intracellular domain between transmembrane helices M3 and 
M4, and so it is unlikely that all of these interactions will take place at once. 
Complexes are likely to be dynamic and transient in nature, allowing regulation 
of receptor actions at particular locations and under specific conditions. 
 
Gephyrin and γ2 subunits appear to be interdependent for synaptic clustering of 
GABAA receptors (Essrich et al., 1998; Fischer et al., 2000), although the 
interaction with gephyrin occurs via α subunits (Tretter et al., 2008; Tretter et al., 
2011). There are also gephyrin-independent means of receptor clustering, such 
as interactions with dystrophin (Knuesel et al., 1999). Gephyrin’s roles probably 
extend beyond synaptic anchoring of GABAA and glycine receptors, because it 
interacts with numerous binding partners that may regulate cytoskeleton 
dynamics, local protein translation and receptor trafficking (Fig. 1.2).  
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Figure 1.2 –GABAA receptor binding partners 
GABAA receptors are modulated by interactions with a host of other proteins, some of 
which are discussed in the main text. Receptor delivery to the cell surface involves 
trafficking proteins GABARAP (GABAA receptor associated protein), KIF5 (kinesin 
family motor protein 5) and PRIP (phospholipase-C related inactive protein), whilst 
endocytosis for recycling or degradation involves proteins AP2 (clathrin adaptor protein 
2) and PLIC1 (protein that links integrin-associated protein with the cytoskeleton-1). 
Synaptic clustering of receptors involves interaction with dystrophin or with gephyrin, 
which itself interacts with a number of proteins. Through these interactions, gephyrin 
may bind to and regulate the cytoskeleton, as well as modulate protein translation via 
Raft1 (rapamycin and FKB12 target protein). GABAA receptors can also bind proteins 
involved in modulating receptor phosphorylation state, such as RACK1 (receptor for 
activated C kinase1), PKCβII (protein kinase C, isoform βII) and PRIP. Phosphorylation 
serves to regulate GABAA receptor function and trafficking, and may do so by 
modulating receptor interactions with its binding partners (see main text). 
 
Receptor targeting mechanisms are more sophisticated than simply directing to 
a synaptic or extrasynaptic site: specific receptors can be localised at particular 
synapses within a neuron. For example, within hippocampal pyramidal cells, α1 
subunits are uniformly distributed, but α2 subunits are concentrated at synapses 
local to the axon initial segment (Nusser et al., 1996). Targeting may depend on 
signals from the presynaptic cell, because distinct interneurons synapse onto 
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these different regions of the principal cell: α1 subunits are at synapses with 
parvalbumin-positive basket cells, whilst α2 subunits are clustered at synapses 
from cholecystokinin-positive basket cells and parvalbumin-positive chandelier 
cells (Nyiri et al., 2001; Luscher & Keller, 2004; Mohler, 2006a)). Subcellular 
targeting has been probed using an artificial synapse model, which 
demonstrates that as-yet undefined determinants within α2 vs. α6 subunits 
direct them to the appropriate location (Wu et al., 2012). Indeed, ectopically-
over-expressed α6 subunits can direct receptors to extrasynaptic sites within 
neurons, and ‘dominates’ over γ2 subunits within the same receptor in this 
targeting (Wisden et al., 2002). 
 
Although anchored by gephyrin and/or dystrophin, synaptic GABAA receptors 
are by no means static entities. Receptors are constantly trafficking into and out 
of the synaptic zone by membraneous transport (exo- and endocytosis), as well 
as by lateral mobility within the membrane. Receptor internalisation involves 
interaction of β and/or γ subunits with the clathrin adaptor protein, AP2, 
depending on their phosphorylation state (Kittler et al., 2000; Kittler et al., 2005; 
Luscher et al., 2011a). After internalisation, receptors may either recycle back to 
the cell surface, or are targeted to the lysosome for degradation. The latter 
route is favoured by lysine ubiquitination of the γ subunit (Arancibia-Carcamo et 
al., 2009), whilst cell surface re-delivery is favoured by interaction of PLIC1 with 
α and β subunits (Bedford et al., 2001). Cell surface delivery of GABAA 
receptors is also facilitated by interaction of β subunits with PRIP (Kanematsu et 
al., 2006; Mizokami et al., 2007) and the kinesin family motor protein, KIF5 (via 
adaptor protein Huntingtin-associated protein 1, HAP1 (Twelvetrees et al., 
2010)). Trafficking from the Golgi apparatus to the cell surface also involves 
interaction of γ subunits with GABARAP and with tubulin (the latter interaction 
may occur via GABARAP and/or through HAP1-KIF5 complexes) (Item & 
Sieghart, 1994; Wang et al., 1999; Kneussel et al., 2000; Kittler et al., 2001). 
The cycling of GABAA receptors into and out of the cell surface membrane 
appears to be occurring constitutively, because disruption of either process can 
influence both the cell surface expression of γ-subunit containing GABAA 
receptors, and synaptic GABAergic currents. For example, over a short 
timescale (minutes) disruption of clathrin-mediated endocytosis increases 
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synaptic current amplitudes (Kittler et al., 2000); conversely, impairing cell 
surface delivery by disrupting the KIF5-HAP1 interaction reduces current 
amplitudes (Twelvetrees et al., 2010). Furthermore, despite their interaction with 
anchoring proteins, synaptic GABAA receptors also show lateral mobility within 
the membrane (Thomas et al., 2005). Movement of receptors into and out of 
synaptic sites by this mechanism may represent the major means of altering 
synaptic strength, and may occur over faster timescales than vesicular transport 
mechanisms (Thomas et al., 2005). 
 
 
1.1.3. GABAA receptor modulation: ligands and post-translational modification 
 
A number of endogenous and exogenous ligands are allosteric modulators or 
direct agonists of GABAA receptors including barbiturates, benzodiazepines, 
neurosteroids and Zn2+ (details below). GABAA receptor activity can also be 
modulated by direct modifications of the channel, including phosphorylation 
(details below), protonation (Huang & Dillon, 1999; Wilkins et al., 2002, 2005) 
and redox modifications of cysteine residues (Amato et al., 1999; Pan et al., 
2000).  
 
Pharmacological modulation by barbiturates and benzodiazepines 
The effects of barbiturates on GABAA receptor currents depends on their 
concentration: potentiation, direct activation and inhibition occur with increasing 
concentration (e.g. pentobarbitone shows all three responses, with efficacies 
dependent on receptor subunit composition (Thompson et al., 1996)). By 
increasing GABAA receptor currents, these compounds are effective as 
anxiolytics and hypnotics. However, clinical barbiturate use has now been 
superseded by that of benzodiazepines, which are also allosteric potentiators of 
GABAA receptors, but are safer in overdose (Smith & Rudolph, 2012). 
 
Responses to classical benzodiazepines (e.g. diazepam) require the presence 
of a γ subunit and absence of the benzodiazepine-insensitive α4 or α6 isoforms 
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(Pritchett et al., 1989; Wieland et al., 1992). Their numerous behavioural effects 
have been linked to their action at distinct GABAA receptor α subunit isoforms 
(Table 1.1). Targeting benzodiazepines to specific α subunits may therefore 
produce specific behavioural effects. Particular efforts have focussed on 
generating α2-targeting benzodiazepines as non-sedating anxiolytics (see 
Section 1.3.2).  
 
Isoform Benzodiazepine effect References 
α1 sedation, amnesia, anticonvulsion 
(Rudolph et al., 1999; McKernan et 
al., 2000) 
α2 anxiolysis and myorelaxation 
(Low et al., 2000; Crestani et al., 
2001) 
α3 anxiolysis
1
 and myorelaxation 
(Crestani et al., 2001; Dias et al., 
2005) 
α5 sedative tolerance (van Rijnsoever et al., 2004) 
Table 1.1 – Subunit-specific actions of benzodiazepines 
There are six α subunit isoforms, and whilst all are neurosteroid sensitive (Hosie et al., 
2009), α4 and α6 subunits preclude benzodiazepine response due to a single amino 
acid substitution (H to R) in the otherwise conserved binding site (Wieland et al., 1992). 
Introducing this substitution into the benzodiazepine-responsive subunits (i.e. α1H101R, 
α2H101R, α3H126R or α5H105R) abolishes their response to benzodiazepines in recombinant 
systems, but leaves other properties of the channel unaffected (Wieland et al., 1992; 
Benson et al., 1998). This table summarises the results of characterising knock-in mice 
with each of these point mutations, which allowed dissection of the isoforms 
responsible for the various behavioural effects of benzodiazepines. 
1Note that α3H126R mice did not lack anxiolytic response to diazepam (Low et al., 2000), 
but a role for this subunit was supported by observations of anxiolysis with an α3-
selective benzodiazepine (Dias et al., 2005) 
 
Endogenous modulation by Zn2+ 
Experimentally, transmission through GABAA receptors can be modulated by 
Zn2+ ions either directly (inhibitory effects on subunit combinations lacking γ2 
subunits) or indirectly (by enhancing synaptic release of GABA in the 
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hippocampus) (Hosie et al., 2003; Smart et al., 2004). Histological stains for 
Zn2+ demonstrate a strong presence in the telencephalon, hippocampus, 
cerebral cortex and amygdala, suggesting that Zn2+ modulation occurs 
endogenously (Smart et al., 2004). Chelation of Zn2+ ions increased the 
amplitude of CA3 pyramidal cell IPSCs evoked by stimulation of mossy fiber 
inputs, confirming a role for baseline endogenous Zn2+ in modulating 
GABAergic transmission (Ruiz et al., 2004). 
 
Endogenous modulation by kinases/phosphatases 
The intracellular loops of β and γ subunits are phosphorylated at a number of 
residues (Table 1.2) found within consensus sequences for a number of protein 
kinases. Phosphorylation at these sites may increase or decrease GABAergic 
currents by modulating receptor gating properties and/or trafficking processes 
that determine the number of receptors at the cell surface (see reviews: Smart, 
1997; Brandon et al., 2002; Kittler & Moss, 2003; Song & Messing, 2005; 
Arancibia-Carcamo & Kittler, 2009; Houston et al., 2009b). The precise effects 
on GABAergic currents depend not only on the kinase and subunit isoforms in 
question, but also seem to vary with the preparation being studied. For 
example, Ca2+/calmodulin-dependent kinase II (CaMKII) failed to modulate 
receptors expressed in human embryonic kidney 293 (HEK293) cells, but did so 
if receptors were expressed in a neuroblastoma cell line (Houston et al., 2009b). 
 
Protein kinase C (PKC)-dependent phosphorylation can increase cell surface 
expression of receptors by disrupting the interaction between β/γ subunits and 
AP2 (Kittler et al., 2000; Kittler et al., 2005; Luscher et al., 2011a). Interestingly, 
protein kinase B (PKB/Akt)-dependent phosphorylation of the same residues as 
PKC, rather than influencing receptor internalisation, increases cell surface 
delivery of newly-synthesised receptors – i.e. phosphorylation effects depend 
not only on the residues acted upon, but also where in the cell it takes place 
(Luscher et al., 2011a). It must not be forgotten that GABAA receptors are not 
the only target of these enzymes: Connolly et al. (1999) found that stimulating 
PKC in HEK293 cells decreased cell surface expression of α1β2γ2 receptors, 
but that the effect does not require phosphorylation at β2S410, γ2S327 or γ2S343. 
Chapter 1: Introduction  24 
 
 
GABAA receptor subunit Residues Kinases 
β1 
S409 PKA
1
, PKB
5
, PKC
1,3
, PKG
1
 
S384, S409 CaMKII
4
 
β2 S410 PKA
1
, PKB
2,5
, PKC
1,3
, PKG
1
,
 
CaMKII
1,4
 
β3 
S408, S409 PKA
1
, PKB
5
, PKC
1,3
, PKG
1
 
S383, S409 CaMKII
4
 
γ2 
S327, S343 PKC
1,3
, CaMKII
1,4
 
S348, T350 CaMKII
4
 
Y365, Y367 Tyrosine kinases
1,2
 
Table 1.2 – Phosphorylation sites on GABAA receptors 
GABAA receptor β and γ subunit phosphorylation sites are listed alongside the kinases 
that are able to phosphorylate them. Underlined residues are unique to the γ2L isoform 
(i.e. absent from the γ2S isoform). Table compiled using reviews by 1Brandon et al. 
(2002), 2Luscher and Keller (2004), 3Song and Messing (2005), 4Houston et al. (2009b), 
5Luscher et al. (2011a). 
 
Phosphorylation is a readily-reversible post-translational modification, and so 
receptor phosphorylation state is likely to be dynamically regulated in vivo. 
Indeed, brain-derived neurotrophic factor (BDNF) stimulation of cultured 
hippocampal and cortical neurons induces a transient rise and fall in β3 subunit 
phosphorylation (Jovanovic et al., 2004; Kanematsu et al., 2006). Synaptic 
current amplitudes increase in parallel with the PKC-mediated β3 
phosphorylation, which is temporally associated with increased cell surface 
expression of receptors (Jovanovic et al., 2004). The latter stages of the BDNF 
response, where synaptic current amplitudes diminish and β3 subunits are 
dephosphorylated, involve the recruitment of protein phosphatases 1 and 2A 
(PP1/PP2A) by PRIP (Kanematsu et al., 2006). It is not clear whether this latter 
stage involves reduced cell surface expression (Kanematsu et al., 2006), or 
reduced currents without an altered surface expression (Jovanovic et al., 2004). 
Nevertheless, these investigations concur that β3 phosphorylation is only 
transient in nature after BDNF treatment.  
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Neurosteroids as endogenous modulators 
Steroid compounds not only modulate gene expression by binding to 
transcription factors of the nuclear receptor family, but they also have non-
genomic actions within the CNS (Paul & Purdy, 1992; Rupprecht & Holsboer, 
1999; Belelli et al., 2006). These “neuroactive steroids”, or “neurosteroids”, are 
compounds that are produced endogenously and can affect the function of 
several neuronal receptors, including NMDA (N-Methyl-D-aspartate), AMPA (2-
amino-3-(3-hydroxy-5-methyl-isoxazol-4-yl)propanoic acid), kainate, glycine, 
serotonin, nicotinic acetylcholine, oxytocin, sigma-type-1 and GABAA receptors 
(Rupprecht & Holsboer, 1999; Mellon & Griffin, 2002; Strous et al., 2006). The 
two major neurosteroids in vivo, allopregnanolone and allo-tetrahydro-deoxy-
corticosterone (THDOC), are among the most potent known endogenous 
modulators of GABAA receptors (Paul & Purdy, 1992). Immunohistochemical 
analysis demonstrates that these two neurosteroids are mostly concentrated in 
cell bodies and dendrites of excitatory neurons, with little or no labelling of 
gliaform cells or inhibitory interneurons, suggesting that they act in a paracrine 
or autocrine manner to modulate principal cell firing (Saalmann et al., 2007). 
 
That GABAA receptors are a major molecular target for neurosteroids was made 
apparent by a combination of radioisotope (measuring 36Cl- flux into 
synaptosomes) and electrophysiological studies. These studies demonstrated 
that the action of neurosteroids and their analogues is biphasic: low (nM) 
concentrations augment GABA-induced Cl- conductance, whereas higher (µM) 
concentrations directly stimulate GABAA receptor activation – producing slow 
inward currents that resemble the direct responses to pentobarbital (Harrison & 
Simmonds, 1984; Harrison et al., 1987; Puia et al., 1990; Paul & Purdy, 1992). 
The majority of estimates for in vivo neurosteroid concentrations support a role 
for potentiation at GABAA receptors, but sufficient levels to directly activate 
these receptors may be achieved under specific circumstances, such as in 
mother and foetus during late pregnancy (Ichikawa et al., 1974; Paul & Purdy, 
1992; Biedermann & Schoch, 1995; Luisi et al., 2000; Nguyen et al., 2003). 
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At the molecular level, neurosteroids are thought to act by altering the kinetics 
of receptor entry into and exit from desensitised states (Zhu & Vicini, 1997) and 
may increase the efficacy of ion channel gating (Bianchi & Macdonald, 2003). At 
the cellular level, neurosteroid-mediated potentiation at GABAA receptors 
enhances synaptic (Belelli & Herd, 2003; Harney et al., 2003) and tonic currents 
(Stell et al., 2003). Both responses are expected to hyperpolarize the cell 
membrane and/or shunt excitatory inputs, and thus reduce the neuron’s 
probability of firing. There is also a class of neurosteroids that antagonize 
GABAA function: the so-called “excitatory steroids” – mostly sulphated forms of 
the classical neurosteroids, such as pregnenolone sulphate, or 3β-hydroxy-
steroids (Akk et al., 2001; Wang et al., 2002). They are pro-convulsant in 
animals, act as non-competitive antagonists at the GABAA receptor, and 
probably bind to a site distinct from potentiating neurosteroids; their effects in 
animals may also be due to an enhancement of excitatory glutamatergic 
transmission (Paul & Purdy, 1992; Akk et al., 2001; Wang et al., 2002; Hosie et 
al., 2007). 
 
In our study, we hope to increase understanding of the roles played by 
endogenous neurosteroids, specifically via positive allosteric modulation at α2-
type GABAA receptors. We have particularly focused on their roles in the aetio-
pathology of anxiety and depression. Furthermore, we have explored 
therapeutic potential for α2-subunit-targeting neurosteroids in these disorders. 
The following sections therefore provide details regarding current knowledge of 
neurosteroid physiology (Section 1.2) and its links to anxiety (Section 1.3) and 
depression (Section 1.4). 
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1.2. Neurosteroid physiology and pharmacology 
 
1.2.1. Endogenous neurosteroids: synthesis and roles 
 
Neurosteroids are synthesized in vivo from a cholesterol precursor, via a range 
of enzymatic conversions (see Fig. 1.3). Neurosteroid distribution within the 
brain is not uniform, with the highest levels generally in the olfactory bulb, 
striatum and cortex, and lower levels in brainstem, suggesting there will be a 
regional variation in neurosteroidogenesis and neurosteroid-mediated 
modulation of GABAergic transmission (Uzunov et al., 1996; Bixo et al., 1997; 
Bernardi et al., 1998; Saalmann et al., 2007). Neurosteroids and their 
precursors can also be produced in peripheral steroidogenic tissues such as the 
adrenal cortex and gonads. For example, menstrual-cycle-related changes in 
circulating progesterone can influence brain allopregnanolone levels, with key 
consequences for sufferers of catamenial epilepsy (see Section 1.2.4). 
Furthermore, stress-induced rises in brain neurosteroid levels are thought to 
involve production of these compounds in the adrenal glands (Purdy et al., 
1991; Barbaccia et al., 1998). However, a change in peripheral levels cannot 
necessarily be projected to cause changes in CNS levels of a given 
neurosteroid. Indeed, the rises in serum and brain allopregnanolone and 
THDOC levels during pregnancy do not directly correlate with the rise in serum 
progesterone (in rats (Concas et al., 1998) or humans (Luisi et al., 2000)) – i.e. 
peripheral progesterone is not the only source for brain allopregnanolone. 
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Figure 1.3 – Neurosteroid synthesis pathways 
The steps involved in converting cholesterol into GABAA receptor modulating 
neurosteroids are shown. A number of additional neuroactive compounds can also be 
produced by modifications of the various intermediates (black) (for details, see Mellon 
& Griffin, 2002; Stoffel-Wagner, 2003), but this figure focuses on the major positive 
(green) and negative (red) allosteric modulators of GABAA receptors. The neurosteroid 
profile of a particular brain region will depend on the enzymes present locally; in 
humans, hippocampal and temporal lobe expression and/or enzymatic activity has 
been demonstrated for P450scc, 21β-hydroxylase, 5α-reductase and 3α-HSD (Stoffel-
Wagner, 2003). The initial conversion of cholesterol to pregnenolone occurs within 
mitochondria, requiring the activity of two transporters: StAR (steroidogenic acute 
regulatory protein (Stocco & Clark, 1996)) and TSPO (the 18 kDa translocator protein), 
the latter of which is sensitive to stimulation by benzodiazepines (Papadopoulos & 
Lecanu, 2009). Abbreviations: 3β-HSD, 3β-hydroxy-steroid dehydrogenase; 3α-HSD, 
3α-hydroxy-steroid dehydrogenase; P450scc, cytochrome P450 cholesterol side-chain 
cleavage; P450c17, 17α hydroxylase, c17,20 lyase. Note that the HSD enzymes are 
also referred to as hydroxy-steroid oxido-reductase (HSOR) enzymes. 
 
The levels of neurosteroids have been measured most commonly by radio-
immunoassay (Purdy et al., 1990a) or by mass fragmentography (MF) (Uzunov 
et al., 1996). The former method is limited by the antibody specificity, but pre-
separation of the various steroids extracted from the sample by high-
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performance liquid chromatography (HPLC) can eliminate the problem of cross-
reactivity with other neurosteroid metabolites (Purdy et al., 1990a). The MF 
approach is more technically demanding, but has been proposed to be a more 
sensitive approach, capable of accurately measuring picomolar levels of steroid 
(Uzunov et al., 1996). The estimates of baseline rodent brain neurosteroid 
levels vary, with reports for allopregnanolone ranging from very low (<3 nM 
(Purdy et al., 1991; Vallee et al., 2000)), to levels sufficient to potentiate GABAA 
receptors (3-10 nM (Uzunov et al., 1996); 2-20 nM (Bernardi et al., 1998)). 
Baseline allopregnanolone levels in human brains may be higher (e.g. in 
women, may range from 30-70 nM, depending on serum progesterone levels 
(Bixo et al., 1997)), but human brain samples are less readily available, and 
obtained post-mortem. 
 
Allopregnanolone and THDOC levels increase during pregnancy (Concas et al., 
1998; Luisi et al., 2000) and in response to stressors (Purdy et al., 1991; Paul & 
Purdy, 1992) or drugs – including nicotine (Porcu et al., 2003), gamma-hydroxy 
butyrate (Barbaccia et al., 2002) and some antidepressants (Uzunov et al., 
1996). Increased production of endogenous neurosteroids is also believed to 
mediate some of the behavioural responses to ethanol, including its 
antidepressant and anticonvulsant effects (VanDoren et al., 2000; Hirani et al., 
2002; Khisti et al., 2002; Helms et al., 2012).  
 
Dysregulation of neurosteroids is associated with a range of diseases, including 
premenstrual dysphoric disorder, panic disorder, anxiety and stress, 
depression, schizophrenia and bipolar disorder, eating disorders, and dementia 
(Mellon & Griffin, 2002; Strous et al., 2006). It is often difficult to determine 
whether the altered neurosteroid levels seen in some of these diseases is a 
consequence or cause of the condition, especially because some steroids have 
biphasic effects (e.g. pregnenolone sulphate is anxiolytic at low doses, but 
anxiogenic at higher doses (Strous et al., 2006)). The roles for neurosteroids in 
anxiety and depression will be discussed in more detail below (Sections 1.3 and 
1.4).  
 
Chapter 1: Introduction  30 
 
 
1.2.2. Neurosteroid binding to GABAA receptors 
 
The effects of a range of neurosteroids and their analogues on GABAA receptor 
activity demonstrated stereospecificity and a biphasic action (potentiation at low 
concentration, activation at high concentration (Purdy et al., 1990b; Paul & 
Purdy, 1992)). It was therefore proposed that there would be two specific 
neurosteroid binding sites on the GABAA receptor: an “activation site” and a 
“potentiation site”. Identification of these sites was not a trivial task (see review 
by Hosie et al., 2007), but was eventually achieved by electrophysiological 
characterisation of site-directed mutants expressed in HEK293 cells (Hosie et 
al., 2006); the key residues for neurosteroid function are highlighted on Fig. 1.4. 
Note that with this updated GABAA receptor model, the activation site residues 
identified by Hosie et al. (2006), now point away from the interface between α 
and β subunits, where neurosteroid was proposed to bind. Indeed, more recent 
etomidate photolabelling suggests a model of the transmembrane domain (Li et 
al., 2009; Olsen & Li, 2011) that is incompatible with that of Hosie et al. (2006). 
Residues βY284 and αT236 are therefore more likely to be involved in a 
transduction mechanism, rather than direct binding of neurosteroid. The 
orientations of residues in the potentiation site, on the other hand, are still 
compatible with the model of Hosie et al. (2006). 
 
When heterologously-expressed receptors are studied, there are small isoform-
dependent differences in responses that may be of relevance when considering 
the low nM concentrations of neurosteroids found in vivo: minimal potentiating 
doses for allopregnanolone were 3 nM at α1β1γ2 and α3β1γ2, 10 nM at 
α6β1γ2, and 30 nM at α2/4/5β1γ2 subunit combinations (Belelli et al., 2002). 
Interestingly, receptors incorporating a δ subunit show increased efficacy 
relative to equivalent γ-containing combinations (Belelli et al., 2002; Bianchi & 
Macdonald, 2003; Lambert et al., 2003; Hosie et al., 2009). However, this effect 
is probably not due to an interaction of neurosteroid with the δ subunit, because 
the potentiation site is entirely confined within the α subunit (Hosie et al., 2009). 
Furthermore, a single point mutation of the conserved potentiation-site 
glutamine in the α4 subunit to leucine (α4Q246L) ablates neurosteroid potentiation 
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of α4β3δ receptors (Hosie et al., 2009). The increased sensitivity of αβδ 
combinations is probably a reflection of the partial agonist nature of GABA at 
these receptors (c.f. αβγ receptors, where GABA is a full agonist) (Bianchi & 
Macdonald, 2003). 
 
 
Figure 1.4 – GABAA receptor subunit assembly and neurosteroid binding sites 
Ribbon diagrams depict the secondary structure of the transmembrane regions of α 
(green) and β (red) subunits, viewed in the plane of the membrane, and detail the 
proposed neurosteroid potentiation (A) and direct activation (B) sites. Structures are a 
3D homology model of an α1β2γ2 GABAA receptor, based on the crystal structure of 
the Caenorhabditis elegans glutamate-gated chloride channel, GluCl (Hibbs & Gouaux, 
2011), courtesy of Dr. Marc Gielen. Residues important for neurosteroid binding are 
highlighted as solid spheres, whilst the proposed neurosteroid binding pockets (Hosie 
et al., 2006) are indicated by grey ovals. The potentiation site is contained within the α 
subunit, involving transmembrane helices M1 and M4 (key residues in α1 are Q241, 
N407 and Y410, which are conserved across all α subunit isoforms). Within this model, 
the position of key conserved residues in the direct activation site – α1 T236 and β2 
Y284 – appear inconsistent with the proposed neurosteroid binding roles for these 
residues.  
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1.2.3. Physiological modulation of GABAA receptors by neurosteroids  
 
The neurosteroids allopregnanolone and THDOC enhance GABAergic 
transmission by slowing the decay of IPSCs (Belelli & Herd, 2003; Harney et al., 
2003) and/or increasing the magnitude of tonic currents (Stell et al., 2003). 
Some investigators have proposed that physiological (low nM) levels of 
neurosteroid will be ineffective at synaptic GABAA receptors – for example, Stell 
et al. (2003) found that DG GC tonic currents were sensitive to 10 nM THDOC, 
but phasic events only to 100 nM of this neurosteroid. Because tonic currents 
are often carried by αnβnδ combinations (e.g. in DG GCs (Nusser & Mody, 
2002; Stell et al., 2003) and cerebellar GCs (Brickley et al., 2001)), they might 
be better poised to respond to endogenous steroids than synaptic αnβnγ 
combinations (Bianchi & Macdonald, 2003). However, there is some evidence 
for modulation of phasic events by physiological neurosteroid levels. Firstly, 
Puia et al. (2003) showed that decreasing endogenous allopregnanolone levels 
in neocortical brain slice tissue (using SKF-10511, an inhibitor of 5α-reductase 
type I and II) speeds the IPSC decay times recorded from pyramidal neurons. 
Furthermore, CA1 PC miniature IPSCs (mIPSCs) respond to 10 nM 
allopregnanolone (Harney et al., 2003), whilst tonic currents in these cells 
appear neurosteroid-insensitive (Stell et al., 2003). It therefore seems likely that, 
in vivo, endogenous neurosteroids will modulate both phasic and tonic currents, 
with the extent of modulation of each current depending on the neurosteroid-
sensitivity of the underlying GABAA receptor composition. 
 
Interestingly, the sensitivities of various neurons to neurosteroids do not always 
correlate with the relative sensitivities of the major GABAA receptor isoforms 
expressed in these cells (Belelli et al., 2006). By a comparison of responses 
across the literature, it would seem that IPSC sensitivity to neurosteroid can 
vary with cell type (Harney et al., 2003) and age of animal (Cooper et al., 1999; 
Mtchedlishvili et al., 2003), and may depend on differences in local neurosteroid 
metabolism (Belelli & Herd, 2003), receptor subunit composition (Brussaard et 
al., 1997; Cooper et al., 1999; Mtchedlishvili et al., 2003) and relative kinase 
and phosphatase activities (Brussaard et al., 2000; Fancsik et al., 2000; Harney 
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et al., 2003; Koksma et al., 2003). It is possible that some cells would respond 
to the basal in vivo levels of neurosteroids, whilst others will only be  modulated 
by neurosteroids when concentrations are increased – by stress or pregnancy, 
for example (e.g. Harney et al. (2003) show that synaptic events in CA1 PCs 
respond to basal allopregnanolone levels (10 nM), whilst DG GCs will only 
respond to heightened levels (300 nM)). 
 
As was discussed in Section 1.1.3, the effects of phosphorylation on GABAA 
receptor function appear to depend on the receptor subunit composition, the 
kinase, and the cell-type studied. These observations can be extended to 
kinase/phosphatase modulation of neurosteroid sensitivity. For example, 
Harney et al. (2003) attribute the differential allopregnanolone sensitivity 
(measured by IPSC decay prolongation) of hippocampal PCs and DG GCs to 
distinct activities of PKC and PKA within these cells. Constitutive activity of PKC 
and G protein appears to be required for allopregnanolone sensitivity in 
magnocellar neurons of the supraoptic nucleus (SON) of rats: IPSC decay 
prolongation by 1 µM of this neurosteroid is prevented by inhibitors of these 
proteins, whilst activators of these proteins do not further enhance the response 
(Fancsik et al., 2000). Interestingly, the latter cell type is unaffected by inhibition 
of PKA, further supporting the notion that there is a cell-type variation in the 
kinases that affect neurosteroid modulation (i.e. PKA activity is more important 
in CA1 PCs (Harney et al., 2003) than SON magnocellar neurons (Fancsik et 
al., 2000)). Even within the same cell type, however, there is conflicting 
evidence for the effects of phosphorylation: unlike the work by Fancsik et al. 
(2000), others find that inhibition of PKC is required for neurosteroid sensitivity 
of SON magnocellar neurons and that constitutive activity of phosphatases 
PP1/PP2A determine allopregnanolone sensitivity of these cells during 
pregnancy (Brussaard et al., 2000; Koksma et al., 2003). Some of the 
discrepancies in the literature may relate to the use of broad-range kinase 
modulators (e.g. phorbol esters stimulate a range of PKC isoforms, which may 
have opposing effects on receptor function (Song & Messing, 2005)). 
GABAergic currents in vivo are probably modulated in concert by 
kinases/phosphatases and neurosteroids. For example, a combination of falling 
neurosteroid levels, and reduced neurosteroid sensitivity (by GABAA receptor 
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phosphorylation), are thought to contribute to the increased neuronal firing 
required for timed release of oxytocin at parturition (Brussaard et al., 2000; 
Koksma et al., 2003).  
 
 
1.2.4. Neurosteroids: therapeutic potential 
 
Historically, synthetic neurosteroid analogues were used for general 
anaesthesia during surgery (Prys-Roberts & Sear, 1980). Although the first 
evidence of anaesthetic action for neurosteroids came in the 1940s for 
progesterone (Paul & Purdy, 1992; Belelli et al., 2006), it was not until the 
1980s that this response was shown to involve an enhancement of GABAA 
receptor function (Harrison & Simmonds, 1984; Harrison et al., 1987; Paul & 
Purdy, 1992). Despite their favourable potencies and safety profiles, these 
drugs are no longer used in humans due to the frequency of anaphylactic 
reactions, although these may be due to the Cremphor EL vehicle used (Prys-
Roberts & Sear, 1980). There is resurging interest in translating neurosteroid-
based therapies to the clinic because of their potency and array of favourable 
effects when studied in animal models: neurosteroids can be anxiolytic, 
antidepressant, analgesic, sedative, anticonvulsant, anaesthetic, and can 
suppress the action of the stress-responsive hypothalamic-pituitary-adrenal 
(HPA) axis (Carter et al., 1997; Barbaccia et al., 1998; Rodgers & Johnson, 
1998; Khisti et al., 2000; Winter et al., 2003; Belelli et al., 2006).  
 
The clinical potential for neurosteroids has been well supported for treatment of 
Niemann Pick type C disease and epilepsy. The former is an inherited 
lysosomal storage disorder where patients suffer rapid neurodegeneration, 
which is ultimately fatal. Mouse models of Niemann Pick disease have very low 
allopregnanolone levels, and the administration of allopregnanolone delays the 
onset of motor dysfunction and extends survival (i.e. modulation of GABAA 
receptors by this neurosteroid is crucial for proper brain development and 
survival (Griffin et al., 2004; Mellon et al., 2008)). The anti-seizure activity of the 
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neurosteroid analogue, ganaxolone, has been extensively verified in animal 
models of epilepsy (Carter et al., 1997; Reddy & Rogawski, 2009, 2010) and it 
has had some success in human clinical trials (Nohria & Giller, 2007). There is 
also anecdotal evidence favouring the use of ganaxolone in catamenial epilepsy 
(Reddy & Rogawski, 2009). In this subtype of epilepsy, sufferers experience an 
increase in seizure frequency and severity in response to an ovarian-cycle-
linked fall in allopregnanolone levels, and an associated increase in expression 
of α4-type GABAA receptor subunits (Smith et al., 1998; Reddy & Rogawski, 
2009).  
 
To establish and appreciate the full therapeutic potential of neurosteroids and 
their analogues, it is also important to fully define their normal physiological 
actions at molecular, cellular and systems levels. We predict that neurosteroid 
functions will be separable according to α subunit isoform (as was determined 
for benzodiazepines: see Table 1.1). Our intention was therefore to explore the 
physiological functions and therapeutic potential of neurosteroids in anxiety and 
depression. The following sections will outline the current understanding in 
these fields. 
 
 
 
1.3. Neurosteroids and GABAA receptors in anxiety 
 
1.3.1. The HPA axis and neurosteroids as endogenous anxiolytics 
 
The HPA axis comprises a set of interactions between the hypothalamus, 
pituitary gland and adrenal cortex, and is activated by stress (Mody & Maguire, 
2011). Activation of the axis stimulates production of a series of steroid 
hormones in the adrenal cortex, including allopregnanolone and THDOC. 
Activation of the rat HPA axis by exposure to stress, such as foot-shock or 
forced swim, or by inhibiting GABA synthesis or negatively modulating GABAA 
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receptors, therefore induces an increase in brain and plasma neurosteroid 
levels (Purdy et al., 1991; Barbaccia et al., 1996; Barbaccia et al., 1998; Vallee 
et al., 2000). These rises in neurosteroid are disrupted by adrenalectomy and 
castration, indicating that increased production of these compounds occurs 
mostly in the periphery, rather than in the CNS (Purdy et al., 1991; Barbaccia et 
al., 1998). Indeed, after this surgery, basal and stress-associated levels of 
THDOC are undetectable (Purdy et al., 1991). Basal allopregnanolone levels 
are also greatly lowered after adrenalectomy, but this steroid is still detectable 
in the cerebral cortex after such treatment, indicating another source for its 
production (probably the CNS) (Purdy et al., 1991). By examining the time-
courses of behavioural and neurochemical responses to acute stress (Purdy et 
al., 1991; Barbaccia et al., 1998), this HPA-induced rise in neurosteroids had 
been proposed to represent a feed-back mechanism to recover normal 
GABAergic tone and HPA function after acute stress. Given that injected 
neurosteroids reduce anxiety (Crawley et al., 1986; Wieland et al., 1991), the 
stress-induced production of neurosteroids is thought not only to limit the 
neurochemical response to stress, but also the behavioural response – i.e. 
neurosteroids probably function as endogenous anxiolytics (Barbaccia et al., 
1998). 
 
The hippocampus is one of the main inputs to the hypothalamus that triggers 
HPA axis activation in stress, and is probably a key site for this neurosteroid-
mediated feedback (by enhancing inhibitory neurotransmission in the 
hippocampus). Excessive activation of the HPA axis by chronic stress can be 
particularly damaging to the hippocampus, and reduces the number of 
parvalbumin-positive interneurons (Hu et al., 2010). Diminished inhibitory 
neurotransmission within the hippocampus could therefore trigger pathological 
positive feedback – further activating the HPA axis (with glucocorticoids further 
damaging the hippocampus (Brown et al., 1999; Hu et al., 2010)). Such HPA 
axis dysregulation may account for the hippocampal atrophy observed in 
patients suffering from post-traumatic stress disorder and depression (Brown et 
al., 1999; Sheline, 2003). Furthermore, the consequent impairment of regulation 
of network oscillations may underlie the cognitive defects in stress-related 
disorders (Hu et al., 2010). We have therefore focussed part of our investigation 
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on inhibitory neurotransmission in the hippocampus, probing whether 
neurosteroid modulation of this transmission involves the α2-type GABAA 
receptor. 
 
 
1.3.2. Defining the GABAA receptor α subunits that are important in anxiety and 
anxiolysis 
 
An assortment of evidence is available to support a role for α2-type GABAA 
receptors in anxiety and anxiolysis. Firstly, this subunit is enriched in brain 
regions linked to emotion and anxiety, including the hippocampus and 
amygdala (Sperk et al., 1997; Pirker et al., 2000; Sieghart & Sperk, 2002; 
Mohler, 2006a). Furthermore, α2 knock-out (α2-/-) mice are anxious in a 
conditioned emotional response paradigm (Dixon et al., 2008) and α2H101R 
knock-in mice (benzodiazepine-insensitive at α2-type GABAA receptors) lose 
the anxiolytic response to diazepam (Low et al., 2000). 
 
Not all investigators agree, however, that α2 subunits are the sole mediators of 
anxiolysis. In an investigation by Low et al. (2000), mice insensitive to 
benzodiazepine action at the α3 subunit retain anxiolysis following diazepam 
administration, and so investigators concluded that this subunit was not 
involved in anxiety. This notion is further supported by observations that α3-/- 
mice are not anxious and retain diazepam anxiolysis (Yee et al., 2005). On the 
other hand, an α3-selective inverse agonist is anxiogenic (Atack et al., 2005) 
and an α3-selective agonist is anxiolytic (Dias et al., 2005), both of which 
implicate α3 subunits in anxiety circuitry. Notably, there are confounding issues, 
such as problems with activity effects in locomotor-dependent anxiety tests (see 
discussion by Reynolds et al., 2001), or issues of imperfect selectivity of 
subunit-selective compounds (e.g. the α3-selective inverse agonist shows some 
efficacy at α2 subunits (Atack et al., 2005), and so its anxiogenesis could be α2-
mediated). Nevertheless, both α2 and α3 subunits mediate the myorelaxant 
effects of benzodiazepines: α2 subunits at low doses, and α3 subunits at higher 
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doses (Crestani et al., 2001). It would seem probable that there is an 
overlapping contribution of both subunits in anxiolysis. 
 
It is generally accepted that α1 subunits mediate the sedative effects of 
benzodiazepines (Rudolph et al., 1999). Investigators therefore hoped that 
creating a α2/α3-selective benzodiazepine-like compound that has little activity 
at α1 subunits would be expected to produce anxiolysis without sedation. 
Several such compounds have been generated, including TPA023 (also called 
MK-0777) and MRK-409 (also called MK-0343), which have proven successful 
as non-sedating anxiolytics in pre-clinical assessments (Atack, 2008; Atack et 
al., 2011). However, in spite of promising pre-clinical results, subunit-selective 
compounds have yet to be translated to the clinic. TPA023 failed at phase II 
clinical trials due to toxicity in long-term dosing (Mohler, 2011). MRK-409 
unexpectedly proved sedative in humans, despite a lack of sedation in 
preclinical models; investigators believe this effect is a consequence of partial 
agonist efficacy at α1 subunits, but indicates that humans have a greater 
sedation tendency than animal models (Atack, 2010; Atack et al., 2011). 
Confusingly, Ocinaplon is a compound that shows an anxioselective effect in 
humans and animal models, but has greater efficacy (both absolute and relative 
to diazepam) at α1- than α2-type GABAA receptors (Lippa et al., 2005). 
Nevertheless, the compound TPA023 at least provides proof of principle that 
α2-selective/α1-sparing compounds can be non-sedating anxiolytics in human 
subjects (Atack, 2008). 
 
We propose that neurosteroids will exhibit a similar α-subunit-selective profile, 
and thus predict a role for α2-type GABAA receptors in anxiolytic responses to 
both endogenous and injected neurosteroids. Furthermore, if this hypothesis is 
correct, α2-subunit-selective neurosteroid analogues would be non-sedating 
anxiolytics – opening an alternative drug design avenue to the selective 
benzodiazepine approach. 
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1.4. Neurosteroids and GABAA receptors in depression 
 
1.4.1. Roles for GABAA receptors in depression 
 
For many years, a prevailing theory for depression was the ‘monoamine 
hypothesis’, which postulates that depression results from a reduction in 
monoamine neurotransmission. Iproniazid and imipramine had demonstrated 
antidepressant efficacy in humans, and were later shown to increase serotonin 
and noradrenaline transmission – suggesting that deficiencies in these 
neurotransmitters underlie depression (see review by Krishnan & Nestler, 
2008). Many antidepressant agents therefore aim to raise synaptic levels of 
monoamines, either by blocking degradation (e.g. tranylcypromine, which 
inhibits monoamine oxidases) or re-uptake into neurons (e.g. selective 
serotonin reuptake inhibitors (SSRIs)). Despite their widespread use, these 
drugs are not universally effective, and it is increasingly appreciated that the 
monoamine hypothesis has some shortcomings (Lacasse & Leo, 2005). 
Alternatives to the monoamine hypothesis are emerging, with additional modes 
of action being proposed for common antidepressants, as well as new 
suggestions for the aetiopathology of depression, including a role for 
GABAergic signalling. 
 
Luscher et al. (2011b) and Smith and Rudolph (2012) reviewed the literature in 
support of a role for GABAergic dysfunction in depression. This connection 
might not be a surprise, given that anxiety and depression are often co-morbid 
(Hirschfeld, 2001; Nutt et al., 2006), and that GABAA receptors are linked with 
anxiety (see Section 1.3.2). Co-morbid anxiety and depression is a significant 
challenge because patients often present with greater symptom severity and 
have delayed or diminished response to conventional treatment (Hirschfeld, 
2001; Nutt et al., 2006). A better understanding of the common mechanisms for 
anxiety and depression may therefore help develop better treatment strategies 
for such patients. 
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Arguably the best demonstration of a causative role for GABAergic deficits in 
anxiety and depression comes from study of heterozygous mouse knock-outs 
for the γ2 subunit of GABAA receptors (γ2+/-), which display phenotypes 
consistent with both human disorders, including increased avoidance of 
aversive environments, increased despair and enhanced sensitivity to 
ambiguous cues (Crestani et al., 1999; Earnheart et al., 2007). Furthermore, 
this mouse model recapitulates the HPA axis hyperactivity seen in melancholic 
forms of depression (Shen et al., 2010). Particularly important for the purposes 
of this study, however, are observations that α2-/- mice have phenotypes 
consistent with both anxiety and depression (Dixon et al., 2008; Vollenweider et 
al., 2011) and that several limbic regions whose structure and/or activity is 
altered in depression, including the hippocampus, amygdala and basal ganglia 
(Sheline, 2003; McCabe et al., 2009), are areas rich in GABAA receptor α2 
subunit expression (Wisden et al., 1992; Sperk et al., 1997; Pirker et al., 2000; 
Sieghart & Sperk, 2002; Mohler, 2006a).  
 
There is also evidence from humans in support of a GABAergic signalling deficit 
in depression. A correlation between depressive symptoms and reduced brain 
levels of GABA was noted in cortical biopsies taken from fourteen depressed 
patients (Honig et al., 1988). Although not necessarily representative of brain 
levels, plasma GABA concentrations can be more conveniently determined, and 
were also diminished in approximately 40% of depressed patients compared to 
healthy controls (Petty, 1994). Non-invasive means of measuring brain GABA 
levels were later developed, such as the proton magnetic resonance 
spectroscopic approach of Sanacora et al. (1999). Their work confirmed a 
GABA deficit in the occipital cortex (Sanacora et al., 1999), and prefrontal 
regions (Hasler et al., 2007) of depressed individuals, the latter of which is more 
likely to be of significance for mood disorders. 
 
A role for GABAA receptors in human depression is supported by examining 
subunit mRNAs in post-mortem samples, mostly from depressed suicide 
victims. These studies found increases and decreases in expression of various 
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subunits, including α1, α3, α4 and α5 (Luscher et al., 2011b). However, it is 
important to note that these mRNA fluctuations may not necessarily be 
paralleled by cell surface protein expression levels. By employing single photon 
emission computed tomography (SPECT) with [123I]iomazenil to estimate the 
number of cortical GABAA receptors, Kugaya et al. (2003) found no change 
between 13 depressed patients and 19 healthy controls, which may negate the 
above findings with mRNA levels. Nevertheless, the SPECT approach is not 
without its limitations, particularly an inability to determine which subunit 
combinations make up the GABAA receptors to which [
123I]iomazenil is bound. 
Kugaya et al. (2003) therefore cannot rule out an upregulation of one subunit at 
the expense of another, despite no change in the overall number of 
[123I]iomazenil binding sites. By using post-mortem slices of hippocampus from 
Bipolar 1 patients and healthy controls, Dean et al. (2005) were able to concur 
with such a mechanism: overall binding of [3H]flumazenil was unaltered (i.e. no 
change in overall GABAA receptor expression), but the proportion of 
[3H]flumazenil binding that was sensitive to displacement by zolpidem was 
lowered (note that, unlike [3H]flumazenil, zolpidem does not bind to α5 
subunits). The interpretation of these observations is therefore that Bipolar 1 
patients have an increased expression of α5 subunits, at the expense of other α 
subunits in their hippocampi. 
 
Several genetic association studies fail to link GABAA receptor α subunits with 
major depression and anxiety disorders (Henkel et al., 2004; Pham et al., 2009). 
However, these studies used a broad range of subjects with anxiety and 
depressive symptoms, and links may have been diluted by such 
generalisations; for example, Henkel et al. (2004) do find an association 
between GABAA α3 subunit and unipolar major depressive disorder specifically 
in female subjects. Furthermore, Yamada et al. (2003) find association between 
polymorphisms on genes encoding GABAA receptor α1 and α6 subunits and 
mood disorders in female patients. Horiuchi et al. (2004) also link an α1 subunit 
polymorphism with a cohort of Japanese patients suffering affective disorders. 
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Reductions in brain tissue volume in several areas in depression (reviewed by 
Sheline, 2003) could represent excitotoxic loss of neurons and/or a reduction in 
neurogenesis. Support for reduced neurogenesis comes from the γ2+/- mouse 
model of depression, where reduced γ2 expression impairs survival or 
differentiation of neuronal precursors into mature neurons (Earnheart et al., 
2007). Interestingly, the effects of reducing γ2 levels on hippocampal 
neurogenesis and animal behaviour depend on the developmental stage at 
which the deficit is imposed. A conditional knock-out of γ2 after the fourth 
postnatal week fails to recapitulate effects of losing this subunit during 
embryonic development (Earnheart et al., 2007; Shen et al., 2010). The story is 
not complete, however, since the developmentally-delayed loss of γ2 subunits 
in the model described above retains the HPA axis hyperactivity characteristic 
of depression (Shen et al., 2010), but fails to develop the hippocampal 
neurogenesis defects and  behavioural depression, that occurs if the γ2 deficit 
is imposed during embryogenesis (Earnheart et al., 2007). 
 
Given the above indications that depression involves reduced transmission 
through GABAA receptor subunits, one might predict that potentiating this 
transmission would be a successful treatment strategy. Indeed, Luscher et al. 
(2011b) suggest that current antidepressants, particularly SSRIs, may 
potentiate GABAergic transmission in a number of ways: by increasing 
excitability of GABAergic interneurons; by increasing GABA production via the 
enzyme, glutamate decarboxylase 67 (GAD67); and by increasing levels of 
GABAA receptor-potentiating neurosteroids (see Section 1.4.2). However, 
benzodiazepines – classical potentiators of GABAergic transmission – are not 
generally antidepressant; only alprazolam has demonstrated any efficacy in 
depression, although its use is mostly avoided due to its dependence liability 
(Laakmann et al., 1996). More work clearly needs to be done to fully understand 
the roles GABAA receptor dysfunction in depression. We aim to contribute to 
this by further assessing the roles played by α2-type GABAA receptors in 
depression. 
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1.4.2. Roles for neurosteroids as antidepressants 
 
Plasma and cerebrospinal fluid (CSF) levels of the neurosteroid 
allopregnanolone have repeatedly been shown to be reduced in depressed 
patients relative to healthy controls (Romeo et al., 1998; Uzunova et al., 1998; 
Strohle et al., 1999; Strohle et al., 2000). Furthermore, this allopregnanolone 
deficit is ameliorated by treatment with a range of antidepressants, with the 
recovery of CSF levels (Uzunova et al., 1998), but not plasma levels (Romeo et 
al., 1998), correlating with the degree of symptomatic resolution. By 
characterising the effects of SSRIs on rat brain neurosteroid profiles (Uzunov et 
al., 1996) and on the kinetics of recombinantly-expressed enzymes (Griffin & 
Mellon, 1999), the increased allopregnanolone concentration appears to result 
from stimulation of the enzyme 3α-HSD (see Fig. 1.3) changing its properties to 
favour the reductive reaction over the oxidative reaction. It would therefore 
seem that neurosteroids could be used as antidepressants. Importantly, 
however, such correlative observations do not demonstrate whether 
neurosteroid level normalisation is a consequence or cause of diminished 
depressive symptoms. Support for a causative role is provided by observations 
that sex hormones and their neurosteroid metabolites modulate behaviour in 
several rodent models of depression, including forced swim, tail suspension and 
learned helplessness tests (Khisti et al., 2000; Hirani et al., 2002; Dhir & 
Kulkarni, 2008; Shirayama et al., 2011). Antagonism of allopregnanolone’s 
antidepressant effect by bicuculline implicates GABAA receptors as the 
mediators of the response to neurosteroids (Khisti et al., 2000). 
 
At childbirth, the sudden withdrawal from pregnancy-associated high levels of 
progesterone, and its neurosteroid metabolites, is thought to trigger post-partum 
depression in susceptible women (Bloch et al., 2000). Support for these 
proposals comes from progesterone-withdrawal mouse models of post-partum 
depression, where repeated progesterone injections are followed by either a 
progesterone receptor antagonist or finasteride (an inhibitor of 5α-reductase) to 
inhibit further metabolism to neurosteroids. The former demonstrates that some 
of the depressed phenotype involves the progesterone receptor (Beckley et al., 
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2011), but the latter confirms that reduced levels of its metabolites, especially 
allopregnanolone, also contribute to the depressed phenotype in the forced 
swim test (Beckley & Finn, 2007). Mouse models also support a role of GABAA 
receptors in postpartum depression: δ+/- and δ-/- mice are depressed in various 
behavioural tests, but only post-partum – virgin females show no phenotype – 
which suggests a protective role of δ subunit expression (Maguire & Mody, 
2008). 
 
Whilst GABAA receptor potentiation by neurosteroids may account for some 
antidepressant-like effects, there are some important points to note. SSRI 
antidepressants are slow to act in humans, requiring several weeks of dosing 
before a beneficial effect is observed, whilst their effects in rodent behavioural 
models of depression are much more immediate, occurring within minutes 
(Cryan et al., 2005). In addition, although these drugs rapidly alter 3α-HSD 
activity and brain neurosteroid profiles in rats (Uzunov et al., 1996; Griffin & 
Mellon, 1999), chronic fluoxetine treatment in rats actually decreases the 
plasma and brain concentrations of THDOC and allopregnanolone (Serra et al., 
2002). Furthermore, other antidepressants, such as imipramine, do not 
influence 3α-HSD activity or neurosteroid levels in rodents (Uzunov et al., 1996; 
Griffin & Mellon, 1999). Finally, sulphated steroids, which negatively modulate 
GABAA receptors, are also antidepressant in mice (Dhir & Kulkarni, 2008).  
Therefore, although neurosteroid potentiation at GABAA receptors can produce 
antidepressant-like effects in animal models, they are by no means a universal 
feature of antidepressant function. We therefore aim to screen the 
antidepressant potency of the neurosteroid THDOC, and assess whether this 
function depends on positive allosteric modulation of α2-type GABAA receptors. 
 
 
1.4.3. The nucleus accumbens in reward and depression 
 
The nucleus accumbens (NAcc) forms part of the mesolimbic dopamine 
pathway, which is believed to process rewarding stimuli, and to be involved in 
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motivational reward-seeking pathways. Major inputs to this structure are 
dopaminergic projections from the ventral tegmental area (VTA), glutamatergic 
projections from the hippocampus, as well as inputs from prefrontal association 
cortices and the basolateral amygdala (Heimer et al., 1997). Drugs of abuse, 
including cocaine and benzodiazepines, engender rewarding effects by 
increasing dopamine release in the NAcc, often by relieving inhibitory restriction 
on VTA dopamine neuron firing (Hyman & Malenka, 2001; Luscher & Ungless, 
2006; Tan et al., 2011). NAcc activity is under extensive inhibitory control: the 
vast majority (95%) of neurons in the NAcc are GABAergic medium spiny 
neurons (MSNs), which not only project to outputs (such as the ventral 
pallidum), but also make collateral connections with one another (Heimer et al., 
1997). Changes in GABAergic transmission may occur during addiction and 
withdrawal – for example, the level of extracellular GABA increases in the rat 
NAcc after withdrawal from daily cocaine injections (Xi et al., 2003).  
 
The mesolimbic dopamine pathway is not only involved in response to addictive 
drugs, but is also activated by a number of natural rewards, such as food. 
Anhedonia, a reduced pleasure in response to normally rewarding stimuli, is a 
core symptom of depression, suggesting that a defective mesolimbic dopamine 
pathway can underlie some features of depression (Shirayama & Chaki, 2006). 
It is possible that the antidepressant function of neurosteroids could involve 
their activity within the mesolimbic dopamine system. Direct injection of 
allopregnanolone into the NAcc was not antidepressant in a learned 
helplessness model of depression (Shirayama et al., 2011), but these 
experiments have not definitively ruled out a role for the NAcc in antidepressant 
functionality of endogenously-synthesised neurosteroids. We have therefore 
examined inhibitory neurotransmission within the NAcc, and its response to 
neurosteroid. The roles of the GABAA receptor α2 subunit in this response were 
also assessed. 
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1.5. Thesis Aims 
 
1.5.1. Generation of an α2Q241M knock-in mouse 
 
Hydrophobic substitution of a critical α1Q241 residue (or equivalent in other α 
subtypes) selectively disrupts neurosteroid binding to the potentiation site, 
eliminating neurosteroid potentiation, with minimal effects on GABA activation 
and receptor modulation by other allosteric ligands (barbiturates, 
benzodiazepines) (Hosie et al., 2006; Hosie et al., 2009). We have therefore 
used such a mutation to generate a transgenic knock-in mouse line that 
harbours the mutation α2Q241M. By ablating neurosteroid potentiation at α2-type 
GABAA receptors, this knock-in mutation allows us to examine the α2-subunit 
specific functions of neurosteroids.  
 
Especially because this mutation is influencing the response to an endogenous 
compound, one must verify a lack of compensatory alterations in the knock-ins. 
We have addressed this question using Western blot and quantitative 
immunofluorescence assays to study GABAA receptor α subunit expression. 
Because this mutation is not expected to alter diazepam or pentobarbital 
sensitivity of mutant channels compared to wild-types, we can utilise these 
compounds as positive controls within this study, to demonstrate that the effects 
of GABAA receptor potentiation are intact within the transgenic animals.  
 
 
1.5.2. Electrophysiological characterisation of α2Q241M mice 
 
The roles of the α2 receptor isoform in the cellular responses to neurosteroids 
have been examined with whole cell patch-clamp recordings in acute brain slice 
tissue. The α2 subunit has been classically associated with synaptic events, 
IPSCs (Prenosil et al., 2006), but we cannot rule out a role in extrasynaptic tonic 
currents, and so both types of inhibition have been assessed. The areas chosen 
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for study, the hippocampus and NAcc, strongly express the α2 isoform, and are 
key candidates for roles in anxiety and depression. To screen for effects of the 
mutation on baseline neurotransmission, periods of control recording were 
compared between wild-type and α2Q241M knock-in mice. Slices were also 
treated with diazepam or THDOC, to evaluate the effect of the knock-in 
mutation on sensitivity to these compounds.  
 
 
1.5.3. Behavioural characterisation of α2Q241M mice 
 
In this study, analyses have focussed on anxiety and depression-related 
phenotypes, to assess the contribution of neurosteroids and α2-type GABAA 
receptors to these disorders. We propose that neurosteroids may exert their 
anxiolytic and antidepressant actions through α2 and α3-type GABAA receptors. 
If our hypotheses are correct, homozygous α2Q241M mutant mice would be 
predicted to show impaired anxiolysis and antidepression in response to 
injected neurosteroid. Behavioural phenotypes of untreated mice would also 
provide insight into the functions of endogenous neurosteroids acting at α2-type 
GABAA receptors. 
 
 
1.5.4. Summary of thesis aims 
 
1. To establish that the α2Q241M mutation has the desired properties for this 
study: loss of neurosteroid potentiation without altered GABA sensitivity 
or benzodiazepine-mediated potentiation (Chapter 3). 
 
2. To establish that α2Q241M knock-in mice have no compensatory changes 
in receptor expression (Chapter 3). 
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3. To examine the consequences of α2Q241M knock-in for inhibitory 
neurotransmission and its response to modulators (Chapter 4). 
 
4. To define the GABAA-receptor α2-specific roles of endogenous and 
injected neurosteroids in anxiety and depression-type behaviours 
(Chapter 5). 
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Chapter 2: Materials and Methods 
 
2.1. Materials 
 
2.1.1. Reagents 
 
EDTA-Free Halt Protease Inhibitor Cocktail (100x) was purchased from Thermo 
Fisher Scientific Inc. (Rockford, Illinois, USA); as were the bicinchoninic acid 
(BCA) Assay Kit and the SuperSignal West Pico Chemiluminescent Substrate. 
Protogel 30% w/v Acrylamide:0.8% w/v Bis-Acrylamide was purchased from 
National Diagnostics (Atlanta, Georgia, USA). Protein Molecular Weight 
Standards (Broad Range) were purchased from Bio-Rad Laboratories Ltd. 
(Hemel Hempstead, UK). Polymerase Chain Reaction (PCR) was performed 
using the Phusion Hot Start High-Fidelity DNA Polymerase kit (Thermo Fischer 
Scientific Inc.) and primers from Eurofins MWG Operon (Ebersberg, Germany). 
All other chemicals were obtained from Sigma-Aldrich (Steinheim, Germany) or 
VWR International (Leuven, Belgium) unless indicated otherwise.  
 
 
2.1.2. Antibodies 
 
Table 2.1 provides details regarding sources and working dilutions for all 
primary and secondary antibodies used in this study. The specificity of anti-
GABAA-receptor antibodies used in Western blotting was confirmed using 
recombinantly expressed receptors. Briefly, Human Embryonic Kidney 293 
(HEK293) cells were electroporated as described in Section 2.5.2. Two days 
later, cells were washed in ice-cold phosphate-buffered saline (PBS; 137 mM 
NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4, pH 7.4) and scraped off 
the culture dish in ice-cold RIPA buffer (150 mM NaCl, 20 mM Tris pH 8.0, 5 
mM ethylene-diamine-tetra-acetic acid (EDTA), 1% v/v NP40, 0.5% w/v sodium 
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deoxycholate, 0.1% w/v sodium dodecyl-sulphate (SDS), 1 mM phenylmethane-
sulfonylfluoride and 1x EDTA-Free Halt Protease Inhibitor Cocktail). Cells were 
disrupted by rotating in the RIPA buffer (1 h at 4 oC); debris was removed by 
sedimentation (30 min, 13,000 rotations per minute (r.p.m.), 4 oC, Eppendorf 
5415R centrifuge). Further processing (BCA assay and SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE)) was performed as described in Section 2.3.2. 
Each antibody tested produced a band between markers 45 and 66 kiloDaltons 
(kDa), in the appropriate lane only (Fig. 2.2). Using the defined blotting 
conditions (Section 2.3.2) and antibody dilutions (Table 2.1), it was therefore 
evident that that these antibodies are GABAA α-subunit isoform specific. 
 
 
 
2.2. Animals 
 
All procedures involving animals were performed according to the Animals 
(Scientific Procedures) Act, 1986 (ASPA) and had obtained local ethical 
approval. When obtaining tissue for electrophysiology or Western blotting, 
animals were decapitated under terminal isoflurane anaesthesia. After 
behavioural testing, animals were culled by cervical dislocation according to 
Schedule 1 of the ASPA. Given that the steroid hormones of the oestrus cycle 
have a strong influence on brain neurosteroid levels in female mice (Corpechot 
et al., 1997), only male mice were used in our experiments. 
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Antibody 
WB 
dilution 
IF 
dilution 
Epitope Details Source 
P
ri
m
a
ry
 A
n
ti
b
o
d
ie
s
 
mouse monoclonal anti-GABAA α1 1:1,000 - Amino acids 355-394 of mouse GABAA α1 NeuroMab
 1
 
rabbit polyclonal anti-GABAA α1 - 1:20,000 Amino acids 1-16 of rat GABAA α1 gift from Dr Jean-Marc Fritschy
 2
 
guinea-pig polyclonal anti-GABAA α2 - 1:1,000 Amino acids 1-9 of rat GABAA α2 gift from Dr Jean-Marc Fritschy
 2
 
guinea-pig polyclonal anti-GABAA α2 1:1,000 - Amino acids 29-37 of rat GABAA α2 Synaptic Systems
 3
 
rabbit polyclonal anti-GABAA α2 1:500 - Amino acids 1-10 of rat GABAA α2 gift from Dr Werner Sieghart
 5
 
rabbit polyclonal anti-GABAA α3 1:1,000 1:1,000 Amino acids 29-37 of human GABAA α3 Alomone Labs
 4
 
rabbit polyclonal anti-GABAA α4 1:4,000 1:500 Amino acids 1-14 of rat GABAA α4 gift from Dr Werner Sieghart
 5
 
rabbit polyclonal anti-GABAA α5 - 1:500 Amino acids 1-12 of rat GABAA α5 gift from Dr Werner Sieghart
 5
 
mouse monoclonal anti-β-Tubulin 1:1,000 - Tubulin from rat brain SigmaAldrich
 6 
 (clone TUB2.1) 
S
e
c
o
n
d
a
ry
 
A
n
ti
b
o
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Alexa Fluor® 555 goat anti-guinea pig IgG (H+L) - 1:2,000 - Invitrogen Ltd.
 7
 
Alexa Fluor® 555 goat anti-rabbit IgG (H+L) - 1:2,000 - Invitrogen Ltd.
 7
 
HRP-conjugated goat anti-rabbit IgG (H&L) 1:10,000 - - Rockland Immunochemicals for Research 
8
 
HRP-conjugated goat anti-mouse IgG(H&L) 1:10,000 - - Rockland Immunochemicals for Research 
8
 
HRP-conjugated donkey anti-guinea-pig IgG(H&L) 1:1,000 - - Jackson ImmunoResearch Laboratories 
9
 
Table 2.1 – Details of antisera employed in this project 
Details of antisera utilised in this project for Western blot (WB) or immunofluorescence (IF). Secondary antibodies for WB were conjugated to Horseradish 
peroxidise (HRP).1 UC Davis, University of California, USA; 2 University of Zurich, Switzerland; 3 Goettingen, Germany; 4 Jerusalem, Israel; 5 Medical University Vienna, Austria; 6 
Steinheim, Germany; 
7
 Paisley, UK; 
8
 Philadelphia, Pennsylvania, USA; 
9
 Stratech Scientific, Suffolk, England 
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2.2.1. Generating GABAA receptor α2
Q241M mutant mice 
 
Mike Lumb, a molecular biology technician in the lab, performed this stage of 
the project. Escherichia coli-based recombineering technology (obtained from 
National Cancer Institute at Frederick, Maryland) was employed to create a 
targeting vector containing exon 8 of GABAA receptor α2 subunit gene with 
base pair changes for the point mutation Q241M (Fig. 2.1 Ai), utilising an RP23 
Bacterial Artificial Chromosome library clone derived from a C57BL/6 mouse. 
Using commercial facilities for homologous recombination (GenOway, Lyon, 
France), the vector was introduced into 129Sv/Pas embryonic stem (ES) cells 
by electroporation. Positive and negative selection procedures were used to 
enrich for cells that had successfully undergone homologous recombination. 
PCR and Southern blotting techniques were used to identify ES cell lines that 
had precisely replaced the wild-type α2 sequence with that encoding the 
Q241M mutant: the mutagenesis silently created an Nco-I restriction site, 
allowing identification of homologous recombinants by Nco-I digestion followed 
by Southern blot (band size decreases from 12 Kilobase-pairs (kb) to 6 kb (Fig. 
2.1 B)). These ES cell lines were used to generate transgenic mice with the 
α2Q241M mutation (Fig. 2.1 Aii). Germline-transmitted pups from a chimera x 
C57BL/6J cross (F0 generation) were bred with C57BL/6J Cre-recombinase 
expressing mice, in order to remove the neomycin resistance cassette (F1 
generation; Fig. 2.1 Aiii). Further backcrosses were performed between 
heterozygous (het) α2Q241M mice and C57BL/6J mice. The mice used in the 
experiments described here are from generations F4-F6. 
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Figure 2.1 – Generation of the mutant mice 
A.  i. Targeting construct comprising mouse genomic sequence (dark blue) containing 
point-mutated exon 8 of GABAA α2 gene (red), together with positive and 
negative selection markers Neo (neomycin resistance cassette, light blue) and 
TK (Herpes simplex virus thymidine kinase, light blue). The Neo cassette is 
flanked by loxP sites (green). This construct is housed in a low copy number 
pBluescript KS+ plasmid backbone (pink). 
ii.  Result of successful homologous recombination; mutated exon 8 and neo have 
been incorporated into genomic DNA (dashed dark blue line). TK and pBluescript 
are lost. This corresponds to the genomic DNA from F0 generation mice. 
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iii. Result of breeding recombinant mice with Cre-recombinase expressing mice; 
Neo has been removed, leaving behind a single lox P site. Black arrowheads 
mark locations of primer sites used for genotyping in C. This corresponds to 
genomic DNA in mice from generation F1 and beyond. 
B. Southern blot screen of ES cell lines: the Q241M mutation silently introduces a 
novel restriction site – allowing a screen for restriction fragment length polymorphism. 
Lanes 1-5, heterozygous recombinants; lanes 6-7, wild-type controls. 
C. Primers and protocol for PCR genotyping of mouse genomic DNA, with 
representative results achieved by running PCR products on a 2% w/v agarose gel. 
D. Verification of the point mutation by DNA sequencing. Exon 8 was PCR-amplified 
from mouse genomic DNA of wt (left), het (middle) and hom (right) animals, then 
sequenced. Sequence results local to the point mutation are shown. 
 
 
2.2.2. Breeding 
 
Animals were maintained as het x het breeding pairs, to allow comparison of 
homozygous (hom) knock-ins with wild-type (wt) littermates. Experimental 
animals were males housed in cages of up to five littermates, with access to 
food and water ad libitum, under a 12 h light-dark regime (lights on at 07:30h). 
Males were housed with at least one other littermate post-weaning. For 
electrophysiology and Western blotting, animals were used between postnatal 
days 18 (P18) and 30. For behavioural characterisation and 
immunofluorescence, animals aged between P42 and P70 were used. 
 
 
2.2.3. Genotyping 
 
Genomic DNA was isolated from ear clips and/or post-mortem tail snips by 
incubating overnight in a lysis buffer (100 mM Tris-HCl pH 8.5, 5 mM EDTA, 
0.2% w/v SDS, 200 mM NaCl and 0.1 µg/ml proteinase K (Roche Diagnostics 
GmBH, Mannheim, Germany)) at 37 oC. Debris was removed by centrifugation 
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(15 min, 13,000 r.p.m., room temperature (RT)); DNA was precipitated with 
isopropanol (sedimented at 13,000 r.p.m., 5 min, RT), washed with 70% v/v ice-
cold ethanol (sedimented at 13,000 r.p.m., 5 min, RT), and re-suspended in 
0.05x TE (10 mM Tris, 1 mM EDTA pH 8.0). 
 
The mutant allele can be distinguished from the wt allele by the presence of the 
loxP site remaining after removal of the neomycin cassette on the transgenic 
allele (Fig. 2.1 Aiii). When PCR is performed as outlined in Fig. 2.1 C, the 
presence of the lox P site results in a band 100 base pairs larger in the mutant 
allele than the wt allele. A heterozygous mouse therefore produces two bands 
(Fig. 2.1 C). 
 
 
 
2.3. Western blotting 
 
2.3.1. Protein isolation 
 
Total protein was isolated from four brain areas from each animal: cortex, 
cerebellum, hippocampus and nucleus accumbens (NAcc). The NAcc was 
dissected from 350 µm coronal slices obtained as for electrophysiology (for 
details, see Section 2.6.1). Remaining brain areas were isolated by direct 
dissection from whole brain under a dissecting microscope, and the meninges 
removed. Tissue was disrupted by homogenisation in ice-cold RIPA buffer, 
either in a Dounce homogeniser (VWR International) (cortex, hippocampus, 
cerebellum) or with a Microlance 25-gauge 1/2” needle and 1 ml syringe (BD 
Franklin Lakes, NJ, USA) (NAcc). Cells were disrupted by repeated freeze-thaw 
cycles, with debris removed after each cycle by centrifugation (20 min, 13000 
r.p.m., 4 oC). 
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2.3.2. Polyacrylamide gel electrophoresis (PAGE) and blotting 
 
Protein concentration was determined spectrophotometrically (Bio-Rad 
SmartSpec Plus) according to instructions with the BCA assay kit. Proteins 
were denatured at RT by addition of Laemmli Sample Buffer (150 mM Tris-Cl 
pH 6.8, 6% w/v SDS, 0.3% w/v Bromophenol blue, 30% w/v glycerol and 15% 
v/v β-mercaptoethanol) and run on a 10% SDS-PAGE gel (5% stacking gel) in 
Running Buffer (25 mM Tris, 192 mM glycine, 0.1% SDS) for 1 h at 150 V, using 
a Bio-Rad Miniprotean II system. Proteins were transferred to nitrocellulose 
membranes (Hybond C Extra, Amersham Biosciences, Buckinghamshire, UK) 
at 25 V for 70 min in Transfer Buffer (25 mM Tris, 192 mM glycine, 20% v/v 
methanol) using an XCell II Blot Module (Invitrogen, Carlsbad, USA). 
Successful transfer was confirmed by Ponceau staining (0.1% w/v Ponceau-S 
in 5% v/v acetic acid); the stain was thoroughly washed off the membrane with 
PBS before the blocking and incubation steps. 
 
All blocking, washing and antibody incubation steps were performed on a 
shaker with 4% milk in PBS (plus 0.1% TWEEN-20), the antibody dilutions 
employed are outlined in Table 2.1. Blocking was performed for 1 h at RT, 
whilst primary antibody incubation was overnight at 4 oC, and secondary 
antibody incubation was for 2 h at RT. After each antibody incubation, 
membranes were washed three times (20 min, RT). Blots were finally rinsed in 
PBS and developed using chemiluminescent substrate and visualised with an 
ImageQuant LAS4000 imager. Images were quantified using the Western blot 
plug-in on ImageJ software (Version 1.44p, National Institutes of Health, USA). 
 
After blotting for the relevant GABAA α subunit, blots were subjected to a mild 
stripping procedure (10-20 min incubation in a buffer comprising 200 mM 
glycine, 0.1% w/v SDS, 1% v/v TWEEN-20, pH 2.2) followed by 6 x 5min 
washes in PBS. Successful stripping was confirmed by re-incubation in 
secondary antibody (1 h at RT), washing (3 x 20 min, RT) and developing, 
where no residual signal was observed. Membranes were then re-blotted for 
quantification of β-tubulin expression. The density of each α subunit band was 
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first normalised to its corresponding β-tubulin band, then signals within each 
Western blot were normalised to the average signal of the wt bands in that blot 
(such a normalization procedure has been used by others – e.g. Chandra et al., 
2005). 
 
Before quantitative blots were carried out, titration experiments were performed 
to determine the amount of total protein, which, when blotted under the above 
conditions, produces a signal in the middle of the dynamic range of the 
detection system. When working under such conditions, one maximises the 
chances of detecting any up- or down-regulation of GABAA subunit expression. 
Gels were therefore loaded with increasing amounts of total protein (ranging 
from 5 to 100 µg) from each brain area from three P21-P30 C57BL/6J mice and 
blotted for each GABAA α subunit. These titration curves (Fig. 2.2 and data not 
shown) were used to select an appropriate amount of protein to load when 
quantifying subunit expression from the transgenics (Table 2.2). 
 
Subunit Cortex Hippocampus 
Nucleus 
Accumbens Cerebellum 
α1 15 µg 25 µg 25 µg 20 µg 
α2 25 µg (gp) 25 µg (gp) 20 µg (r) n.d. 
α3 45 µg 25 µg 20 µg n.d. 
α4 30 µg n.d. n.d. n.d. 
Table 2.2 – Amount of total protein loaded for Western blotting 
Results from titration experiments determining the amount of total protein, which, 
when blotted under the defined conditions, produces a signal in the middle of the 
dynamic range of the detection system. Two different antisera were used in 
detecting α2 expression – guinea pig (gp) or rabbit (r) as indicated. n.d. - not 
determined because no reliable signal was obtained with calibration blots (0-100 
µg total protein loaded). 
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Figure 2.2 – Optimising conditions for Western Blotting 
A. Antibodies are specific for their defined α subunit: 20 µg of each HEK293 cell lysate 
was prepared and blotted as described in Section 2.1.2. Images show the blot between 
66 kilodalton (kDa) and 45 kDa markers. Antibodies: α1, mouse monoclonal anti-α1; 
α2(gp), guinea-pig polyclonal anti-α2; α2(r), rabbit polyclonal anti-α2, α3, rabbit 
polyclonal anti-α3; α4, rabbit polyclonal anti-α4. 
B. Calibration curve for the signal (arbitrary units) obtained by blotting increasing 
amounts of C57BL/6J cortical protein for α1; average of 3 blots (error bars = standard 
error of the mean (s.e.m.)). Loading 15 µg total protein from test cortices will give a 
mid-range signal. Inset: representative example blot (bands 5-50 µg correspond to the 
points on the curve below). Similar calibration curves were obtained for other subunits 
and other brain areas. 
 
 
 
2.4. Immunofluorescence 
 
2.4.1 Brain sectioning for immunofluorescence 
 
Three mice of each genotype (wt, het, hom) were sacrificed with a lethal dose of 
sodium pentobarbital (dissolved in 0.9% w/v NaCl to a concentration of 15 
mg/ml, injected at a volume of 10 ml per kg body weight), and subjected to 
cardiac perfusion first with 20 ml ice-cold saline/heparin mix (5000 units heparin 
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per litre (Leo Laboratories Ltd., Buckinghamshire, UK), 0.9% w/v NaCl), then 
with 10 ml ice-cold fixative (4% paraformaldehyde in 0.1 M Phosphate Buffer 
(PB: 12 mM NaH2PO4, 38 mM Na2HPO4)). Brains were removed, and incubated 
for a further 2 h at 4 oC in the fixative. Finally, they were transferred to a 
cryoprotectant solution comprising 0.1 M PB, 0.03% w/v sodium azide and 30% 
w/v sucrose for incubation at 4oC until tissue sank (at least overnight). 
 
Coronal 40 µm slices were cut from frozen brain on a Leica SM200R sliding 
microtome (Leica Microsytems GmBH, Wetzlar, Germany). Sections were 
collected in a 24-well plate (Starstedt Ltd., Leicester, UK), filled with 0.1M PB 
with 0.03% w/v sodium azide, and were stored at 4 oC until staining. During 
sectioning, serial sections were inserted into adjacent wells such that one well 
contains every 6th slice of the nucleus accumbens, or every 12th slice of the 
hippocampus. When staining, sections were taken from the same well, thus 
ensuring a uniform representation along the anterior-posterior axis of the 
structure being examined. 
 
 
2.4.2. Staining sectioned tissue 
 
Tissue sections were rinsed twice with PBS before incubating for 1 h at RT in 
permeabilisation/blocking solution (0.5% bovine serum albumin, 2% normal 
goat serum, 0.2% triton-x-100 in PBS). Sections were incubated overnight at 4 
oC with primary antibody dissolved in the same permeabilisation/blocking 
solution. Secondary antibody was applied to slices at RT for 2 h. After each 
antibody incubation, slices were washed four times in PBS (15 min at RT). All 
incubations and washes were performed by gently shaking slices in 24 well-
plates. Stained slices were mounted on super premium glass microscope slides 
(VWR International) using ProLong Gold Antifade reagent (Invitrogen Ltd. 
(Paisley, UK)). Slides were stored in a dark container at 4 oC, until imaging. 
Controls for non-specific labelling by secondary antibodies were performed by 
staining as described, but omitting primary antibody. 
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2.4.3. Image acquisition and analysis 
 
Image acquisition was performed using a Zeiss Axioscop LSM510 confocal 
microscope (Carl Zeiss Ltd., Welwyn Garden City, Hertfordshire, UK), equipped 
with three laser lines (λ = 488, 543 and 643 nm) and Plan Neofluor 20x air 
(numerical aperture (NA) 0.5) and 63x oil  (NA 1.4) differential interference 
contrast objectives (Carl Zeiss). Images were captured as z-stacks, with images 
in each plane acquired as a mean of 8 scans in 8 bits and stored for analysis.  
For each subunit and brain area, three slices were imaged per animal. Image 
acquisition and analysis were performed blind to the genotype of the animal. 
 
Images of the cornu ammonis 1 (CA1) region of the hippocampus were 
acquired with the 63x lens at 1x zoom, and encompass the cell body layer and 
the apical dendrites. Images of the dentate gyrus (DG) were also acquired with 
the 63x lens at 1x zoom, and encompass the granule cell layer and molecular 
layer of the medial blade of the DG. With the exception of images for α3 
expression, images for the NAcc were acquired with the 63x lens at 1x zoom, 
and represent both core and shell regions. Because the expression of α3 was 
much less uniform throughout the NAcc, showing patches of intense staining in 
both core and shell regions, images for this subunit were instead acquired using 
the 20x lens at 1x zoom. This reduces the spatial resolution of the images, but 
acquires data over a 9.9 times larger surface area, and so compensates for this 
‘patchy’ distribution. 
 
Images were analysed using ImageJ (Version 1.44p). For CA1 and DG, the 
mean fluorescence intensity was determined for separate regions of interest 
(ROIs) encompassing the dendrites and cell bodies. For the NAcc, mean 
fluorescence intensity was measured for the entire image, rather than a specific 
ROI. In both cases, to ensure that the value is representative of the staining 
throughout the brain slice, three readings were taken per image: one from the 
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top, one central and one at the bottom of the z-stack; the average of these 
values was taken to represent the expression of that subunit in that slice. 
 
Bar charts in Fig. 3.5 represent the average mean fluorescence intensity across 
the whole collection of slices. Results are expressed relative to values for wt 
animals, such that het or hom values of 1.0 would represent no change in 
expression; and, for example 1.2 would represent a 20% increase, or 0.8 a 20% 
decrease in expression. 
 
The mean fluorescence intensity approach is less appropriate in images where 
punctae are in the minority against background (e.g. see α1 expression in the 
NAcc, Fig. 3.4 C). In this case, and also for α3 expression in the DG (where the 
mean fluorescence intensity analysis indicated a tendency toward a difference), 
subunit expression was examined in more detail by quantifying immunopositive 
punctae. This was carried out using the FociPicker3D plug-in in ImageJ 
(Guanghua Du, Institute of Modern Physics, CAS, China), which searches for 
local maxima in three-dimensions. As demonstrated in Fig. 2.3 A, when using 
optimal settings (intensity and size thresholds to define positive foci against the 
local background), the program successfully picks out immunopositive punctae, 
and provides measurements of their volume and intensity. 
 
The FociPicker3D approach was not extended to other images for several 
reasons. The plug-in is not suitable for images containing a mixture of diffuse 
and punctate staining (e.g. α4 and α5 subunit immunofluorescence), because it 
fails to distinguish between a small punctae and diffuse immunofluorescence 
(see Fig. 2.3 B). The bright but diffuse staining of some dendritic processes in 
hippocampi stained with α1-selective antiserum poses a similar problem (being 
recognised as a large number of small punctae by FociPicker3D). In addition, 
no settings were found that enabled the FociPicker3D plug-in to satisfactorily 
identify α2 immunopositive punctae in any of the regions imaged, probably 
because of the high background fluorescence in these images (which may 
represent diffuse staining for this subunit). 
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Figure 2.3 – FociPicker3D successfully identifies immunopositive punctae if 
images lack diffuse staining 
A. Series of images demonstrating good correlation between immunopositive punctae 
for α3 staining in the dentate gyrus (top) and punctae identified by FociPicker3D 
(bottom). Images on the left represent the entire field of view (63x zoom), middle 
images represent a zoom into the yellow box, images on the right are zoomed into the 
red box from middle images. With appropriate threshold settings, FociPicker3D 
identifies the majority of immunopositive punctae in the image, and rarely picks up 
background fluorescence as false positives. Scale bars (white) are 30 µm. 
B. Representative example for α5 immunostaining in the CA1 region of the 
hippocampus (raw image on left, Foci Picker result on the right). The program struggles 
to identify true punctae in images that contain diffuse as well as punctate staining. 
Some regions of diffuse staining wrongly identified as regions of many small individual 
punctae. 
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2.5. HEK293 cell culture and electrophysiology 
 
2.5.1. HEK293 cell culture 
 
HEK293 cells were maintained on 10 cm plates (Greiner-Bio-One GmbH, 
Frickenhausen, Germany) in a culture medium comprising Dulbecco’s modified 
Eagle medium supplemented with 10% v/v fetal bovine serum, 100 µg/ml 
streptomycin, 100 U/ml penicillin G and 2 mM glutamine (all from Gibco, 
Invitrogen Ltd.). Plates were incubated at 37 oC in 95% air/5% CO2 (BOC 
Healthcare, Manchester, UK). Cultures were passaged at approximately 70-
80% confluency and plated at appropriate dilution either on to 10 cm plates for 
maintenance, poly-L-lysine (100 µg/mg)-coated 18 mm coverslips (VWR 
international) for electrophysiology, or 6 cm plates (Nunclon-Δ Surface, Thermo 
Fisher Scientific Inc.) for biochemistry. 
 
For passage, cells were washed with 5 ml Hank’s balanced salt solution 
(HBSS), and detached by trypsinisation with 2 ml 0.05% w/v trypsin-EDTA 
(Gibco). Cells were resuspended in 10 ml culture medium, which quenches the 
trypsin, and then pelleted by centrifugation at 1000 r.p.m. for 5 min. Supernatant 
was removed, and the cell pellet re-suspended in 5 ml culture medium by 
trituration with a fire-polished glass Pasteur pipette (VWR International), to 
ensure a single-cell suspension before plating. 
 
 
2.5.2. HEK293 cell transfection 
 
For electrophysiology, HEK293 cells were transfected by a calcium phosphate 
precipitation method. After plating on coverslips, cells were exposed to a 
mixture comprising 1 µg of each cDNA expression vector encoding the required 
GABAA receptor subunits (murine α, β, γ or δ cDNA housed in a pRK5 plasmid 
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vector), 1 µg of cDNA expression vector encoding enhanced green-fluorescent 
protein (eGFP), 20 µl 340 mM CaCl2 and 24 µl 2 x HBSS (280 mM NaCl, 2.8 
mM Na2HPO4, 50 mM HEPES, pH 7.2). Cells were subjected to 
electrophysiology 18-48 h later. 
 
For Western blotting, cells were prepared as described in Section 2.5.1., except 
that after trypsinisation, cells were pelleted and washed by resuspending in 10 
ml OptiMEM I (Gibco) and again sedimented by centrifugation. This cell pellet 
was resuspended in 400 µl OptiMEM I per transfection and transferred to 
BioRad 0.4 cm electrode gap cuvettes containing the appropriate cDNA vector 
mixture (2 µg per GABAA receptor subunit). Cells were then electroporated 
using a BioRad gene pulser II electroporator, and recovered with 0.5 ml culture 
medium before plating on poly-L-lysine-coated 6 cm culture dishes. Protein was 
harvested from cells 2-3 days post-electroporation. 
 
 
2.5.3. HEK293 cell electrophysiology 
 
Coverslips containing transfected HEK293 cells were transferred to a recording 
chamber, and continuously perfused at RT with Krebs solution, containing 
(mM): 140 NaCl, 4.7 KCl, 1.2 MgCl2, 2.5 glucose, 11 HEPES and 5 CaCl2 (pH 
7.4). Whole-cell recordings were undertaken from transfected (GFP-positive) 
HEK293 cells located using epifluorescence optics (Nikon Eclipse E600FN, 
Nikon Instruments Europe B.V. Surrey, UK). Membrane currents were recorded 
using a Multiclamp 700A amplifier (Molecular Devices, Sunnyvale, California, 
USA) in the voltage-clamp configuration (holding potential of -20 mV). Currents 
were filtered at 4 kHz (8th order Bessel, -48 dB/octave) and digitized at 50 kHz 
(Digidata 1322A, Molecular Devices), and displayed using Clampex software 
(version 8.2, Molecular Devices). Patch pipettes (4-5 M ) were filled with an 
internal solution containing (mM): 120 KCl, 1 MgCl2, 11 EGTA, 10 HEPES, 1 
CaCl2, 4 ATP (pH 7.2). The osmolarity of the internal solution was 300 ± 20 
miliOsmoles/litre (mOsm/l), measured using a vapour pressure osmometer 
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(Wescor Inc, Utah, USA). Responses of cells to brief (2-4 s) applications of 
GABA, alone or in combination with other drugs, were recorded using the gap-
free recording mode in Clampex. Substance applications were made using a Y-
tube (Fig. 2.4), and with 2 min recoveries between applications. 
 
Figure 2.4  – Schematic representation of 
the Y-tube 
Auxiliary/wash and Y-tube/drug-application 
tubes are arranged as depicted. Between 
drug applications, solenoids are open – 
allowing Krebs to flow over the cell, and drug 
to flow to waste under vacuum pressure. 
During applications, solenoids close, allowing 
drug to be applied to the cell (dotted line) in 
the absence of washing Krebs. 
 
Responses were measured by comparing peak amplitude to the baseline 
holding current in Clampfit software (version 10.2, Molecular Devices). To 
monitor for run-up or run-down of GABA responses, a defined concentration of 
GABA was applied at regular intervals to the same cell. Between applications, 
series resistance (Rs) was monitored. Experiments were terminated if Rs 
changed by more than 20%. GABA concentration-response curves were 
constructed by plotting mean peak responses against the GABA concentration, 
and fitting these data using the Hill equation (equation 1). 
 
Equation 1 
I[GABA] = Imax * ([GABA]
n / (EC50
n + [GABA]n)) 
Where I[GABA] is the peak current activated by GABA at a concentration [GABA], 
Imax is the maximal current response to GABA, EC50 is the concentration of 
GABA producing a current response 50% of the maximal response, and n is the 
Hill coefficient. 
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GABA concentration-response curves (Fig. 3.1) demonstrate that 0.5 µM GABA 
corresponds to an EC15 concentration (producing 15% of the maximal 
response) for both α2WTβ3γ2s and α2Q241Mβ3γ2s combinations. This 
concentration was selected for determining potentiation by THDOC and/or 
diazepam. The peak response to 0.5 µM GABA + drug was divided by that 
produced by a preceding control application of 0.5 µM GABA alone. The 
diazepam potentiation curve was fit with a modified version of equation 1, to 
include the pedestal (equation 2). 
 
Equation 2 
P[dzp] = Pmin + (Pmax – Pmin) * ([dzp]
n / (EC50
n + [dzp]n)) 
Where P[dzp] is the peak potentiation activated by 0.5 µM GABA plus a particular 
concentration of diazepam ([dzp]), Pmax is the maximal potentiation achieved 
with diazepam, EC50 is the concentration of diazepam producing 50% of the 
maximal potentiation, and n is the Hill coefficient. 
 
 
 
2.6. Brain slice electrophysiology 
 
2.6.1. Preparation of slices 
 
Coronal slices (350 µm) were obtained from wild-type and transgenic mice 
using a Leica VT1200s vibroslicer (Leica Microsytems GmBH, Wetzlar, 
Germany). Sections of nucleus accumbens were cut in an ice-cold artificial 
cerebrospinal fluid (aCSF) comprising (mM): 85 NaCl, 2.5 KCl, 1.25 Na2H2PO4, 
26 NaHCO3, 1 CaCl2, 4 MgCl2, 25 glucose, 75 sucrose and 2 kynurenic acid. 
Hippocampal slices were cut in ice-cold aCSF comprising (mM): 130 K-
gluconate, 15 KCl, 0.05 EGTA, 20 HEPES, 4 Na-pyruvate, 25 glucose and 2 
kynurenic acid, pH 7.4). Slices were transferred to a holding chamber in a water 
bath set at 37 oC, whilst the solution was slowly exchanged over 1 h to a 
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recording aCSF of composition (mM): 125 NaCl, 2.5 KCl, 1.25 Na2H2PO4, 26 
NaHCO3, 2 CaCl2, 1 MgCl2, 25 glucose. Slices were then maintained in the 
holding chamber at RT. All aCSF solutions were continuously bubbled with 
95%O2/5%CO2 (BOC Healthcare). 
 
 
2.6.2. Whole-cell patch clamp recording 
 
Whole-cell recordings were undertaken at RT from single neurons located using 
infra-red optics (Nikon Eclipse E600FN, Nikon Instruments Europe B.V. Surrey, 
UK) fitted with a Basler SLA750-60fm Camera (Basler Vision Technologies, 
Ahrensburg, Germany). Membrane currents were recorded as described for 
HEK293 cells (Section 2.5.3), using patch pipettes (3.8-4.5 M ) filled with an 
internal solution containing (mM): 140 CsCl, 2 NaCl, 10 HEPES, 5 EGTA, 2 
MgCl2, 0.5 CaCl2, 2 Na-ATP, and 2 QX-314 Bromide (Ascent Biochemicals, 
Abcam plc, Cambridge, UK). Solution osmolarity was adjusted with sucrose, 
usually 5 mM for hippocampal slices (approximately 305 mOsm/l) and 12.5 mM 
for NAcc slices (approx. 315 mOsm/l). 
 
Slices were continuously perfused with recording aCSF supplemented with 
kynurenic acid, to isolate GABAergic events. The neurosteroid, THDOC was 
dissolved as a 10 mM stock solution in dimethyl sulphoxide (DMSO), and 
diazepam was dissolved as a 100 mM stock in DMSO. These drugs were 
diluted to the appropriate final concentration in the recording aCSF, and applied 
to cells in the bath after a period of stable control recording. Drugs were allowed 
to equilibrate in the bath for at least 5 min; control or ‘mock’ recordings were 
performed to confirm that there are no changes in synaptic currents due to the 
DMSO vehicle, or washout of intracellular contents independent of drug (i.e. 
cells were challenged with 0.01% (v/v) DMSO1, or simply held in control aCSF 
                                            
1
 Equivalent to the highest % DMSO applied to cells (when administering 100 nM THDOC) 
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for an equivalent duration to experiments where drug was applied)2. 
Experiments were completed by the bath application of 20 µM (-)-bicuculline-
methiodide: to confirm that all events were GABAergic, and to allow any GABA-
mediated tonic currents to be measured. Recordings were made in 2 min 
epochs, between which Rs was monitored, and experiments were terminated if 
Rs changed by more than 20%. 
 
 
2.6.3. Analysis of spontaneous inhibitory post-synaptic currents (sIPSCs) 
 
To determine the frequency of sIPSC events in a given recording, all visible 
events in an epoch were identified using MiniAnalysis software (Synaptosoft 
Inc., Fort Lee, New Jersey, USA), and inter-event interval times determined. Not 
all events are appropriate for further analysis because, for example, their decay 
is contaminated with the presence of another sIPSC event. Only clean, 
uncontaminated events were selected for decay fitting in MiniAnalysis, using 
either a mono- or bi-exponential function. The best fit was determined by eye 
and also by the increasing value of the parameter R2. In order to combine 
analysis of mono- and bi-exponentially decaying events, decay times were 
transformed to a weighted decay time, w, according to equation 3. 
 
 Equation 3 
w = (A1. 1 + A2. 2) / (A1 + A2); 
Where 1 and 2 are the time constants for a biexponential decay, and A1 and A2 
are the relative amplitude contributions of 1 and 2, respectively. For 
monoexponential decay, terms A2 and 2 are absent (i.e. w = 1). 
 
For each IPSC event, four parameters were measured: rise time, amplitude, w 
and area (charge transfer). A minimum of 100 events per condition (control vs. 
                                            
2
 Both controls gave equivalent results so have been combined 
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drug) were fitted, and average sIPSC parameters were determined. The results 
are expressed as a percentage change for the test epoch relative to the control 
epoch in that cell; i.e. +30% and -30% would represent a 30% increase and 
decrease, respectively, for a particular parameter.  
 
 
2.6.4. Analysis of tonic GABA currents 
 
Tonic currents are revealed by observing a reduced holding current and root 
mean square (r.m.s.) current noise on application of the competitive GABAA-
receptor antagonist, 20 µM bicuculline. Changes in holding current were often 
small (less than 10 pA) and changes in r.m.s. noise proved to be a more robust 
and reliable measure of changes in tonic current in this study. WinEDR (version 
3.1) software (John Dempster, University of Strathclyde, Glasgow, UK) was 
employed to measure r.m.s. noise over 100 ms epochs of a recording. The 
presence of any synaptic events in a single 100 ms epoch will increase the 
r.m.s. value, and so such epochs must be excluded from analysis. It is possible 
to do this manually by scrolling through records and marking those 
contaminated epochs for exclusion, but we used an automated procedure. 
Briefly, Microsoft Excel was employed to compare the r.m.s. value of each 100 
ms epoch to a user-defined threshold, and automatically exclude those with 
values above the threshold as ‘contaminated’. The threshold is defined as a 
proportion of the median r.m.s. current over a local 5 s window of recording (50 
x 100 ms epochs). This ‘thresholding approach’ was validated by comparison 
with a small section of data (approx. 60 s) where contaminated 100 ms epochs 
were excluded manually. This threshold was then applied to the remainder of 
the data from that cell. For both tonic and synaptic current analyses, time 
courses indicated that the full effect of drug was achieved within 5 min, and so 
data report the changes in r.m.s. noise or IPSC parameters after at least 5 min 
equilibration of drug. 
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2.7. Behavioural Analyses 
 
2.7.1. Animal handling and drug administration 
 
All experimental procedures were performed between 07:30h and 12:30h. 
Animals were transferred from their housing facility to the experimental room 1 
hour before testing commenced. During this habituation time, mice were housed 
individually in cages, with access to ample food and water. All animals were 
used in a single behavioural test, and were experimentally naïve. Before 
behavioural testing, mice were subjected only to routine handling for husbandry 
and ear notching. 
 
Where drugs were administered, mice received substances by intraperitoneal 
injection (27 gauge ½” needle, 1 ml syringe) at a volume of 10 ml per kg body 
weight. The timings of injection were either 15 min (THDOC, sodium 
pentobarbital) or 30 min (diazepam) before behavioural testing. THDOC was 
dissolved in 0.9% w/v NaCl containing 25% w/v 2-hydroxypropyl-β-cyclodextrin 
vehicle. Diazepam was prepared in 0.9% w/v NaCl containing 3.5 % v/v DMSO 
vehicle. Sodium pentobarbital was dissolved directly in 0.9% w/v NaCl. Dose-
ranges and timings for injection were determined by examining those used 
elsewhere in the literature and by performing preliminary experiments with 
these mice (e.g. timecourses for the action of THDOC elsewhere (Crawley et 
al., 1986) and here (Fig. 2.8) indicate that anxiolytic and motor-impairing effects 
peak within 15 min post intraperitoneal injection). 
 
 
2.7.2. Elevated plus maze 
 
The elevated plus maze is a standard screen for anxiety-like behaviour, 
validated with anxiolytic drugs (Pellow et al., 1985; Pellow & File, 1986). The 
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maze comprised a horizontal black Perspex cross, with a central square of 50 x 
50 mm, from which extend four arms, each to a length of 300 mm (Fig. 2.5). 
Two ‘closed’ arms were surrounded by black Perspex walls (height 150 mm), 
and the other two ‘open’ arms had only a raised edge (approx. 2 mm). The 
maze was elevated 500 mm above the floor of the experimental room, and the 
illumination across the arms was uniform and low intensity (approximately 25 
lux, equivalent to 25 lumen per square metre). 
 
Mice were placed in the centre of the maze, initially facing one of the closed 
arms. Their movements within the maze over a 5 min trial were monitored with 
a Sony Handycam (HDR-CX-190E) camcorder mounted 1.5 m directly above 
the maze. Between tests, the maze was wiped down with distilled water, and 
allowed to dry. The number of entries into each arm and the time spent in each 
arm was scored blind to genotype. A mouse was defined as having entered an 
arm when all four paws were within the boundary of the arm. The percentage 
time in an arm is expressed as (time in arm / total time of experiment) x 100. 
 
 
Figure 2.5 – The elevated plus maze 
The maze is depicted from plan (top) 
and side elevation views (bottom). The 
closed arms (C) have black Perspex 
walls 15 cm high, whilst open arms (O) 
have only a slight raised edge. The 
maze is elevated by mounting on a 
tripod, and behaviour on the maze is 
scored from a video captured by a 
camera mounted above the maze. 
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For examining baseline anxiety levels, three mice were tested each day – one 
of each genotype – in a randomized order. When examining the anxiolytic 
effects of drugs, mice were tested in pairs (one hom and one wt), where the 
drug dose received, and the order in which mice were tested (wt first vs. hom 
first) had been randomised. Videos were scored blind to both the genotype and 
drug administered. 
 
Note that whilst some investigators include a series of ethological measures of 
‘risk assessment’ in their anxiety studies (Rodgers & Johnson, 1995, 1998), we 
have not included this analysis here for a number of reasons. There is a degree 
of subjectivity and ambiguity when scoring particular risk assessment 
behaviours, not aided by our study using a black mouse, which is filmed on a 
black background under dim lighting. Moreover, it is difficult to say what a 
reduction in risk assessment behaviour actually represents: reduced anxiety, 
increased anxiety or activity effects (Blanchard et al., 1990). We have therefore 
focussed on spatiotemporal scores for anxiety (percentage time on open arms 
etc.), which respond more consistently to a range of anxiolytics than ethological 
measures (Rodgers & Johnson, 1998). 
 
 
2.7.3. Light-Dark Box 
 
The light-dark box is a standard screen for anxiety-like behaviour, with validity 
for anxiolytic drugs (Crawley & Goodwin, 1980). The box dimensions were 20 x 
45 cm, which were divided into a light zone (850 lx) and a dark zone (50 lx) 
connected by a small doorway. The light zone has an area twice that of the dark 
zone and the floors of each zone are marked with a grid to allow scoring of 
activity (Fig. 2.6). A mouse was placed initially in the light zone, facing away 
from the doorway, and was then allowed to freely explore the box for 10 min. 
Three mice did not move for at least the first 5 min of the test, and have been 
excluded from the analysis. Between tests, the box was wiped clean with 
distilled water, and allowed to dry. 
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Figure 2.6 – The light-dark box  
Plan view is shown. The light zone 
consists of white Perspex floor and walls 
(25 cm high), and the dark zone of black 
Perspex. Zones are connected by a small 
doorway at floor level. The floor of each 
zone is divided into equally-sized squares 
(5 x 5 cm) to allow activity to be scored 
(see main text).  
 
 
To compare the effects of genotype on baseline anxiety, four mice were tested 
each day (two wt and two hom) – in a randomised order. To compare the effect 
of drug treatments, mice were tested in pairs – one wt and one hom; the order 
in which they were tested (wt first, or hom first), and the drug dose received, 
were randomised.  
 
A video record of the test was scored blind to the genotype and any drug 
treatment of the mouse. Scoring assessed the time to leave the light zone, the 
time spent in each zone, the number of transitions between each zone. In 
addition, the exploratory activity within each zone was measured by counting 
the number of grid-lines crossed, then correcting for the amount of time spent in 
each zone (i.e. activity is expressed as line crossings per second).  
 
 
2.7.4. Tail-suspension test 
 
The tail suspension test is a standard screen for depression, with validity for 
anti-depressant drugs (Steru et al., 1985; Thierry et al., 1986). Mice were 
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suspended by the tail with 19 mm wide PVC insulation tape (Powerlink Plus+, 
Lancashire, UK) from a metal bar, raised 55 cm above the benchtop (see Fig. 
2.7). Because of the tendency of the C57BL/6J strain to climb their tail in this 
test, the ‘climbstopper’ approach described by Can et al. (2012) was used – i.e. 
a small plastic cylinder (4 cm long, 1 cm internal diameter, approximately 1 
gram weight) was placed over the base of the tail before attaching the sticky 
tape. With the equipment depicted in Fig. 2.7, four mice can be tested 
simultaneously. The mice cannot observe or interact with each other due to the 
opaque dividers between compartments. Two wt and two hom animals were 
tested together, with the drug dose applied, and compartment in which they 
were placed, determined in a counterbalanced, randomised design. The 
behaviour of mice was filmed over a 6 min period. 
 
The scoring was performed blind to the genotype and drug dose applied, using  
an Xnote stopwatch (dnSoft Research Group) to count the cumulative time for 
which the mouse is immobile over the six minutes of the test (Can et al., 2012). 
Small movements of front paws, without hind leg movements, are not counted 
as escape-related mobility; similarly pendulum-like motion, resulting from 
momentum gathered in previous bouts of motion, is not counted as mobility. An 
increased immobility can represent a depressed phenotype, although care must 
be taken to ensure this is not a sedative effect. Conversely a decrease in 
immobility is thought to represent a reduction in depression, again taking care to 
ensure this is not a stimulant effect. 
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Figure 2.7 – Tail suspension 
test equipment  
A white box 60 cm in height is 
divided into four compartments, 
13 cm wide and 11 cm deep. 
Mice are suspended from an 
aluminium bar (grey), elevated 
55 cm above the bench top, 
using sticky tape (blue). Before 
attaching to the bar, tails are 
also fitted with a climbstopper 
(see main text). Dividers 
between compartments (black 
lines) prevent mice from 
observing one-another during 
the test. 
 
 
2.7.5. Rotarod 
 
The rotarod test is a standard screen for motor coordination defects induced by 
genetic mutation or drug treatment of rodents (Dunham & Miya, 1957; Jones & 
Roberts, 1968). Mice were placed on a five-station rotarod treadmill apparatus 
(Med Associates Inc., Vermont, USA) with the rod rotating at an initial speed of 
4 r.p.m. The rod was then programmed to accelerate uniformly over a period of 
5 min up to a final speed of 40 r.p.m. If a mouse failed the test by falling off the 
rod before the full 5 min trial, it was removed from the apparatus until the next 
trial. The time at which a mouse fell from the rotarod was recorded by the 
MedAssociates software, triggered by a photocell beam break. In some 
instances, a mouse will hold on to the rod and rotate with it – termed a ‘passive 
rotation’ – this is also considered a failure; the time at which this occurred was 
noted manually. If a mouse completed the full test, the ‘time to failure’ was 
simply set as the duration of the test (300 s). 
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The performance of each mouse on his first encounter on the rod (green bar, 
Fig. 2.8) was used as a measure of the baseline motor coordination. Each 
mouse was subjected to further training on the rotarod, such that a consistent 
performance was attained before the effect of drug was assessed. Training 
consisted of 5 trials on the rotarod per day, with a 10 min break between trials 
(Fig. 2.8); training was carried out over four consecutive days. On the fifth day, 
each mouse mice was injected intraperitoneally with THDOC (or vehicle) 15 min 
before his first exposure to the rod (arrow, Fig. 2.8). The drug dose 
administered to each mouse was pre-determined by a counterbalanced 
randomisation procedure. 
 
To assess any impairment of motor coordination caused by a drug, the 
performance of each mouse under drugged conditions was expressed relative 
to that mouse’s average performance on the rod on the preceding day (i.e. 
average of blue trials, Fig. 2.8). Each mouse was tested five times under the 
influence of drug, once every 15 min, starting from 15 min after injection. The 
recovery from any motor impairment induced by THDOC was fast (Fig. 2.8B), 
therefore the effect of THDOC was expressed as the time to failure on the first 
trial after injection, normalised to the trials on day 4 of training. 
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Figure 2.8 – Rotarod protocol 
A. The rotarod protocol; each downward bar represents a 5 min trial on the 
accelerating rotarod, mice were rested 10 min between exposures. The first exposure 
(green) gives a measure of baseline motor coordination. On the testing day, mice were 
injected (red arrow) 15 min before exposure to the rotarod. The performance under the 
influence of drug (red) is normalised to the average performance under non-drugged 
conditions after training (blue). 
B. The motor-impairing effects of 20 mg/kg THDOC were short-lived, and most clearly 
apparent in the first trial (15 min after injection); recovery to baseline was achieved by 
trial 3 (45 min after injection). Comparisons therefore focus on the trial-1 effects of 
THDOC. 
 
 
 
2.8. Statistics 
 
All data are presented as mean ± standard error of the mean (s.e.m.). Graphical 
representations of data were plotted using Microcal OriginPro (version 8.5; 
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OriginLab Corporation, Northampton, MA, USA), and figures assembled using 
CorelDraw (version X4; Corel UK Ltd., Maidenhead, Berks, UK). 
 
For most of the data analyses, parametric comparisons (analysis of variance 
(ANOVA) and t-test) were first considered for use. These tests assume that the 
data are normally distributed, and that the variances of the compared groups do 
not differ. Tests were performed to verify that these constraints were met (e.g. 
Bartlett’s test to compare standard deviations of data sets). Where the data did 
not satisfy these conditions, they were variously transformed (e.g. logarithmic 
transform), and the criteria were reassessed before proceeding with any 
statistical comparison. In instances where transformation was unable to 
produce data satisfying the conditions for parametric comparison, data were 
instead subjected to non-parametric analysis using the Kruskal-Wallis test. If, by 
applying the Kruskal-Wallis test to all the data indicated a significant variation 
between discrete groups, individual pairwise comparisons were performed 
using InVivoStat (British Association for Psychopharmacology, Cambridge, UK), 
which recommends the Behrens-Fisher test in preference to the Mann-Witney 
(although both tests generally gave equivalent results), primarily because it 
allows for non-normal distributions (e.g. skewed) and heteroscedascity of the 
data (Munzel & Hothorn, 2001). Furthermore, when comparing the analysis of 
known data-sets, the Behrens-Fisher test gave the most robust statistics 
(Steland et al., 2011). 
 
Parametric one-way ANOVA and t-test comparisons were performed using 
InStat 3 (GraphPad Software, La Jolla, California, USA), with all-pairwise 
comparisons performed, and adjusted for multiple comparisons with the method 
of Bonferroni. For the time-course analysis of light-dark box results, repeated 
measures ANOVA was performed, with individual pairwise comparisons 
performed for each time bin relative to bin 1, using Dunnett’s test. 
 
Parametric two-way ANOVA were performed using InVivoStat to report the 
Fisher’s least-significant difference (LSD) p-values from planned individual 
pairwise comparisons (i.e. not every individual pairwise comparison was made, 
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but only a selected proportion were chosen, on the basis of scientific relevance, 
before the experiment commenced). Even though the probability of a type I 
error (inappropriate rejection of a null hypothesis) was reduced by using only 
planned comparisons, the risk of such an error is high when considering the 
large numbers of comparisons made within each experiment (as high as 25). 
We therefore adjusted the LSD p-values using the method of Benjamini and 
Hochberg (Benjamini et al., 2001). This is a means to control the 'false 
discovery rate', which limits the proportion of type I errors to 5%. When 
considering such a large number of comparisons, we favour this approach over 
that of Bonferroni (which reduces the significance level, alpha, in proportion to 
the number of comparisons made). The Bonferroni method controls the family-
wise error rate, ensuring a 5% chance of a single type I error from all 
comparisons made, but this increased robustness comes at the price of a high 
type II error rate (failing to reject null hypotheses that should be rejected). 
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Chapter 3: Creating a transgenic mouse with disrupted neurosteroid 
potentiation at the GABAA receptor α2 subunit 
 
3.1. Introduction 
 
As discussed in the Section 1.2.2, observations that GABAA receptor Cl
- 
conductance is modulated in a stereo-selective and biphasic manner by 
neuroactive steroids led to proposals that there are two specific neurosteroid 
binding sites on the GABAA receptor: an “activation site” and a “potentiation 
site” (Harrison & Simmonds, 1984; Harrison et al., 1987; Puia et al., 1990; Paul 
& Purdy, 1992). In defining these neurosteroid binding sites, Hosie et al. (2006) 
demonstrated that hydrophobic substitution of a critical α1Q241 residue was 
sufficient to selectively disrupt neurosteroid potentiation. For example, mutation 
α1Q241M eliminated potentiation by allopregnanolone, with minimal effects on 
receptor activation by GABA and modulation by other allosteric ligands 
(barbiturates, benzodiazepines). This work also demonstrated that the full effect 
of neurosteroid binding to the activation site is only achieved by concomitant 
binding of neurosteroid molecules to the potentiation site (i.e. mutation α1Q241M 
disrupts both potentiation and direct activation by neurosteroids). Hydrophobic 
substitution of the conserved α1Q241 residue has been extended to the other five 
α subunit isoforms, in every case the substitution disrupted potentiation by 
neurosteroids (Hosie et al., 2009). 
 
This discovery provided a unique opportunity to dissect the roles of the various 
α subunit isoforms in the physiological and pharmacological functions of 
neurosteroid molecules. By creating a knock-in transgenic mouse in which 
genomic DNA encoding specific α subunit has been replaced with a Q-to-M 
mutant copy of the receptor, one can assess the consequences of losing 
neurosteroid modulation of that receptor subtype on synaptic inhibition and 
mouse behaviour. Whilst such questions could be addressed with α-subunit 
knock-out mice, this approach is often hampered by lethality (e.g. γ2 knock-out 
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mice are not viable, restricting study to heterozygous knock-outs (Gunther et al., 
1995)) or results in compensatory changes in expression of other subunits (e.g. 
α1-/- mice show increased expression of α2 and α3 subunits (Kralic et al., 
2002)). With the knock-in approach, mutant receptors should be expressed and 
respond to GABA as if wild-type (Hosie et al., 2006). Phenotypic changes in the 
mouse would therefore probably result from lack of neurosteroid function at this 
receptor, rather than a compensatory alteration in expression. However, caution 
should be exercised when making such an assumption: our model would 
involve losing response to endogenous molecules, and the effects of losing any 
such modulation under baseline conditions may be significant, and theoretically 
could result in compensatory changes. The latter half of this chapter deals with 
verifying a lack of compensation in our transgenic model. 
 
In this body of work, the Q-to-M substitution has been introduced in the α2 
subunit – i.e. knock-in mice harbouring the mutation α2Q241M have been 
generated. Whilst the α2Q241M mutation has been shown to disrupt potentiation 
by neurosteroid (Hosie et al., 2009), further criteria must be met by the mutation 
for it to be appropriate for the mouse model; specifically that GABA sensitivity is 
preserved, and subunit expression should be unperturbed. We would also 
expect benzodiazepine potentiation to be unaffected by the mutation. These 
features have been verified in this study by characterising responses of α2β3γ2 
GABAA receptors expressed in HEK293 cells. This approach was also used to 
probe the effects of concurrent modulation of these receptors with neurosteroids 
and benzodiazepines. 
 
The α2 isoform was selected as the first candidate for generating a knock-in 
mouse because of its strong links with the mammalian anxiety circuitry (see 
Section 1.3.2), and we predict that neurosteroid anxiolysis will occur via α2-type 
GABAA receptors. This hypothesis is addressed in later chapters, but firstly 
screens must be performed to ensure a lack of underlying compensatory 
changes that could account for any behavioural effects of the mutation. In this 
study, assays to measure GABAA receptor expression at the protein level have 
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been chosen (Western blot and quantitative immunofluorescence), as these are 
the proteins that ultimately mediate inhibitory transmission. GABAA receptor 
subunits α1-α5 were selected as the most likely candidates to be up- or down-
regulated in response to the mutation, and so subjected to quantitation. Assays 
were focussed on four brain areas that express GABAA receptor α2 subunits – 
cortex, hippocampus, cerebellum and nucleus accumbens (Laurie et al., 1992a; 
Wisden et al., 1992; Sperk et al., 1997; Pirker et al., 2000; Sieghart & Sperk, 
2002). 
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3.2. Results 
 
3.2.1. Confirming that α2Q241M has no effect on GABA and diazepam sensitivity 
of αβγ receptors 
 
The effects of α2Q241M on receptor function were examined by characterising α2-
containing GABAA receptors expressed in HEK293 cells. This cell line has been 
used widely as a platform for expression and study of GABAA receptor 
properties. Because of their non-neuronal origin, these cells do not express 
endogenous GABAA receptors (although there has been evidence for some low 
level expression of β3, γ3 and ε subunits (Thomas & Smart, 2005)), allowing 
one to control the composition of GABAA receptor heteropentamers under 
study. For electrophysiology, cells were transfected with expression plasmids 
for each of the subunits in the combination α2β3γ2S, together with an 
expression plasmid for eGFP (see Section 2.5). This combination of receptor 
subunits is thought to be representative of native α2-type GABAA receptors in 
vivo (Benke et al., 1994; McKernan & Whiting, 1996).  The eGFP allows 
identification of transfected cells, by their green fluorescence, for study by 
whole-cell patch clamp electrophysiology. 
 
Peak current responses of wild-type (α2β3γ2S) and mutant (α2Q241Mβ3γ2S) 
receptors were measured in response to brief (2-4 s) applications of GABA at 
concentrations 0.01-1000 µM (Fig. 3.1 C). GABA concentration-response data 
were collected for each cell, and fitted with the Hill equation (Equation 1, 
Section 2.5.3). Mean Hill-fit parameters, EC50 (the concentration of GABA 
eliciting a 50% maximal response) and n (Hill coefficient), for wild-type and 
mutant receptor combinations are not different (Table 3.1). This is consistent 
with previous observations that the α2Q241M mutation is without effect on the 
GABA sensitivity of the α2β3γ2S receptor (Hosie et al., 2009). The lack of effect 
of the α2Q241M mutation on the GABA sensitivity can also be appreciated by 
noting the good superimposition of the mean GABA concentration-response 
curves for these receptors (Fig. 3.1 A). 
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To confirm that the α2Q241M mutation did not affect benzodiazepine modulation, 
concentration-potentiation curves for diazepam potentiation of wild-type and 
mutant receptors were constructed, as outlined in Section 2.5.3. Briefly, peak 
current responses of a transfected cell to 0.5 µM GABA (EC15 response) co-
applied with varying concentrations of diazepam were normalised to peak 
current responses to 0.5 µM GABA alone within that cell. As above, 
concentration-potentiation curves were constructed for each cell, this time using 
a modified Hill equation, to include a pedestal (Equation 2, Section 2.5.3). The 
mean fit parameters, summarised in Table 3.1, are very similar. There is a small 
but significant increase in the Hill coefficient for mutant vs. wild-type receptors, 
but when mean data are plotted together (Fig. 3.1 B) the concentration-
potentiation curves are superimposed. The diazepam sensitivity of the α2β3γ2S 
receptor combination is therefore unchanged by α2Q241M mutation, consistent 
with previous work characterising this mutation on α1 (Hosie et al., 2006). 
These data demonstrate that this substitution specifically abolishes potentiation 
by neurosteroids. 
 
Dose relationship 
 
wild-type Q241M 
GABA concentration-response 
EC50 (µM) 3.0 ± 0.8 3.2 ± 0.4 
n 1.2 ± 0.2 1.2 ± 0.1 
Diazepam concentration-potentiation 
Pmin 0.9 ± 0.04 1.0 ± 0.03 
Pmax 2.9 ± 0.2 2.9 ± 0.3 
EC50 (nM) 50 ± 16 38 ± 11 
n 1.0 ± 0.1 1.7 ± 0.3* 
Table 3.1 – Hill fit parameters for GABA and diazepam responses 
Summary of the fits (mean ± s.e.m.) for GABA and diazepam concentration-response 
curves. Pmax and Pmin correspond to the maximum and minimum points on the 
diazepam potentiation curve. The Q241M mutation significantly increases the Hill 
coefficient (n) for diazepam potentiation (* p < 0.05 vs. wild-type, Mann-Witney test). 
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Figure 3.1 – Mutation α2Q241M has no effect on the GABA or diazepam sensitivity 
of α2β3γ2S receptors expressed in HEK293 cells 
A. and B.  Concentration-response curves for wild-type (blue) and mutant (grey) 
α2β3γ2S receptors expressed in HEK293 cells. Peak GABA responses are 
normalised to the maximal response in each cell (A). Potentiation of GABA EC15 
responses by diazepam (B) is expressed as the peak response to GABA plus 
diazepam relative to the response to GABA alone. Each graph represents the mean 
responses across 7-8 cells (error bars, s.e.m.; 3-8 data points per concentration). 
C. Representative membrane currents on short applications of the indicated GABA 
concentrations (µM) to wild-type (blue) and mutant (grey) receptors 
 
 
 
 
Chapter 3: Creating a transgenic mouse with disrupted neurosteroid 
potentiation at the GABAA receptor α2 subunit  86 
 
 
3.2.2. Probing the effect of α2Q241M on responses to both THDOC and diazepam 
 
When considering the effect of pharmacological potentiators of GABAA 
receptors in vivo, one must not forget that neurosteroid molecules are produced 
endogenously. This suggests that whilst the potentiating effect of diazepam on 
α2Q241Mβ3γ2S receptors may be normal when receptors are assessed in 
HEK293 cells, the level of diazepam potentiation may not be ‘wild-type like’ 
when taking place on a background of endogenously-synthesised neurosteroid 
in vivo. 
 
To assess the significance of this, transfected HEK293 cells were used to 
examine the effects of co-applying the neurosteroid THDOC together with 
diazepam, on the potentiation of an EC15 GABA response. A typical experiment 
is depicted in Fig. 3.2 C; briefly, peak current responses to 0.5 µM GABA were 
compared with those achieved by co-application of 0.5 µM GABA together with 
either DMSO vehicle (V), 100 nM THDOC (T) alone, 500 nM diazepam (D) 
alone, or both THDOC and diazepam (T + D) together. As can be seen in Fig. 
3.2 A, in wild-type α2β3γ2S receptor-expressing cells there is no effect of 
vehicle, and the effects of T and D are similar, and are approximately additive, 
when both substances are applied together. Conversely, in mutant 
α2Q241Mβ3γ2S receptor expressing cells (Fig. 3.2 B), there is no effect of 
THDOC alone or when co-applied with diazepam (i.e. potentiation by T + D co-
application is no different to that for D alone).  
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Figure 3.2 – Mutation α2Q241M specifically abolishes the potentiating effect of 
THDOC on GABA EC15 responses of α2β3γ2S receptors expressed in HEK293 
cells 
A. and B.  Bar charts outlining the degree of potentiation achieved by co-application of 
vehicle (V), 100 nM THDOC (T), 500 nM diazepam (D) or both THDOC and diazepam 
(T + D) with 0.5 µM GABA (G). Responses are normalised to the preceding peak 
response to 0.5 µM GABA alone. Effects of THDOC and diazepam are additive in wild 
type receptors (A, n=11 cells); THDOC has no effect on α2Q241M mutant receptors (B, 
n=6 cells). Significant effects of treatments are highlighted: ** p < 0.01 effect of 
substance vs. G alone; ++ p < 0.01 effect of T + D vs. response to T alone or D alone 
(ANOVA, multiple comparisons corrected with Benjamini-Hochberg adjustment). 
C. Representative membrane currents for wild-type (blue) and α2Q241M mutant (grey) 
α2β3γ2S receptors expressed in HEK293 cells. 
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3.2.3. Generating an α2Q241M knock-in transgenic mouse 
 
The process of generating the mouse strain is described more fully in Section 
2.2.1; this stage of the project was performed by performed by Mike Lumb, a 
molecular biology technician in the lab, in collaboration with GenOway (Lyon, 
France). Briefly, wild-type exon 8 of α2 subunit genomic DNA in embryonic stem 
(ES) cells was precisely replaced with exon 8 containing the desired base-pair 
changes (CAA to ATG) for point mutation Q241M. ES cells that have 
successfully undergone homologous recombination were used to generate a 
transgenic mouse line with the α2Q241M mutation on a C57BL/6J background.  
 
Homozygous (hom) knock-in mice are viable and fertile, and there are no overt 
effects of the mutation on the general appearance of the mice. Animals were 
maintained as heterozygous (het) breeding pairs, to allow comparison of hom 
knock-ins with wild-type (wt) littermates. This is preferable over separately 
maintaining wt and hom lines, where genetic drift between the two populations 
could contribute to, or account for, any observed phenotypic differences (Bailey, 
1982). 
 
 
3.2.4. α2Q241M has no effect on the expression of GABAA receptor subunits α1-
α4 in Western blot assays 
 
Total protein was isolated from four brain regions of interest (cortex, cerebellum, 
hippocampus and nucleus accumbens (NAcc)) as described in Section 2.3.1. 
Equal amounts of protein from six wt, six het and six hom males were subjected 
to Western blot analysis for each of the four GABAA subunits α1, α2, α3, and α4 
(where detectable) using subunit-selective antisera (subunit specificity of 
antibodies was confirmed by blotting recombinant receptors – for details see 
Section 2.3.2). 
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Figure 3.3 – No change in expression of GABAA subunits α1-α4 
Bar charts detail the relative expression levels of each GABAA receptor subunit in 
protein samples from each brain area. There are no significant effects of genotype on 
expression of any subunit in any brain area tested (p values in black indicate results of 
parametric one-way ANOVA, those in green refer to non-parametric Kruskal-Wallis test 
results). n.d. - not determined because no reliable signal was obtained with calibration 
blots. Bottom: representative Western blots. 
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The blotting conditions were optimised by running a series of titrations to 
determine the amount of total protein which, when blotted under the conditions 
outlined in Section 2.3.2, produces a signal in the middle of the dynamic range 
of the detection system. When working under such conditions, one maximises 
the chances of detecting any up- or down-regulation of GABAA subunit 
expression. As can be seen from results of the Western blot assay (Fig. 3.3), 
there are no significant effects of genotype on subunit expression for any of the 
detectable subunits in any of the brain areas assayed.  
 
 
3.2.5. α2Q241M has no effect on the expression of GABAA receptor subunits α1-
α5 in quantitative immunofluorescence assays  
 
Three mice of each genotype (wt, het, hom) were sacrificed with a lethal 
overdose of sodium pentobarbital and brains were fixed by cardiac perfusion as 
described in Section 2.4.1. Thin (40 µm) coronal sections were obtained from 
frozen brain, and subjected to immunofluorescent staining and confocal z-stack 
image acquisition. Representative example images for the three areas studied – 
CA1 region of the hippocampus, the dentate gyrus (DG) and the NAcc – are 
shown in Fig. 3.4. The CA1 images encompass the cell body layer and apical 
dendrites, the DG images encompass the granule cell layer and molecular layer 
of the medial blade, and NAcc images include both core and shell regions. 
 
The staining for α1 in both hippocampal regions is similar, showing a mixture of 
punctate and diffuse staining, with some cells showing much more intense 
staining of cell bodies and dendrites than others. Such a distribution of α1 has 
been seen by other investigators staining under similar conditions, using a 
different antiserum (Benke et al., 1994; Mtchedlishvili et al., 2003). Staining for 
α1 in the NAcc was rather different, showing a variable number of bright 
Chapter 3: Creating a transgenic mouse with disrupted neurosteroid 
potentiation at the GABAA receptor α2 subunit  91 
 
 
punctae against a high background. This led to problems with quantification, as 
discussed in more detail below. 
 
Immunostaining for α2 was similar and strong in all three areas examined. 
Punctate staining is seen throughout cell body and dendritic layers of both 
regions of the hippocampus. Similar staining for α2 in the DG has been 
previously published (Benke et al., 1994). Uniformly-distributed punctate 
staining is also seen throughout the NAcc core and shell (as would be expected 
from the work of Pirker et al. (2000)). 
 
As expected from immunohistochemical work by other investigators (Sperk et 
al., 1997), immunofluorescent staining for α3 is much less intense than α1 and 
α2, showing fewer bright punctae against a very low background. The 
expression of α3 was rather heterogeneous throughout the NAcc: some clusters 
of cells showing very intense staining, whilst other areas have fluorescence at 
background levels. There were no obvious structural correlations that could 
explain this variation – neither a difference in core vs. shell regions of the NAcc, 
nor a clear anterior-posterior pattern of staining between coronal slices. The 
only common feature noted was a thin bright band of staining surrounding a 
dark region which often correlated with the very edge of the shell (asterisks on 
Fig. 3.4 C), but this was not true of every slice (c.f. wt, het and hom images in 
Fig. 3.4 C, all representing expression in a similar position of the NAcc). To 
ensure the mean fluorescence measure of expression accounts for this patchy 
distribution, images of α3 in the NAcc were acquired with a lower power lens 
(20x magnification vs. 63x in all other images) to encompass a larger field of 
view. 
 
The α4 subunit shows a stronger expression in molecular layer than the granule 
cell layer of the DG, with an almost opposite distribution in CA1 (i.e. intense 
diffuse staining in the cell bodies and proximal regions of dendrites, and less 
intense staining in the dendritic region). It was also noted that there was an 
anterior-posterior variation in α4 expression, with more intense staining of 
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coronal sections corresponding to more anterior slices. This subunit also 
appears to be expressed well in the NAcc, as was expected from 
immunohistochemical work (Pirker et al., 2000), and shows a mixture of diffuse 
and punctate staining uniformly throughout the structure. 
 
The α5 isoform shows strong diffuse staining of cell bodies in all three regions 
studied. Staining in CA1 is very much like that for α4, except that no clear 
anterior-posterior variation was noted. In both CA1 and DG images, α5 can also 
be seen to have punctate staining uniformly throughout the dendritic region. 
This pattern for hippocampal α5 staining is most consistent with that seen by 
Prenosil et al. (2006). Similar strong expression of α5 in cell bodies is noted for 
staining in the NAcc, with no obvious difference between core and shell regions. 
Interestingly, Wisden et al. (1992) fail to detect α5 subunit expression in the 
NAcc at the level of mRNA. However, Pirker et al. (2000) observed α5 subunit 
expression in the NAcc using immunohistochemistry, which is described as 
weak and diffuse; unfortunately an image of this staining is not presented in this 
work, precluding a detailed comparison with our α5 staining pattern. 
 
 
Figure 3.4 – Immunofluorescent localisation of GABAA subunits α1-5 in coronal 
sections of hippocampus and nucleus accumbens (images on following pages) 
A. Representative images for immunofluorescent staining in the CA1 region of the 
hippocampus. Images were acquired with the 63x lens at 1x zoom, and encompass the 
cell body layer and the apical dendrites. Scale bar, 30 µm. 
B. Representative images for immunofluorescent staining in the dentate gyrus. Images 
were acquired with the 63x lens at 1x zoom, and encompass the granule cell layer and 
molecular layer of the medial blade. Scale bar, 30 µm. 
C. Representative images for immunofluorescent staining in the nucleus accumbens. 
Images for α1, α2, α4 and α5 were acquired with the 63x lens at 1x zoom; images for 
α3 were acquired with the 20x lens at 1x zoom. Scale bars, 30 µm. Red asterisks 
highlight examples of where strong α3 subunit immunoreactivity corresponds with the 
outer edge of the nucleus accumbens shell. 
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Fig 3.4 A – Hippocampal CA1 immunofluorescence: representative examples 
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Fig 3.4 B – Dentate gyrus immunofluorescence: representative examples 
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Fig 3.4 C – Nucleus accumbens immunofluorescence: representative examples 
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When quantifying the immunofluorescence, the simplest possible approach was 
employed to ensure that most of the image data was taken into account, and 
that analysis bias was minimised. For images of DG and CA1, z-stacks were 
split into two large regions of interest (ROIs) that encompass either the cell 
body layer or the dendritic region. The mean fluorescence intensity of the entire 
ROI was measured at three points in the z-stack (top, middle, bottom) and 
averaged. This process was performed for images from three coronal sections 
each from three animals of each genotype (i.e. mean values represent data 
from 9 z-stacks). This approach was chosen, rather than attempting to quantify 
expression in finer detail in individual cells, because there is no experimenter 
bias that would be involved in defining cells or dendrites for quantitation. To 
quantify expression in the NAcc, mean fluorescence intensity was measured for 
the entire image, rather than a specific ROI. The results of this simple method of 
quantitation are depicted in Fig. 3.5; no significant variation of subunit 
expression with genotype was detected for any of the subunits tested. 
 
On closer inspection, one may note that some subunits show a trend towards a 
difference in subunit expression across genotypes: α3 expression tends to be 
reduced in the hom DG cell bodies and dendrites; α4 and α5 tend toward 
increased expression in hom DG dendrites; and α1 expression tends to be 
lower in the hom NAcc. These cases are therefore considered in more detail. 
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Figure 3.5 – Quantitation of immunofluorescent staining for GABAA subunits α1-
α5 in coronal sections of hippocampus and nucleus accumbens 
The relative mean fluorescence intensities for each subunit in each brain area are 
summarised in these bar charts. See Section 2.4.3 for details. There are no significant 
effects of genotype on expression of any subunit in any brain area (p values refer to 
Kruskal-Wallis test results).  
 
The contribution of background fluorescence to the mean fluorescence intensity 
values measured here can be a source of error. For example, there are few α1 
punctae against high background fluorescence in the NAcc, so the background 
dominates the mean fluorescence intensity, and could account for the variation 
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seen in apparent expression. A similar problem is faced for α3 expression in the 
DG. In these cases, images were examined with the FociPicker3D plug-in in 
ImageJ, which identifies and quantifies immunopositive punctae by searching 
for local fluorescence maxima in three-dimensions. With these images, the 
plug-in is successful at identifying punctae against the background staining (see 
Section 2.4.3 and Fig. 2.3). Results of this quantitation (Fig. 3.6) confirm that 
there are no changes in the density of immunopositive punctae (punctae per 
unit volume), the size of these punctae, or their intensity, across genotypes. 
 
Interestingly, the number of α1-positive punctae was highly variable from slice-
to-slice for the NAcc (e.g. one het animal gave slices with 112, 234 and 3874 
punctae). There was no obvious positional correlation, either anterior vs. 
posterior or shell vs. core, that could explain this variability. Nevertheless, the 
average puncta densities across all images show no clear variation with each 
genotype, nor are those punctae any different in size or intensity between 
genotypes. 
 
The FociPicker3D approach was not successfully applied to the α4 and α5 
images because they contain a mixture of punctate and diffuse staining (see 
Section 2.4.3 and Fig. 2.3 for more details). Most α5 subunit staining is 
concentrated in the cell body layer in the DG, so the tendency toward 
fluorescence differences in the molecular layer is not a cause for concern. In 
contrast, α4 in the DG is more strongly expressed in the molecular layer, so a 
tendency toward increased mean fluorescence intensity in this region may 
represent an altered expression of this subunit in the knock-in mice. 
Statistically, however, this difference is not significant: the overall Kruskal-Wallis 
test produces a p value of 0.23. Individual pairwise comparisons also fail to 
reach significance (wt vs. het p=0.20, wt vs. hom p=0.20, het vs. hom p>0.99). 
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Figure 3.6 – Quantitation of immunofluorescent punctae for GABAA subunits α3 
in the dentate gyrus and α1 in the nucleus accumbens 
The relative mean density, size and intensities of immunopositive punctae for α3 and 
α1 subunits in the dentate gyrus (DG) and nucleus accumbens (NAcc), respectively, in 
coronal sections from wt, het and hom animals. Punctae were defined using the 
FociPicker3D plug-in for ImageJ software (see main text for details), using either entire 
z-stack images, or just the dendritic ROI (for DG α3 expression). There are no 
significant effects of genotype on expression of either subunit (p values refer to 
Kruskal-Wallis test results). 
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3.3. Discussion 
 
3.3.1. α2Q241M and GABAA receptor function 
 
The mutation α2Q241M has already been shown to abolish potentiation by the 
neurosteroid allopregnanolone (Hosie et al., 2009). Here we extend this finding 
to the neurosteroid THDOC, which fails to potentiate EC15 GABA responses at 
100 nM, when α2Q241M is expressed in the receptor combination α2β3γ2S (Fig. 
3.2). GABA sensitivity is retained in α2Q241M-mutant receptors, which also show 
similar maximal current responses (1 mM GABA responses: wt – 950 ± 100 pA, 
Q241M – 1400 ± 180 pA; p=0.07, unpaired t-test), which is consistent with 
unaltered cell surface expression of the mutant receptors in HEK293 cells. 
Assuming that these properties extend to α2Q241M receptors when expressed in 
vivo, transgenic α2Q241M knock-in mice would be preferred over α2 knock-out 
mouse to study the roles of the GABAA receptor α2 subunit in physiological and 
pharmacological responses to neurosteroids: in the knock-in, the retained 
expression and GABAergic function of the α2-type GABAA receptor would 
ensure that phenotypes of the mouse result only from the loss of neurosteroid 
function at that receptor. 
 
Although not probed in this study, it is expected from previous work (Hosie et 
al., 2006), that neurosteroids will retain action at the direct activation site. 
Nevertheless, the concentrations of neurosteroids required to achieve direct 
activation of the GABAA receptor are in the micromolar range – current 
measurements of neurosteroid levels suggest such concentrations will at best 
be at the very extremes of physiology (e.g. neurosteroid measures in pregnancy 
peak at 100 nM (Paul & Purdy, 1992)), and probably play little role in normal 
function of neurosteroids. Direct activation may become relevant during 
experiments probing responses to injected neurosteroid molecules, where 
levels at the synapse may well climb to those required for direct activation. In 
addition, the full effect of direct activation by neurosteroid appears to require 
concomitant binding and function of neurosteroids at the potentiation site (Hosie 
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et al., 2006). Both potentiation and direct activation by neurosteroids will 
therefore be defective at α2-type GABAA receptors in α2
Q241M knock-in mice. 
 
As was demonstrated for the equivalent mutation on α1-type GABAA receptors 
(Hosie et al., 2006), α2Q241Mβ3γ2S receptors have a wild-type-like response to 
diazepam potentiation (Fig. 3.1). This confirms that the mutation has not simply 
disrupted the ability of the GABA receptor to be potentiated per se, but that the 
lesion is specific to the action of neurosteroids via the potentiation site. The 
1:1:1 ratio of cDNA expression vectors we used was sufficient in this study for 
expression and co-assembly of the γ2 subunit with α2 and β3, as indicated by 
their responses to diazepam (receptors lacking the γ2 subunit would be 
diazepam-insensitive (Pritchett et al., 1989)). 
 
 
3.3.2. No compensatory changes in GABAA receptor α subunit expression in 
α2Q241M mice 
 
Whilst it is generally suggested that a knock-in mouse is preferable over a 
knock-out mouse, because there is a lower risk of compensatory up- or down-
regulation of expression of various proteins, this should always be confirmed. 
For example, a microarray analysis of mice with an α1 or α2-subunit-directed 
knock-in mutation in two residues (S270H, L277A) – that disrupt ethanol 
sensitivity – reveal an array of changes to mRNA levels, implying multiple 
changes to many genes (Harris et al., 2011). Furthermore, unlike the alcohol 
(Harris et al., 2011) or benzodiazepine (Low et al., 2000) site models, our 
transgenic model is losing sensitivity to a modulator that is present 
endogenously. Any compensatory changes in protein expression, particularly 
GABAA receptor subunits, resulting from knocking in the α2
Q241M mutation would 
be interesting, but would also confound the investigation: do any of the 
phenotypes of the mouse result directly from loss of neurosteroid modulation of 
GABAA receptor α2 subunits, or indirectly as a consequence of compensatory 
alterations in the mouse? 
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There are several possible approaches in screening for compensatory changes. 
We chose to focus on methods that assay expression at the protein level 
(Western blot, immunofluorescence), rather than measuring mRNA levels 
(quantitative PCR, microarray) because it is changes of protein expression 
levels that are of functional importance. Our experiments have focussed solely 
on the expression levels of GABAA subunits α1-α5 as likely candidates for 
compensatory changes (the α6 subunit is not widely expressed, only being 
present in cerebellar granule cells and the cochlear nucleus (Laurie et al., 
1992a; Pirker et al., 2000) and was not studied here). Analysing lysates of 
cortex, hippocampus, cerebellum and NAcc for α1-α4 expression showed no 
major global alterations in expression of these subunits. Not every subunit was 
detectable in all brain areas by Western blot (Fig. 3.3), and attempts to utilise an 
α5-selective antiserum in Western blots have proven unsuccessful, but this 
subunit was successfully assayed by immunofluorescence. Similarly, the anti-α4 
antiserum was unable to produce a reproducible, quantifiable, signal for 
expression in whole-tissue lysates from hippocampus or nucleus accumbens, 
but this subunit is nicely detected by immunofluorescence. Subunits α1-α3 were 
successfully probed by both methods. Immunofluorescence allows subunit 
expression patterns to be examined in finer detail than Western blotting. 
Quantitative immunofluorescence focussed on subunits α1-α5 in the areas that 
were subjected to electrophysiological analysis (CA1, DG and NAcc, see 
Chapter 4). Overall, neither method has demonstrated any significant change in 
subunit expression for any of the five subunits. 
 
When comparing immunofluorescent staining obtained in this study with 
immunostaining patterns in other published work, similarities and differences 
can be noted. In accord with work by Mtchedlishvili et al. (2003) and Benke et 
al. (1994), α1 antiserum stains some cells and processes in hippocampal slices 
much more brightly than others, but is otherwise characterised by widespread 
immunopositive punctae. The low abundance of α3 staining in the hippocampus 
is also in agreement with observations by others (Sperk et al., 1997; Pirker et 
al., 2000; Prenosil et al., 2006). Other commonalities include the more intense 
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staining for α2 and α4 subunits in the molecular layer of the dentate gyrus 
(Benke et al., 1994; Pirker et al., 2000; Prenosil et al., 2006). Poor expression 
for α1 subunits in the NAcc has also been demonstrated at mRNA (Sarviharju et 
al., 2006) and protein (Pirker et al., 2000) levels. In addition, the expression 
pattern for α2 in the DG resembles that in work published by others (Benke et 
al., 1994). 
 
Variable hippocampal expression patterns have been described for GABAA 
receptor α5 subunits in the literature. Our work and that of Prenosil et al. (2006) 
finds strong staining in cell bodies, whilst Sperk et al. (1997) and Pirker et al. 
(2000) demonstrate an absence of α5 from the cell body layers. Cell-body 
dominant staining for α5 subunits has also been observed in hippocampal 
sections from young (P7) rats (Ramos et al., 2004), but these investigators then 
observe a pattern reminiscent of Sperk et al. (1997) and Pirker et al. (2000) in 
adult animals. Conversely, punctate staining of cell bodies have been observed 
in hippocampal slices from one month old mice (Farisello et al., 2012). The 
staining patterns obtained in this study were highly reproducible and consistent 
from animal-to-animal and slice-to-slice. Perhaps this apparent variability 
between studies is a consequence of differences in animal age and species, 
and detection methods and antibodies used. 
 
The expression of α subunit isoforms in the NAcc has been reported at the level 
of mRNA (Wisden et al., 1992) and protein (Pirker et al., 2000). The low level of 
staining we observe for α1 subunits is in agreement with these studies. 
Furthermore, our staining patterns for α2, α4 and α5 subunits in the NAcc are 
consistent with the description provided in the work by Pirker et al. (2000), who 
note that all three subunits show diffuse labelling, with the strongest signal for 
α2, and weakest for α5. The NAcc expression levels of α3 are described as low 
by both studies (Wisden et al., 1992; Pirker et al., 2000), but a figure is not 
available for a detailed comparison with our α3 staining pattern. 
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One important caveat of the approach used in this study is that they are 
reporting total protein levels, not just that at the cell surface. If 
immunofluorescence was performed without triton-x-100, only cell surface 
subunit expression would be revealed. However, the thickness of the slices 
used in this study (40 µm) demanded the use of triton-x-100 for antibody access 
to below-surface regions of the slice. Whilst immunostaining neuronal cultures 
may seem a suitable alternative approach to bypass the accessibility issue, the 
subunit expression patterns in a cultured neuron will be further removed from 
natural physiology than obtaining slices from fixed adult mouse brain. Another 
means to address this issue would be to co-stain slices for other markers; for 
example looking at the apposition of GABAA receptor punctae with a pre-
synaptic marker, such as GAD65 or GAD67, would indicate which GABAA 
receptor punctae represent functional, synaptic GABAA receptors. Such an 
experiment would also help to demonstrate whether normal numbers of 
synaptic connections are formed in hom mice. 
 
One must also remember that simply because there is no change in the amount 
of GABAA receptor α subunit, this does not guarantee that their modulation by 
other means is unaffected. Phosphorylation of GABAA receptors represents a 
major means of modulation in vivo, which can also interact with neurosteroid 
modulation (see Sections 1.1.3 and 1.2.3). Perhaps future experiments should 
probe GABAA receptor phosphorylation states in lysates from the α2
Q241M mice 
(e.g. using a phospho-specific antibody in Western blot).  
 
Taken overall, the Western and immunofluorescence data presented here 
suggest that the phenotypes of this transgenic mouse are not a result of large 
changes in protein expression of the GABAA subunits α1-α5. It would be 
surprising if loss of neurosteroid function at α2-type GABAA receptors is not 
accommodated for in some way, and so it may be sensible to consider using a 
microarray or proteomic approach to screen for differences in expression 
patterns in hom vs. wt mice. Any ‘hits’ from this screen could then identify 
targets for further validation. Furthermore, we have not assessed the levels of 
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neurosteroid in the mouse strain, which may represent another avenue for 
compensatory changes. 
 
 
3.3.3. Endogenous neurosteroids may modulate the in vivo response to other 
GABAA receptor potentiators 
 
Retained sensitivity of the Q241M mutant receptors to potentiators such as 
benzodiazepines (Fig. 3.1) and pentobarbital (Hosie et al., 2006) suggests that 
these compounds could be useful for positive controls in this study – for 
example if the anxiolytic response to neurosteroids is diminished in the α2Q241M 
mice, is this a specific consequence of losing the neurosteroid potentiation site, 
or is there some general defect in the anti-anxiety circuitry? If the mice retain 
normal responses to diazepam or pentobarbital, then the latter hypothesis could 
be discounted. 
 
However, there are a few complications to note. Firstly, neurosteroids are 
endogenous molecules, and so any modulator injected into a mouse will have 
its effects on GABAA receptors on top of the baseline modulation by 
endogenous neurosteroids. Secondly, certain benzodiazepines induce an 
increase in endogenous synthesis of neurosteroids, and these have been 
shown to underlie a component of the full in vivo response to these compounds 
(e.g. midazolam’s anti-seizure activity is partly mediated by neurosteroid 
synthesis (Dhir & Rogawski, 2012)). By co-applying neurosteroid with diazepam 
in recombinantly expressed receptors (Fig. 3.2), it can be seen how the α2Q241M 
mutation could affect responses to diazepam in vivo, where endogenous 
neurosteroids are present. This effect must therefore be considered in 
experiments in later chapters that use diazepam and pentobarbital as positive 
controls in these mice. 
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3.4. Conclusions 
 
1. The α2Q241M mutation specifically abolishes potentiation of 
heteropentameric αβγ GABAA receptor function by neurosteroids, whilst 
activation by GABA and potentiation by diazepam are unaffected when 
channels are studied in a heterologous expression system. 
 
2. Transgenic knock-in mice have been generated, in which the wild-type 
copy of α2 genomic DNA has been precisely replaced with a Q241M 
point-mutated version of the receptor. 
 
3. The α2Q241M mutation has no overt effects on the expression of GABAA 
receptor subunits α1-α5 in the transgenic strain, whether present in the 
heterozygous or homozygous state – i.e. phenotypes of the knock-in 
mice can be attributed to the loss of neurosteroid potentiation (rather 
than altered GABAA receptor subunit expression and distribution). 
 
4. Neurosteroids are present endogenously, and so the mutation may alter 
responses to other GABAA receptor potentiators in a whole animal. 
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Chapter 4: Electrophysiological consequences of losing neurosteroid 
modulation at GABAA receptor α2 subunits 
 
4.1. Introduction 
 
Neurosteroids can enhance tonic and phasic GABA transmission, with either 
response expected to reduce neuronal excitability by hyperpolarising the neuron 
and/or by shunting excitatory inputs. The roles of α2 subunits with regards to 
these responses can be defined using homozygous α2Q241M mutant mice: any 
deficiency in the neurosteroid response could be attributed to the lack of 
neurosteroid potentiation at these receptors. To screen for any phenotypic 
effect of the α2Q241M mutation, this investigation focussed on cells within the 
hippocampus and nucleus accumbens, which are known to strongly express the 
GABAA receptor α2 subunit (Fig 3.4; Sperk et al., 1997; Pirker et al., 2000; 
Sieghart & Sperk, 2002; Mohler, 2006a). 
 
 
4.1.1. GABAergic neurotransmission in the hippocampus 
 
The hippocampus is implicated in many processes, including cognition, 
emotion, and the formation of spatial memories (Fanselow & Dong, 2010). 
Moreover, hippocampal pathologies are linked to epilepsy, anxiety disorders 
and depression (de Lanerolle et al., 2003; Bannerman et al., 2004; MacQueen 
& Frodl, 2011). The cytoarchitecture and circuitry of the hippocampus have 
been well defined and comprise two interlocking layers of pyramidal and 
granule cells (Fig. 4.1), both of which are under extensive GABAergic control. 
Hippocampal inputs into the hypothalamus are a major site for stress activation 
of the HPA axis (Brown et al., 1999) and the hippocampus is proposed to be the 
site at which neurosteroids limit HPA axis activation by enhancing GABAergic 
inhibition in this area (see Section 1.3.1). Some of the anxiolytic function of 
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endogenous neurosteroids may involve their action in the hippocampus, and we 
propose that α2-type GABAA receptors will play a central role in this response. 
We have therefore examined inhibitory neurotransmission within the 
hippocampus of α2Q241M knock-in mice using whole-cell patch clamp 
electrophysiology. Experiments have focused on CA1 pyramidal cells (CA1 
PCs) and dentate gyrus granule cells (DG GCs) within acute brain slices. 
Effects of the α2Q241M mutation are likely to be detected in these cell types, as 
both express the α2 subunit. Furthermore, the enrichment of α2 subunits at the 
axon initial segment of CA1 PCs places this receptor in an ideal position to 
inhibit action potential generation (Nusser et al., 1996) and this subunit has 
already been demonstrated to play a significant role in generating IPSCs in 
these cells (Prenosil et al., 2006). Neurosteroid-mediated potentiation of these 
receptors may therefore have profound consequences for firing of these 
neurons within the hippocampal circuit. 
 
A number of observations suggest that tonic currents may dominate in 
mediating the anxiolytic response to endogenous neurosteroid. The increased 
neurosteroid efficacy at δ-containing receptors makes them better poised to 
respond to low levels of endogenous neurosteroids (Belelli et al., 2002; Brown 
et al., 2002; Stell et al., 2003). Furthermore, the anxiolytic response to 
neurosteroid is impaired in δ-/- mice (Mihalek et al., 1999), and Shen et al. 
(2007) find that reduced tonic transmission in the hippocampus induces anxiety 
during puberty in female mice. This may lead to the assumption that α2 
subunits, which are thought to traffic to synaptic, as opposed to extrasynaptic, 
sites (Nusser et al., 1996; Prenosil et al., 2006), will play little role in 
neurosteroid-mediated anxiolysis. However, we are unaware of any evidence 
directly excluding α2 subunits from passing tonic currents. Indeed, synaptic 
receptors could be recruited to support tonic inhibition under certain conditions 
(e.g. increased ambient GABA and/or endogenous neurosteroid levels in the 
synapse could tonically open these channels). Furthermore, receptors can 
move into and out of synaptic sites by lateral mobility within the membrane 
(Thomas et al., 2005); when present peri- or extra-synaptically, classically 
‘synaptic’ α2-type receptors could be involved in passing tonic currents, if they 
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are activated by this exposure to ambient GABA. Indeed α5βnγ2 receptors have 
such a dual role, being responsible not only for CA1 PC tonic currents (see 
Section 1.1.1), but also for a proportion of IPSCs within these cells (‘GABAslow’ 
IPSCs (Banks et al., 1998; Prenosil et al., 2006)). Finally, roles for synaptic 
transmission in anxiety cannot be ruled out: synaptic α2-containing receptors 
mediate benzodiazepine anxiolysis (Low et al., 2000), and several investigators 
find hippocampal IPSCs are modulated by physiologically-relevant 
concentrations of neurosteroid (e.g. Harney et al., 2003). The contribution of α2-
type GABAA receptors to both types of GABA current has therefore been 
assessed in our investigation. 
 
 
Figure 4.1 – Hippocampal networks relevant to anxiety and depression 
The hippocampus has two major subdivisions, the cornu ammonis (CA) and the 
dentate gyrus (DG). Both components can be divided into ‘cell body’ and ‘molecular’ 
layers. Principal cells reside in the cell body layers: in the CA region, these are 
pyramidal cells (blue line) that can be divided into three regions (CA1-CA3), and in the 
DG, principal cells are granule cells (green line). Inhibitory GABAergic interneurons 
(not shown) are found in the molecular layers. Highlighted is the classical ‘trisynaptic 
circuit’ (black arrows), starting with inputs via the entorhinal cortex (EC), and ending at 
the subiculum (sub). Red arrows indicate some of the connections to other brain 
regions that are relevant to emotional state and mood disorders (Fanselow & Dong, 
2010). Note that the connections are simplified, with many more reciprocal 
connections existing between the various subregions of the hippocampus. 
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4.1.2. GABAergic neurotransmission in the nucleus accumbens 
 
The nucleus accumbens (NAcc) forms part of the mesolimbic dopamine 
pathway, which is believed to play roles in addiction and depression (see 
Section 1.4.3). NAcc activity is under extensive inhibitory control: the vast 
majority (95%) of neurons in the NAcc are GABAergic medium spiny neurons 
(MSNs), which not only project to outputs (such as the ventral palladium), but 
also make collateral connections with one another (Heimer et al., 1997). 
Reduced neurosteroid and GABAergic function is implicated in the aetio-
pathology of depression. We propose that the antidepressant functionality of 
neurosteroids could involve potentiation at α2-type GABAA receptors in the 
NAcc. 
 
Synaptic currents in the NAcc have been shown to be, at least in part, mediated 
by α2-type GABAA receptors: Dixon et al. (2010) find mIPSCs are smaller and 
faster decaying in α2-/- mice, without any compensatory change in α subunit 
expression that could account for this change in IPSC properties. Furthermore, 
these investigators demonstrated that repeated stimulation of signalling through 
α2-type GABAA receptors (using Ro15-4513 in α2
H101R knock-in mice) induces 
behavioural sensitisation to Ro15-4513 and to cocaine, in a mechanism 
independent of dopamine release in the NAcc (Morris et al., 2008; Dixon et al., 
2010). Thus, although signalling through α2-type GABAA receptors may not be 
directly involved in the rewarding effects of addictive drugs (Dixon et al., 2010), 
synaptic signalling through this receptor does appear to be involved in 
strengthening behaviour toward the cues associated with drug taking (another 
aspect of addiction). By extension, it is possible that the same signalling is 
involved in learning to direct behaviour toward natural rewards, and so 
dysfunctional phasic transmission through α2-type GABAA receptors could 
contribute to depression. We therefore decided to characterise inhibitory 
neurotransmission in NAcc MSNs, using α2Q241M mice to elucidate any roles for 
neurosteroid potentiation at α2 subunits in modulating both tonic and phasic 
transmission. 
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4.1.3. Modulation of synaptic and tonic GABAergic currents by benzodiazepines 
and neurosteroids 
 
Spontaneous synaptic events (sIPSCs) and tonic currents have been assessed 
in CA1 PCs, DG GCs and NAcc MSNs within acute brain slices from our 
transgenic mouse strain. Properties of individual sIPSCs were assessed by 
fitting procedures to define the synaptic event rise time, amplitude, weighted 
decay time ( w) and charge transfer (area). The frequency of sIPSCs was also 
monitored by measuring the inter-event interval (I.E.I.). The level of tonic 
currents was measured by determining the change in root mean square (r.m.s.) 
current noise on application of 20 µM bicuculline. Baseline parameters were 
compared across genotypes to define any effects of the α2Q241M mutation on 
basal inhibitory neurotransmission, both phasic and tonic. 
 
Following stable baseline recording, GABAA receptor modulators THDOC or 
diazepam were applied. These modulators are expected to increase the 
duration of the decay phase of IPSCs: benzodiazepines (Otis & Mody, 1992; 
Bai et al., 2001; Nusser & Mody, 2002; Dixon et al., 2008), and neurosteroids 
and their analogues (Belelli & Herd, 2003; Harney et al., 2003) have been 
shown to increase the decay times of miniature IPSCs (mIPSCs) from CA1 
PCs, DG GCs and NAcc MSNs in acute brain slices. Reported effects on IPSC 
amplitude vary – sometimes an increase is observed (e.g. Prenosil et al., 2006) 
– but often amplitude is unchanged (e.g. Otis & Mody, 1992); no increase in 
amplitude would indicate that synaptic receptors are saturated by the GABA 
released during baseline transmission. Any effects of these potentiators on 
IPSC frequency would indicate a pre-synaptic action, which has been observed 
in some, but not all neural circuits (e.g. allopregnanolone increased the 
frequency of GABAergic events in Xenopus laevis motorneurones (Reith & 
Sillar, 1997), but THDOC has no effect sIPSC frequency recorded from GCs in 
the cerebellum or DG (Stell et al., 2003)). The sensitivity of tonic currents to 
neurosteroids and diazepam depend on the subunit composition of GABAA 
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receptors passing the currents: responses to classical benzodiazepines require 
the presence of a γ subunit and absence of the benzodiazepine-insensitive α4 
or α6 isoforms (Pritchett et al., 1989; Wieland et al., 1992); and although 
neurosteroids potentiate via the α subunit (i.e. will potentiate all GABAA receptor 
currents), the δ subunit confers a greater efficacy to neurosteroid potentiation 
than γ-containing equivalents (Belelli et al., 2002; Brown et al., 2002; Hosie et 
al., 2009). Here we have assessed the effects of knocking-in α2Q241M on the 
modulation of synaptic and tonic GABAergic currents by benzodiazepines and 
neurosteroids. 
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4.2. Results 
 
4.2.1. α2Q241M alters baseline inhibitory neurotransmission in acute slices of 
hippocampus and nucleus accumbens 
 
All electrophysiological experiments started with a period of stable baseline 
recording, and data from these control epochs can be compared across 
genotypes – any genotypic differences will indicate baseline effects of the 
mutation. Because this mutation has no effect on GABA sensitivity (Section 
3.2.1; Hosie et al., 2006; Hosie et al., 2009), nor an effect on GABAA receptor 
expression (subunits α1-α5, Sections 3.2.4, 3.2.5), one may predict that 
baseline inhibitory neurotransmission will be unaltered in knock-in mice 
compared to wt littermates. However, endogenous neurosteroids may play a 
significant role in modulating inhibitory neurotransmission recorded from brain 
slice tissue (Belelli & Herd, 2003; Puia et al., 2003); if the α2 subunit is involved 
in responding to these endogenous steroids, genotypic differences in phasic or 
tonic GABA transmission will be expected at baseline. We have recorded from 
MSNs in the two main anatomical regions of the NAcc – ‘shell’ and ‘core’ – 
which are associated with distinct outputs, and functions (Heimer et al., 1997; 
Shirayama & Chaki, 2006). However, we found no core vs. shell differences in 
baseline transmission (nor responses to THDOC or diazepam), so these data 
have been combined in the analyses below. 
 
Phasic inhibition 
Loss of neurosteroid potentiation at α2 subunits has some significant effects on 
baseline inhibitory synaptic neurotransmission measured in all three cell types 
(Table 4.1), most consistently a 20-30% decrease in w decay time for 
recordings from homozygous animals compared to wild-types (Fig. 4.2). The 
α2Q241M mutation also has a significant effect on w when present in the 
heterozygous state for CA1 PCs, and tends toward an effect in het NAcc MSNs, 
although this difference is not quite significant (NAcc MSN, wt vs. het; p = 
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0.062, Behrens-Fisher test). Frequencies (measured by inter-event intervals) 
and amplitudes of sIPSCs are unaffected by genotype in recordings from any of 
the cell types. There is a slight tendency for sIPSC rise times to be faster in 
knock-in animals, although the only significant reductions are for hom vs. wt 
CA1 PCs and het vs. wt NAcc MSNs. The charge transfer per sIPSC (area 
values in Table 4.1) correlates well with w, tending to be decreased in 
recordings from knock-ins vs. wild-types. Reductions in sIPSC area vs. wild-
types are significant for het CA1 PCs and NAcc MSNs, and for hom DG GCs. 
 
 
Figure 4.2 – α2Q241M speeds the decay of baseline IPSCs 
Representative baseline sIPSCs recorded from CA1 PCs, DG GCs and NAcc MSNs of 
each genotype (each event represents an average of at least 100 individual IPSCs). 
The events have been displayed with a peak-scaled amplitude to allow comparison of 
IPSC decays. Events in cells from wt animals (black) are slower to decay than those 
from het (blue) and hom (red) animals. 
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Baseline sIPSC Parameters wt het hom 
CA1 PCs 
(25 wt, 15 het, 15 
hom) 
rise time (ms) 1.85 ± 0.09 1.59 ± 0.09 1.49 ± 0.10* 
amplitude (pA) -31.6 ± 1.4 -31.9 ± 1.5 -36.5 ± 1.9 
w (ms) 15.2 ± 0.5 11.8 ± 0.4*** 11.5 ± 0.6*** 
area (pA.ms) -383 ± 19 -304 ± 14** -348 ± 26 
I.E.I. (ms) 202 ± 27 146 ± 37 145 ± 27 
DG GCs 
(19 wt, 21 hom) 
rise time (ms) 2.02 ± 0.13 - 1.84 ± 0.13 
amplitude (pA) -39.9 ± 2.3 - -37.6 ± 1.6 
w (ms) 19.0 ± 1.0 - 13.7 ± 0.7**** 
area (pA.ms) -654 ± 69 - -424 ± 26*** 
I.E.I. (ms) 595 ± 134 - 401 ± 44 
NAcc MSNs 
(32 wt, 45 het, 20 
hom) 
rise time (ms) 2.45 ± 0.09 2.13 ± 0.07* 2.43 ± 0.19 
amplitude (pA) -46.8 ± 2.3 -42.9 ± 2.0 -45.8 ± 3.4 
w (ms) 26.5 ± 1.6 22.8 ± 1.2 21.0 ± 1.7* 
area (pA.ms) -1050 ± 74 -845 ± 70* 857  ± 101 
I.E.I. (ms) 478 ± 52 613 ± 64 744 ± 160 
Table 4.1 – Comparing baseline sIPSCs recorded from acute brain slices 
sIPSC properties (mean ± s.e.m.) from control epochs in the three cell types. In this 
table, and those that follow, numbers in brackets indicate number of cells (recordings in 
each case have been obtained from at least 4 animals). Statistically significant 
differences are highlighted: * - p<0.05, ** - p<0.01, *** - p<0.001, and **** - p<0.0001 vs. 
wt. (all pairwise Behrens-Fisher comparisons for CA1 PCs and NAcc MSNs, unpaired t-
tests for DG GCs). 
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Tonic inhibition 
The baseline tonic currents recorded from all three cell types showed no 
consistent variation with genotype (Table 4.2). NAcc MSNs tend toward 
reduced amplitude with the α2Q241M mutation (i.e. tonic current wt>het>hom), 
but there is no overall effect of genotype on tonic current (one-way ANOVA for 
effect of genotype, p=0.256). Genotype also has no effect on the tonic current 
observed in CA1 PCs (one-way ANOVA for effect of genotype, p=0.341), or DG 
GCs (unpaired t-test wt vs. hom, p=0.883).  
 
Baseline tonic currents wt het hom 
CA1 PCs (20 wt, 14 het, 13 hom) 0.73 ± 0.11 0.80 ± 0.16 0.81 ± 0.16 
DG GCs (19 wt, 21 hom) 0.31 ± 0.06 - 0.33 ± 0.09 
NAcc MSN (18 wt, 18 het,17 hom) 0.61 ± 0.08 0.49 ± 0.07 0.40 ± 0.07 
Table 4.2 – Comparing baseline tonic currents in slice recordings 
Tonic currents (mean ± s.e.m.) measured in CA1 PCs, DG GCs and NAcc MSNs. 
Numbers represent the root mean square (r.m.s.) current noise (pA) attributable to 
GABAA receptor currents (i.e. the difference between the r.m.s. noise in control epochs 
and that recorded after bicuculline treatment). Numbers in brackets indicate number of 
cells (recordings in each case were obtained from at least 4 animals). 
 
 
4.2.2. α2Q241M specifically diminishes neurosteroid potentiation of synaptic 
inhibitory neurotransmission 
 
Following stable baseline recording, GABAA receptor modulators THDOC or 
diazepam were applied. Effects of these compounds on sIPSC parameters are 
expressed as a percentage change from the control condition within that cell. To 
confirm that any observed effects were due to GABAA receptor potentiation, 
rather than, for example, an effect of the DMSO vehicle or the prolonged 
recording period, ‘mock’ experiments were performed (see Section 2.6.2). If α2 
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subunits are significantly involved in the neurosteroid response of these 
currents, the response to THDOC will be reduced in slices from knock-in 
animals. Because the sensitivity to diazepam should be unaffected by the 
α2Q241M mutation (Section 3.2.1), diazepam responses serve as a positive 
control for GABAA receptor potentiation, and any deficit in response may 
indicate some compensatory change is present in the knock-in mouse.  
 
THDOC treatment of CA1 PCs, as expected, increased sIPSC decay time (Fig. 
4.3 and Table 4.3). In cells from all three genotypes, 100 nM THDOC has 
significant effects compared to ‘mock’-treated cells, but effects of the 50 nM 
application were only significant for CA1 PCs from wt and het animals (for hom 
animals, 50 nM THDOC vs. mock, p=0.693). The extent of w prolongation also 
appears to depend on genotype: the 100 nM THDOC response of cells from 
hom mice is significantly diminished compared to those from wt mice. The 
response of cells from het animals to 100 nM THDOC is similar in magnitude to 
wt, but there is a higher variance on this response, and data are not significantly 
different to responses recorded in either wt or hom CA1 PCs. 
 
The pattern of THDOC concentration-effects on sIPSC area mirrored the 
changes seen for w (Table 4.3) – i.e. THDOC tends to increase the charge 
transfer per event, and the effect appears smaller in cells from hom animals 
than het or wt. However, there is a higher variance on these data, and only 
overall effects of drug reach significance in two-way ANOVA analyses (effect of 
drug, p<0.001, F=9.97, 2 degrees of freedom (d.f.); effect of genotype, p=0.249, 
F=1.43, 2 d.f.; interaction p=0.605, F=0.69, 4 d.f.). None of the individual 
pairwise comparisons between groups are statistically significant after 
correction for multiple comparisons. There were no significant changes in rise-
times in response to THDOC, and no clear trend for a change in the sIPSC 
amplitude with application of THDOC. There were no significant changes in 
event frequencies in response to application of THDOC to CA1 PCs from 
animals of any genotype. 
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Figure 4.3 – THDOC effects on sIPSC decay time in CA1 pyramidal cells are 
diminished in recordings from homozygous knock-ins 
A. Bar chart detailing concentration-response relationships for THDOC effects on w 
decay time for sIPSCs recorded from CA1 pyramidal cells in acute hippocampal slices 
from animals of each genotype. ** p<0.01 and *** - p<0.001 for effect of THDOC vs. 
mock, # - p<0.05 for wt vs. hom (all pairwise Behrens-Fisher comparisons). 
B. Representative sIPSCs for CA1 PCs from wild-types and homozygotes. The 
averaged control sIPSC (black) is superimposed on the averaged sIPSC after 
equilibration with 100 nM THDOC (red). Each event represents an average of at least 
100 individual IPSCs, and is displayed with amplitude peak-scaled to allow 
comparison of IPSC decays. 
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CA1 PC sIPSCs: drug effects wt het hom 
rise time 
mock -2.7 ± 4.7 (n=7) 2.3 ± 5.3 (n=4) -2.0 ± 4.1 (n=4) 
50 nM THDOC 8.3 ± 6.9 (n=6) 3.8 ± 4.5 (n=5) 3.2 ± 4.3 (n=6) 
100 nM THDOC 8.1 ± 4.1 (n=12) 9.8 ± 1.9 (n=6) 0.5 ± 3.1 (n=5) 
amplitude 
mock -2.8 ± 4.3 (n=7) -4.8 ± 8.7 (n=4) -8.1 ± 5.8 (n=4) 
50 nM THDOC 18.3 ± 5.7 (n=6) -1.3 ± 3.0 (n=5) 1.2 ± 2.8 (n=6) 
100 nM THDOC 6.3 ± 7.6 (n=12) 10.9 ± 7.5 (n=6) 4.8 ± 6.6 (n=5) 
w 
mock 6.4 ± 1.8 (n=7) 2.5 ± 1.6 (n=4) 5.7 ± 1.4 (n=4) 
50 nM THDOC 18.5 ± 2.2 (n=6)** 18.6 ± 3.7 (n=5)*** 13.6 ± 3.7 (n=6) 
100 nM THDOC 30.4 ± 3.0 (n=12)*** 32.9 ± 8.2 (n=6)*** 16.0 ± 1.0 (n=5)*** # 
area 
mock 4.1 ± 4.5 (n=7) -0.8 ± 10.6 (n=4) -2.9 ± 7.2 (n=4) 
50 nM THDOC 40.5 ± 9.0 (n=6) 19.1 ± 5.2 (n=5) 16.1 ± 3.7 (n=6) 
100 nM THDOC 37.2 ± 9.6 (n=12) 50.9 ± 18.6 (n=6) 22.8 ± 8.9 (n=5) 
I.E.I 
mock 13.3 ± 7.4 (n=7) -20.1 ± 13.2 (n=4) 0.74 ± 27.9 (n=4) 
50 nM THDOC 80.0 ± 57.7 (n=6) 15.4 ± 8.0 (n=5) 8.2 ± 3.4 (n=6) 
100 nM THDOC 22.7 ± 6.5 (n=12) 28.2 ± 31.5 (n=6) 6.7 ± 5.9 (n=5) 
Table 4.3 – THDOC-induced changes CA1 PC sIPSC parameters 
Percentage changes (mean ± s.e.m.) in CA1 PC sIPSC parameters in response to 
THDOC application. ** p<0.01 and *** - p<0.001 for effect of THDOC vs. mock, # - 
p<0.05 for wt vs. hom (all pairwise Behrens-Fisher comparisons). 
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As expected, the α2Q241M mutation diminished the sensitivity of synaptic 
receptors to the neurosteroid THDOC in recordings from CA1 PCs. The impact 
of genotype was apparent at the higher concentration of the neurosteroid, so 
experiments in DG GCs and NAcc MSNs focused only on 100 nM THDOC. 
These experiments also included diazepam as a positive control. The 
concentration of diazepam chosen, 500 nM, induces a similar level of 
potentiation as 100 nM THDOC when applied to recombinant GABAA receptors 
expressed in HEK293 cells (Fig. 3.2). In slices from wt animals, both 
substances have similar significant effects on sIPSC decay times in recordings 
from DG GCs and NAcc MSNs (Fig. 4.4, Table 4.4, Table 4.5). Consistent with 
our observations in CA1 PCs, the decay time prolongation by 100 nM THDOC 
is significantly reduced in DG GCs and NAcc MSNs from hom animals. In 
contrast, diazepam prolongation of sIPSC decay time is unaltered in DG GCs 
and NAcc MSNs from the homozygous knock-in animals compared to those of 
wt animals. These data are therefore consistent with the effects of the α2Q241M 
mutation examined in HEK293 cells – disrupting neurosteroid potentiation 
without any effect on benzodiazepine sensitivity. 
 
As with CA1 PCs, 100 nM THDOC and genotype have no significant effects on 
rise time, amplitude, area or frequency of sIPSCs recorded from DG GCs; there 
is also no significant effect of 500 nM diazepam on these parameters (Table 
4.4). Two-way ANOVA analysis of the area data reveal a significant effect of 
treatment (p=0.034, F=3.75, 2 d.f.), but no overall effect of genotype (p=0.307, 
F=1.08, 1 d.f.), and no interaction effect (p=0.207, F=1.65, 2.d.f.). None of the 
individual pairwise comparisons survive correction for multiple comparisons, but 
some of the unadjusted least significant difference (LSD) comparisons are of 
note (wt mock vs. wt THDOC, p=0.035; wt mock vs. wt diazepam, p=0.023; and 
THDOC wt vs. hom, p=0.056). It therefore seems that there are at least some 
tendencies for the changes in charge transfer to correlate with changes seen 
with w (i.e. THDOC being effective in wt/ineffective in hom, and diazepam 
being effective in both wt and hom).  
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Figure 4.4 – Homozygous α2Q241M specifically disrupts neurosteroid 
potentiation of sIPSCs in DG GCs and NAcc MSNs 
A. THDOC and diazepam effects on w decay time for sIPSCs recorded from DG 
GCs. ** - p<0.01 for effect of THDOC or diazepam vs. mock, + - p<0.05 for 
diazepam vs. THDOC, ## - p<0.01 for wt vs. hom (ANOVA, multiple comparisons 
corrected with Benjamini-Hochberg adjustment). 
B. THDOC and diazepam effects on w decay time for sIPSCs recorded from NAcc 
MSNs. ** p<0.01 for effect of THDOC or diazepam vs. mock treatment; + - p<0.05 
and ++ - p<0.01 for effect of diazepam vs. THDOC; ## - p<0.01 for hom vs. het and 
hom vs. wt (ANOVA, multiple comparisons corrected with Benjamini-Hochberg 
adjustment). 
C. and D. Representative sIPSCs for wild-type and homozygote DG GCs (C) and 
NAcc MSNs (D). The averaged sIPSC in the control epoch (black) is superimposed 
on the averaged sIPSC after equilibration with 100 nM THDOC (red) or 500 nM 
diazepam (green). Each event represents an average of at least 100 individual 
sIPSCs, and is displayed with amplitude peak-scaled to allow comparison of 
decays. 
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DG GC sIPSCs: drug effects wt hom 
rise time 
Mock 4.5 ± 1.8 (n=5) 13.3 ± 3.1 (n=7) 
100 nM THDOC 2.8 ± 7.9 (n=7) 7.4 ± 7.6 (n=7) 
500 nM diazepam 7.6 ± 4.5 (n=7) 21.7 ± 4.0 (n=7) 
amplitude 
Mock 17.3 ± 3.2 (n=5) 21.7 ± 8.8 (n=7) 
100 nM THDOC 25.2 ± 7.8 (n=7) 16.5 ± 3.9 (n=7) 
500 nM diazepam 30.0 ± 6.4 (n=7) 25.1 ± 7.1 (n=7) 
w 
Mock 14.6 ± 3.6 (n=5) 19.4 ± 5.2 (n=7) 
100 nM THDOC 63.6 ± 7.0 (n=7)** 27.8 ± 5.7 (n=7) ## 
500 nM diazepam 56.5 ± 5.2 (n=7)** 47.4 ± 5.7 (n=7)** + 
area 
Mock 42.2 ± 8.0 (n=5) 60.2 ± 18.9 (n=7) 
100 nM THDOC 108.4 ± 21.2 (n=7) 53.8 ± 12.3 (n=7) 
500 nM diazepam 113.9 ± 15.1 (n=7) 105.4 ± 30.6 (n=7) 
I.E.I 
Mock -14.2 ± 8.2 (n=5) - 3.9 ± 11.1 (n=7) 
100 nM THDOC 19.0 ± 15.3 (n=7) -7.4 ± 11.3 (n=7) 
500 nM diazepam -16.3 ± 5.4 (n=7) -12.0 ± 6.5 (n=7) 
Table 4.4 – Changes in DG GC sIPSC parameters 
Percentage changes (mean ± s.e.m.) in DG GC sIPSC parameters after application 
of THDOC or diazepam. ** - p<0.01 for effect of THDOC or diazepam vs. mock, + - 
p<0.05 for diazepam vs. THDOC, ## - p<0.01 for wt vs. hom (ANOVA, multiple 
comparisons corrected with Benjamini-Hochberg adjustment). 
 
In recordings from NAcc MSNs, there are no effects of drug or genotype on the 
rise time, amplitude or frequency of sIPSCs (Table 4.5). Unlike the hippocampal 
recordings, however, the effects on charge transfer reach statistical 
significance: diazepam and THDOC significantly increase the areas of sIPSCs 
recorded from wt and het animals, whilst only diazepam is effective in cells from 
hom animals (i.e. no effect of THDOC in NAcc MSNs from hom mice). 
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NAcc MSN sIPSCs: drug effects wt het hom 
rise time 
mock 9.3 ± 5.0 (n=12) 6.6 ± 3.9 (n=15) 7.4 ± 5.3 (n=7) 
100 nM THDOC 4.0 ± 4.2 (n=11) 5.6 ± 4.1 (n=21) 12.1 ± 11.0 (n=8) 
500 nM diazepam 11.7 ± 10.8 (n=9) 14.8 ± 8.8 (n=9) 14.5 ± 5.1 (n=5) 
amplitude 
mock -2.9 ± 8.2 (n=12) -6.1 ± 5.9 (n=15) 7.7 ± 3.8 (n=7) 
100 nM THDOC -6.2 ± 13.0 (n=11) 3.4 ± 2.9 (n=21) -2.3 ± 4.5 (n=8) 
500 nM diazepam 10.9 ± 6.1 (n=9) 7.5 ± 9.9 (n=9) 12.3 ± 9.7 (n=5) 
w 
mock 8.1 ± 2.0 (n=12) 5.1 ± 2.0 (n=15) 7.2 ± 3.6 (n=7) 
100 nM THDOC 35.1 ± 4.9 (n=11)** 41.8 ± 5.9 (n=21)** 14.4 ± 3.3 (n=8)## 
500 nM diazepam 39.7 ± 5.2 (n=9)** 60.2 ± 9.8 (n=9)** + 41.7 ± 5.5 (n=5)** ++ 
area 
mock 4.9 ± 9.2 (n=12) -2.9 ± 6.2 (n=15) 16.8 ± 8.3 (n=7) 
100 nM THDOC 29.9 ± 26.9 (n=11)* 46.0 ± 6.6 (n=21)*** 14.7 ± 7.2 (n=8) 
500 nM diazepam 52.2 ± 6.1 (n=9)* 73.2 ± 17.6 (n=9)* 60.3 ± 11.8 (n=5)** ++ 
I.E.I 
mock 24.5 ± 9.4 (n=12) 35.2 ± 20.9 (n=15) 13.6 ± 14.0 (n=7) 
100 nM THDOC 26.9 ± 12.1 (n=11) 16.7 ± 9.2 (n=21) 37.4 ± 34.7 (n=8) 
500 nM diazepam 4.3 ± 9.6 (n=9) 12.4 ± 11.5 (n=9) -1.1 ± 11.5 (n=5) 
Table 4.5 – Changes in NAcc MSN sIPSC parameters 
Percentage changes (mean ± s.e.m.) in sIPSC parameters of NAcc MSNs after 
application of THDOC or diazepam. * p<0.05, ** p<0.01 and *** p<0.001 for effect of 
drug vs. mock treatment; + - p<0.05 and ++ - p<0.01 for effect of diazepam vs. THDOC; 
## - p<0.01 for hom vs. het and hom vs. wt (ANOVA, multiple comparisons corrected 
with Benjamini-Hochberg adjustment ( w) or all pairwise Behrens-Fisher comparisons 
(area)). 
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4.2.3. α2Q241M specifically diminishes neurosteroid potentiation of tonic inhibitory 
neurotransmission in dentate gyrus granule cells 
 
DG GCs exhibited very little baseline tonic current in slices isolated from 
animals of either genotype (Table 4.2). Nevertheless, application of 100 nM 
THDOC significantly increased the r.m.s. current noise recorded from DG GCs 
of wt mice (Fig. 4.5, Table 4.6). This increase in noise is of GABAA receptor 
origin, because it is reversed by application of 20 µM bicuculline (Fig. 4.5 B). 
This effect of THDOC is not apparent for DG GCs in slices from hom animals, 
suggesting that it involves neurosteroid potentiation at α2-subunit-containing 
receptors. The lack of effect of 500 nM diazepam on r.m.s. noise (Fig. 4.5 A), 
further suggests that the receptors passing this tonic current are devoid of the γ 
subunit. 
 
There were no significant variations of the r.m.s. current noise recorded from 
CA1 PCs (Kruskal Wallis test, p=0.138, 8 d.f) or NAcc MSNs (Kruskal Wallis 
test p=0.367, 8 d.f.) across any of the treatment groups (Table 4.6). There were 
no trends for any effect of THDOC or diazepam on r.m.s. noise recorded from 
5-6 NAcc MSNs of any genotype, so analyses were not extended to the 
remaining 44 recordings. 
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Figure 4.5 – Homozygous mutation α2Q241M specifically disrupts neurosteroid 
potentiation of tonic currents in DG GCs 
A. Bar chart detailing the change in r.m.s. current noise (mean ± s.e.m.) after 
equilibration of DG GCs with THDOC or diazepam. ** - p<0.01 for effect of THDOC 
vs. mock, ++ - p<0.01 for diazepam vs. THDOC, ## - p<0.01 for wt vs. hom (ANOVA, 
multiple comparisons corrected with Benjamini-Hochberg adjustment). 
B. Representative examples of r.m.s. current noise after equilibration under the 
defined condition for wt and hom DG GCs. 
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Tonic currents: drug effects wt het hom 
CA1 
PCs 
mock -0.23 ± 0.13  (n=6) -0.18 ± 0.07  (n=4) -0.05 ± 0.15  (n=3) 
50 nM THDOC -0.16 ± 0.09 (n=4) -0.14 ± 0.11 (n=5) 0.15 ± 0.17 (n=5) 
100 nM THDOC 0.10 ± 0.09 (n=10) 0.69 ± 0.37 (n=5) 0.31 ± 0.20 (n=5) 
DG GCs 
mock 0.15 ± 0.05 (n=5) - 0.12 ± 0.08 (n=7) 
100 nM THDOC 0.70 ± 0.14 (n=7)** - 0.18 ± 0.10 (n=7)## 
500 nM diazepam 0.14 ± 0.06 (n=7)++ - 0.18 ± 0.10 (n=7) 
NAcc 
MSNs 
mock -0.26 ±  0.10 (n=6) -0.08 ± 0.03   (n=6) 0.13 ± 0.27  (n=6) 
100 nM THDOC -0.06 ±  0.18 (n=6) 0.15 ± 0.12   (n=6) -0.10 ±  0.11 (n=6) 
500 nM diazepam -0.06 ± 0.07  (n=6) -0.07 ±  0.14 (n=6) 0.08 ±  0.04 (n=5) 
Table 4.6 – Comparing changes in tonic currents after equilibration with THDOC 
or diazepam 
Summary of the changes (mean ± s.e.m.) in root mean square current noise (pA) after 
equilibration with drug in CA1 PCs, DG GCs or NAcc MSNs. ** - p<0.01 for effect of 
THDOC vs. mock, ++ - p<0.01 for diazepam vs. THDOC, ## - p<0.01 for wt vs. hom 
(ANOVA, multiple comparisons corrected with Benjamini-Hochberg adjustment). 
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4.3. Discussion 
 
4.3.1. Effects of α2Q241M on baseline synaptic and tonic GABA transmission 
 
The α2Q241M mutation has been shown to specifically ablate neurosteroid 
potentiation at α2 3γ2S receptors, without effect on responses to GABA 
(Section 3.2.1; Hosie et al., 2006; Hosie et al., 2009). Furthermore this mutation 
has been successfully introduced into our transgenic mouse strain without any 
obvious changes to the expression of GABAA receptor subunits α1-α5 (Sections 
3.2.4 and 3.2.5). One may therefore predict that the mutation would have no 
effect on baseline inhibitory neurotransmission within the transgenic mouse. In 
fact, results are to the contrary: baseline sIPSCs in knock-in mice decay faster 
than those of wt littermates, reducing the charge transfer per synaptic event. 
This does not necessarily indicate a compensatory alteration in response to the 
α2Q241M mutation. Indeed the unchanged IPSC amplitude suggests that a similar 
number of GABAA receptors are expressed at the synaptic site, and/or that a 
similar amount of GABA is released per synaptic event. Unaltered sIPSC 
frequency would also suggest a lack of presynaptic alterations in the knock-in 
mice. We propose that the difference in baseline decay times is an indication for 
a role of endogenous neurosteroids in modulating inhibitory neurotransmission 
within the slice. There is already a precedent for such a role because inhibiting 
neurosteroid synthesis reduced the decay times of IPSCs recorded from 
pyramidal neurons of the neocortex (Puia et al., 2003). Our results of faster 
decay times for sIPSCs from cells of hom α2Q241M mice may therefore identify a 
role for α2-type GABAA receptors in responding to endogenous neurosteroids. If 
our model is correct, the difference between wt and hom IPSC decays should 
be ablated by removing endogenous neurosteroids from the slices. 
 
Interestingly, some effects of the α2Q241M mutation on baseline sIPSC 
parameters can also be seen in the heterozygous state (see Section 4.2.1). 
There are two α subunits per receptor (Fig. 1.1), and so two neurosteroid 
potentiation sites. Assuming that both copies of the subunit, α2M and α2Q, are 
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expressed in equal amounts and co-assemble in an unbiased manner within 
cells of het animals, we would expect a binomial expression pattern of four 
combinations of wild-type and mutant copies of α2 subunits: α2Qα2Q, α2Qα2M, 
α2Mα2Q and α2Mα2M. By comparing fits of one- and two-site models to 
experimental data, Hosie et al. (2009) suggested that one-site occupation is 
sufficient for full neurosteroid potentiation. Furthermore, using concatameric 
assemblies to control the GABAA receptor composition, Bracamontes and 
Steinbach (2009) showed that both α subunits are capable of contributing to 
neurosteroid potentiation. Effects of mutating each site individually were either 
small or insignificant, and potentiation by neurosteroid was only completely lost 
if both sites were mutated (Bracamontes & Steinbach, 2009). We would 
therefore expect het animals to respond ‘normally’ (like wt) to the endogenous 
neurosteroids in the slice (since only one in four receptor combinations is 
expected to be the insensitive double-mutant, α2Mα2M). However, if there is a 
cell-to-cell variation in the relative expression levels of the neurosteroid-
insensitive (α2Mα2M) and sensitive (α2Qα2Q, α2Qα2M, α2Mα2Q) receptor 
combinations in heterozygotes, cells with a higher proportion of α2Mα2M 
receptors would be expected to have a diminished response to endogenous 
neurosteroids within the slice. Our data on subunit expression cannot 
distinguish the wt and mutant alleles, but a quantitative PCR-based approach 
may help determine the relative expression levels of the two alleles in 
heterozygotes. 
 
CA1 PCs, DG GCs and NAcc MSNs all showed very little response to 
bicuculline, suggesting that baseline tonic currents are small or absent from 
these cells under the conditions of our experiments. This is perhaps not a 
surprise: other investigators frequently require bath application of GABA, or a 
GABA reuptake inhibitor (such as NO-711), in order to achieve a consistent 
tonic current measurement in CA1 PC and DG GCs (e.g. Semyanov et al., 
2003). We have used neither manipulation, in order to preserve slices in a near-
physiological state. Some investigators have observed tonic currents in these 
cells without altering extracellular GABA levels (e.g. Bai et al., 2001; Nusser & 
Mody, 2002); it is difficult to say what condition may underlie the difference 
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between these investigations and ours. Perhaps there are some age- or sex-
related variations in tonic currents; for example the expression of  δ-subunit 
containing receptors, which dominate in DG GC tonic currents (see Section 
1.1.1), increases with increases with age (Laurie et al., 1992b). Our 
investigation focussed on young (P18-30) males, and we cannot discount the 
presence of more robust tonic currents at older ages, or in females, in these cell 
types within our mouse strain. In our investigation, the α2Q241M mutation has no 
effect on the magnitude of the baseline tonic current (Table 4.2). This would 
imply that, at least under the conditions of our experiment, there is no 
involvement of GABAA receptor α2 subunits (or neurosteroid potentiation at 
these subunits) in generating baseline tonic currents. Furthermore, unchanged 
tonic currents would be consistent with a lack of compensatory changes in 
expression of extrasynaptic GABAA receptors in the knock-in mice. 
 
 
4.3.2. α2Q241M specifically diminishes neurosteroid potentiation of synaptic 
transmission  
 
The clearest effect of THDOC and diazepam on the sIPSCs is a prolongation of 
decay times, which is seen in recordings from all three cell types. The lack of 
effect on IPSC amplitude suggests that GABA release during phasic 
transmission is already saturating postsynaptic receptors, and is consistent with 
observations of others (e.g. Otis & Mody, 1992). Effects on sIPSC area are 
consistent with those on decay time, but these effects are less robust, possibly 
because area depends on a combination of decay time (increases in all cells) 
and amplitude (although the average suggests no change, within individual 
cells, amplitude can increase, decrease or remain unchanged). A lack of effect 
of THDOC on inter-event interval is consistent with a lack of presynaptic effects 
of THDOC in the hippocampus and NAcc.  
 
The strong effect we observe for 100 nM THDOC on w from wt DG GCs may 
appear at odds with reports elsewhere of insensitivity of these cells to THDOC 
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(Stell et al., 2003) and their low sensitivity to allopregnanolone (Belelli & Herd, 
2003; Harney et al., 2003). However, the neurosteroid sensitivity of IPSC decay 
time varies with age, receptor subunit composition, cellular differences in 
metabolism and relative kinase/phosphatase activities (see Section 1.2.3). Any 
one of these factors may account for the discrepancies between these 
observations. For example, DG GC IPSC sensitivity to neurosteroid declines 
with age in rats (Cooper et al., 1999; Mtchedlishvili et al., 2003), being highest 
during the first two postnatal weeks; responses to ‘physiological’ levels of 
THDOC (50 nM and 100 nM) are lost soon after (P17-21 (Cooper et al., 1999)). 
Perhaps neurosteroid sensitivity declines at around P30 in mice, which would 
explain why IPSCs are responsive in our work (P18-30 mice) but not in that of 
Stell et al. (2003) (P30-P181 mice).  
 
Since the α2Q241M mutation ablates neurosteroid potentiation of α2β3γ2S 
receptor function in HEK293 cells, one would predict potentiation of GABAergic 
sIPSCs to also be defective in α2Q241M knock-in mice. Focussing on the sIPSC 
w response to THDOC, data are consistent with this prediction: sIPSC decay 
prolongation by 100 nM THDOC is diminished in hom knock-ins all three cell 
types examined. In NAcc MSNs and DG GCs, the response is ablated (i.e. no 
different to the responses of ‘mock’ treated cells); in CA1 PCs, neurosteroid 
sensitivity is significantly diminished, but not completely lost. The most likely 
explanation for residual response in CA1 PCs is the retained neurosteroid-
potentiation functionality of other α subunit isoforms in these cells (α1, α3, α4 
and α5 (Fig 3.4A; Wisden et al., 1992; Prenosil et al., 2006)). It would therefore 
seem likely that α2-type GABAA receptors are responsible for approximately 
50% of sIPSCs recorded from CA1 PCs (decay time prolongation by 100 nM 
THDOC: 16% in hom vs. 30% in wt), and for the majority of sIPSCs in DG GCs 
and NAcc MSNs. Whilst the differential response in cells from hom mice could 
alternatively represent a compensatory change in response to the α2Q241M 
mutation, subunit expression data would argue against this notion (Section 
3.3.2). Furthermore, the IPSC decay time prolongation by 500 nM diazepam is 
undiminished by the α2Q241M mutation in DG GCs and NAcc MSNs (Fig. 4.4). 
These data are consistent with unaltered function of synaptic GABAA receptors 
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(i.e. support a lack of compensatory changes). We therefore propose a key role 
for α2-type GABAA receptors in overall neurosteroid response of sIPSCs.  
 
Neurosteroid and diazepam modulation of sIPSCs recorded from cells of het 
animals are generally the same as those observed in cells from wt mice. The 
response of het NAcc MSNs to 100 nM THDOC, assessed by w prolongation or 
by increased event area, is no different to that seen in wt littermates. Similarly, 
het NAcc MSNs show a wt-like response to 500 nM diazepam. The response of 
het CA1 PCs to 100 nM THDOC are the same as for wt (although pairwise 
comparisons find no significant difference for het vs. hom and for het vs. wt). 
These data appear to be at odds with the effects of het α2Q241M on baseline 
IPSC characteristics discussed in Section 4.3.1; the reason for this discrepancy 
remains unclear. 
 
Interestingly, in NAcc MSNs from heterozygotes, the response to 500 nM 
diazepam is significantly higher than that for 100 nM THDOC. It is not clear why 
this is the case, because these doses of modulator achieve the same degree of 
potentiation of wt α2-type GABAA receptors expressed in HEK293 cells (Fig. 3.2 
A). However, the diazepam and THDOC sensitivity of heterozygous α2Q241M 
mutant receptors has not been examined in HEK293 cells; perhaps the 
concatamer-based approach of Bracamontes and Steinbach (2009) should be 
utilised to examine the effects of mutating a specific single neurosteroid 
potentiation site within the pentamer on diazepam sensitivity. Slice 
electrophysiology could also be extended to determine if this effect is specific to 
NAcc MSNs: the diazepam sensitivity of CA1 PCs of all three genotypes should 
be examined, whilst heterozygous animals should be added to the work in DG 
GCs. 
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4.3.3. α2Q241M reveals a role for α2-type GABAA receptors in tonic currents 
 
Application of 100 nM THDOC significantly increased the r.m.s. current noise 
recorded from DG GCs of wt mice (Fig. 4.5, Table 4.6). This increase in noise is 
of GABAA receptor origin, because it is reversed by application of 20 µM 
bicuculline (Fig. 4.5 B). This effect of THDOC is not apparent in DG GCs in 
slices from hom animals, suggesting that it involves neurosteroid potentiation at 
α2-type receptors. The lack of effect of 500 nM diazepam on r.m.s. noise (Fig. 
4.5 A), further suggests that the receptors passing this tonic current are devoid 
of the γ subunit (Pritchett et al., 1989). Potential receptor combinations 
accounting for this tonic current could therefore be α2βn and α2βnδ. 
 
There were no significant effects of either THDOC or diazepam on the r.m.s. 
current noise recorded from CA1 PCs or NAcc MSNs. Under the conditions of 
our experiments, therefore, it seems that tonic GABA currents in both cell types 
are carried by receptors lacking the γ subunit (which would bestow diazepam 
insensitivity). It has been suggested that neurosteroid insensitivity of tonic 
currents indicates that receptors lack the δ subunit (Stell et al., 2003), but 100 
nM THDOC clearly has an effect on the synaptic (probably γ-type) receptors in 
the same cells, so even a γ-subunit-mediated tonic current would be expected 
to respond to THDOC. Perhaps the neurosteroid insensitivity of the 
extrasynaptic receptors in these cell types can be attributed to their 
phosphorylation state under the conditions of our experiment. 
 
 
4.3.4. Limitations of the electrophysiological characterisation 
 
Any experimental approach to measuring neurotransmission will itself perturb 
normal function, and the further removed the approach is from the intact brain, 
the greater the potential for departure from normality. Work in this thesis utilises 
brain slice tissue, which represents a state closer to in situ physiology than 
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using dissociated neurons in culture, because cells are maintained in their 
native local milieu, and many of their original synaptic inputs are retained. The 
properties of synaptic and tonic currents recorded form cells in brain slices can 
be influenced by the recording temperature, holding voltage, Cl- loading and the 
addition of compounds that influence the ambient GABA concentration (Otis & 
Mody, 1992; Cooper et al., 1999; Overstreet et al., 2000; Semyanov et al., 
2003; Semyanov et al., 2004; Houston et al., 2009a). Importantly, manipulating 
extracellular GABA levels can determine which subunits contribute to that 
current, with a more prominent role for α5-type receptors in CA1 PCs at 
elevated GABA concentrations (Scimemi et al., 2005; Prenosil et al., 2006). It is 
therefore possible that the roles we propose for α2-type GABAA receptors only 
hold under the particular experimental conditions used. It would be interesting to 
expand our study of tonic current to conditions that will raise ambient GABA 
levels, to see if the neurosteroid-stimulated α2-dependent tonic current is 
retained. It would also be interesting to extend the investigation, to screen for 
the effects of α2Q241M within different cell types and at different developmental 
stages, particularly where GABAergic currents may be excitatory (Ben-Ari, 
2002; Szabadics et al., 2006; Chiang et al., 2012). 
 
Most experiments have utilised 100 nM THDOC to potentiate GABAergic 
transmission within the slice. This concentration represents the higher end of 
that which has been measured physiologically (Paul & Purdy, 1992; Concas et 
al., 1998), and some investigators suggest it is better to focus on lower 
concentrations (less than 50 nM) to represent those seen more commonly 
during physiology (Harney et al., 2003; Stell et al., 2003). Interestingly, in our 
work, the 50 nM response of hom CA1 PCs does not seem to be lower than that 
in recordings from het and wt CA1 PCs (Fig. 4.3), which may suggest that the 
α2 subunit is only important in responses to higher neurosteroid levels.  
However, it is difficult to know whether the whole-tissue estimates of 
neurosteroid levels directly correlate with those found at the level of individual 
cells. Endogenous neurosteroids act in a paracrine manner, and applied 
neurosteroids can accumulate within cells (Li et al., 2007), such that the 
concentration of compound in the cell surface membrane (i.e. at the level of the 
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GABAA receptor) may be in excess of that applied in the bath (Chisari et al., 
2010). Furthermore, Belelli and Herd (2003) find that local degradation to 
inactive metabolites may shape the response of different cells within 
hippocampal slices to the same concentration of bath-applied neurosteroid. 
Whether our observed neurosteroid-response deficit relates to physiological 
levels of these compounds therefore awaits methods to accurately measure 
their concentrations at synapses. Encouragingly, however, there are clear 
baseline effects of α2Q241M on IPSC decay time. We propose that this identifies 
an endogenous neurosteroid tone within CA1 PCs, DG GCs and NAcc MSNs, 
that influences synaptic neurotransmission by function at α2-type GABAA 
receptors. 
 
 
 
4.4. Conclusions 
 
1. Baseline sIPSCs are faster-decaying in several cell types from hom mice 
vs. wt littermates, suggesting a role for endogenous neurosteroids in 
setting the duration of inhibitory synaptic transmission. By extension, 
hom mice are predicted to have a diminished inhibitory tone in vivo. 
 
2. IPSC responses to diazepam are unperturbed by the α2Q241M mutation in 
brain slices from the knock-in mice, consistent with a lack of 
compensatory alterations in the mouse strain. 
 
3. Functional potentiation sites on GABAA receptor α2 subunits are required 
for a full response of synaptic events to neurosteroids in CA1 PCs, DG 
GCs and NAcc MSNs.  
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4. In DG GCs, GABAA receptor α2 subunits appear not to be involved in 
baseline tonic currents, but may be recruited to pass such currents at 
high THDOC concentrations. The receptors involved are likely to be peri- 
or extra-synaptic γ-subunit-lacking receptor combinations (α2βn and 
α2βnδ). 
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Chapter 5: Screening anxiety and depression phenotypes of α2Q241M 
knock-ins 
 
5.1. Introduction 
 
5.1.1. Behaviour of α2Q241M mice defines the physiological and pharmacological 
roles of neurosteroids acting at GABAA receptor α2 subunits 
 
The α2Q241M mice generated in this study provide a unique opportunity to 
elucidate the roles of α2-type GABAA receptors in mediating responses to both 
endogenous and injected neurosteroids. Levels of endogenous neurosteroids 
fluctuate during a number of normal and pathological settings, being raised by 
stress (Purdy et al., 1991; Barbaccia et al., 1996) and diminished in depression 
(Romeo et al., 1998; Uzunova et al., 1998; Strohle et al., 1999; Strohle et al., 
2000), for example. Differences in baseline behavioural phenotypes of the 
α2Q241M knock-ins, compared to wild-type littermates, are likely to be a 
consequence of losing regulation by these endogenous neurosteroids at α2-
type GABAA receptors, especially given that we have not found any 
compensatory changes in expression of GABAA receptors α1-α5 that could 
account for changes in behaviour (Chapter 3). 
 
Injected neurosteroids have a number of effects, including anxiolysis (Crawley 
et al., 1986; Wieland et al., 1991), antidepression (Khisti et al., 2000), analgesia 
(Winter et al., 2003), and sedation (Mendelson et al., 1987), all of which imply 
that neurosteroids could prove useful therapeutics for a number of nervous 
system disorders. It remains to be determined whether, as for benzodiazepines, 
different GABAA receptor α-subunit isoforms are responsible for each specific 
behavioural effect of neurosteroids. Examining responses to injected 
neurosteroids in α2Q241M mutant mice will demonstrate which behavioural 
effects listed above depend on potentiation at the GABAA receptor α2 subunit. 
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Behavioural studies in this thesis have focussed on paradigms that assess 
anxiety-like and depression-like behaviours within the α2Q241M knock-in mouse 
strain. 
 
 
5.1.2. GABAA receptor α2 subunits and neurosteroids in anxiety 
 
GABAA receptor α2 subunits are key components of the anxiety circuitry in the 
CNS (see Section 1.3.2). Fundamental observations are that α2 expression is 
strong in brain areas linked to mood and anxiety, including cortex, hippocampus 
and amygdala (Wisden et al., 1992; Sperk et al., 1997; Pirker et al., 2000; 
Sieghart & Sperk, 2002; Mohler, 2006a), and that knock-out of this subunit 
causes an anxiety phenotype (Dixon et al., 2008). Furthermore, the anxiolytic 
response to benzodiazepines is thought to be mediated by α2-type GABAA 
receptors (Low et al., 2000). If GABAA receptor α2 subunits are also central to 
the anxiolytic response to endogenous neurosteroids, one would predict a 
baseline anxiety phenotype for hom α2Q241M mutants, which will be incapable of 
responding to these compounds at α2 subunits. Moreover, this defect would be 
predicted to impair anxiolytic responses to injected neurosteroids. These 
predictions were tested using two behavioural screens for anxiety-like 
behaviour: the elevated plus maze and light-dark box tests.  
 
The elevated plus maze has been validated over many years as a screen for 
anxiety-like behaviour in mice (Lister, 1987; Hogg, 1996). This test, described in 
Section 2.7.2, exploits the aversive properties of open spaces. Mice are faced 
with a choice between exploring regions open to the environment and ‘safer’ 
enclosed regions, which supply thigmotactic cues. Drugs known to be anxiolytic 
in humans, including benzodiazepines, increase the number of entries into and 
percentage time spent on the aversive open arms (Pellow et al., 1985). 
Neurosteroids, such as allopregnanolone and THDOC, have equivalent effects 
on plus maze behaviour (Crawley et al., 1986; Rodgers & Johnson, 1998).  
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The light-dark box also comprises an environment divided into aversive (light 
zone) and safe (dark zone) areas. As with the elevated plus maze, the test was 
validated using benzodiazepine anxiolytics (Crawley & Goodwin, 1980; 
Blumstein & Crawley, 1983), which release innate inhibition on mouse 
exploratory behaviour, and so increase exploration of both zones, especially the 
aversive light zone. Different investigators find divergent effects of anxiolytics on 
the various parameters scored within this paradigm, leading to debate over 
which parameters are the best measures of anxiety (e.g. see discussion by 
Hascoet & Bourin, 1998). Anxiolytic responses can include some or all of the 
following changes: increased time to first exit the light zone, increased time 
spent in the light zone, and an increase in exploratory locomotion within both 
zones. All of these parameters are therefore considered in this study. 
 
 
5.1.3. GABAA receptor α2 subunits and neurosteroids in depression 
 
Common mechanisms may underlie anxiety and depression, because these 
disorders are frequently co-morbid (Hirschfeld, 2001; Nutt et al., 2006). One 
proposal is that deficiencies in GABAergic transmission could account for both 
disorders (see Section 1.4.1). Of particular note for this study, are observations 
that α2-/- mice have phenotypes consistent with both anxiety and depression 
(Dixon et al., 2008; Vollenweider et al., 2011) and that several limbic regions 
whose structure and/or activity is altered in depression, including the 
hippocampus, amygdala and basal ganglia (Sheline, 2003; McCabe et al., 
2009), are areas rich in GABAA receptor α2 subunit expression (Wisden et al., 
1992; Sperk et al., 1997; Pirker et al., 2000; Sieghart & Sperk, 2002; Mohler, 
2006a). These data would support a role for α2-type GABAA receptors in 
depression. 
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Neurosteroids have also been linked with depression (see Section 1.4.2). The 
two key points being a negative correlation between endogenous 
allopregnanolone levels and depression symptoms in humans (Romeo et al., 
1998; Uzunova et al., 1998; Strohle et al., 1999; Strohle et al., 2000), and that 
the antidepressant function of injected neurosteroids in animal models involves 
GABAergic signalling (Khisti et al., 2000). We therefore propose that insufficient 
neurosteroid potentiation at GABAA receptor α2 subunits could underlie co-
morbid anxiety and depression. This postulation was tested here by measuring 
depression-related behaviour in the α2Q241M knock-in mouse strain. As with 
anxiety phenotyping, experiments examined baseline behaviour of wt and hom 
α2Q241M mice, to expose any role for endogenous neurosteroids at α2-type 
GABAA receptors. Responses to injected THDOC were also measured, to 
elucidate any therapeutic potential for neurosteroids at these receptors. 
 
In this study, depression-related phenotypes were screened using the tail 
suspension test paradigm. Mice are held upside-down by their tail for six 
minutes, during which time they fluctuate between two types of behaviour: 
periods of motion that reflect attempts to escape, and periods of immobility 
thought to represent ‘behavioural despair’. This approach was developed in the 
1980s (Steru et al., 1985; Thierry et al., 1986), and was validated by showing 
that known antidepressant drugs decreased behavioural despair (i.e. reduced 
‘immobility time’) in mice. Increases in immobility time would therefore represent 
phenotypic depression. The tail suspension test was chosen in preference to 
the related forced swim test (Porsolt et al., 1978) because it appears to be more 
sensitive to low doses of antidepressant, and does not induce hypothermic 
stress (see discussion in Thierry et al., 1986). 
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5.2. Results 
 
5.2.1. Endogenous neurosteroids act via GABAA receptor α2 subunits to 
determine basal anxiety levels 
 
In both the elevated plus maze (Fig. 5.1) and light-dark box (Fig. 5.2) tests, hom 
knock-in mice have an anxiety-like phenotype under basal conditions. Anxiety 
inhibits the tendency of mice to explore novel environments, and is particularly 
manifest in reduced exploration of the aversive portions of the equipment used 
in these tests. 
 
In the elevated plus maze hom animals spend significantly less time on the 
open arms than wt animals (Fig. 5.1 A), and tend to make fewer entries onto 
these arms (Fig. 5.1 B), although this latter trend does not reach significance (p 
= 0.17, paired t-test before correction for multiple comparison). Importantly, 
these effects are not explained by differences in activity within the maze: closed 
arm entries (Fig. 5.1 C) and total arm entries (Fig. 5.1 D) are invariant across 
genotypes. Heterozygous animals were included in this paradigm, and 
interestingly appear to have an anxiety phenotype intermediate between wt and 
hom animals, with data being neither significantly different to wt nor to hom 
mice. 
 
 
Chapter 5: Screening anxiety and depression phenotypes of α2Q241M 
knock-ins  141 
 
 
 
Figure 5.1 – α2Q241M confers an anxious phenotype in the elevated plus maze 
A. and B. Bar charts detailing the percentage time spent in the open arms (A) and the 
percentage of entries onto open arm (B) for each genotype (n=9 animals per 
genotype).  There is a tendency for hom and het animals to spend less time on, and 
make fewer entries onto the open arms compared to wt. Hom animals spend 
significantly less time on open arms than wt littermates (* - p<0.05 paired t-test, 
Bonferroni corrected for multiple comparisons). 
C. and D. Activity measures – total arm entries (C) and closed arm entries (D) – are 
unchanged across genotypes. 
 
Elevated plus maze findings are corroborated by the behaviour of uninjected 
mice in the light-dark box paradigm. This test focussed on comparing wt and 
hom animals only. Several parameters scored in this procedure are consistent 
with hom mice being anxious relative to wt littermates. Firstly, hom mice leave 
the light zone more quickly at the start of the test than wt mice (Fig. 5.2 A). As 
well as this active avoidance response, anxiety in hom mice also increased their 
passive avoidance responses, manifesting in a decreased number of returns to 
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the light zone (i.e. fewer transitions between zones – Fig. 5.2 B) and a reduced 
time spent in the light zone (and correspondingly more time in the dark zone – 
Fig. 5.2 C). 
 
 
Figure 5.2 – α2Q241M confers an anxious phenotype in the light-dark box 
Homozygotes are faster to exit the light zone (A), make fewer transitions between the 
two zones (B), spend more time in the dark zone (C) and tend to show less exploratory 
activity (D) within the box than wt littermates (n=8 animals per genotype). Significant 
differences between genotypes are marked: * - p<0.05 and ** - p<0.01 (unpaired t-
test). 
 
The reduced exploratory activity of hom mice within the dark zone is also 
consistent with an anxiety phenotype (Fig. 5.2 D). Although the exploratory 
activity in the light zone is no different between wt and hom animals (Fig. 5.2 D), 
all of the other parameters are in line with an anxiety phenotype in hom animals. 
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Data from both tests therefore support the prediction that endogenous 
neurosteroids modulate baseline anxiety, at least in part, by potentiation at α2-
type GABAA receptors. 
 
 
5.2.2. GABAA receptor α2 subunits mediate the anxiolysis of injected 
neurosteroids at low doses 
 
Having demonstrated a role for GABAA receptor α2 subunits in anxiolytic 
responses to endogenous neurosteroids, the investigation was extended to ask 
whether this subunit is also involved in mediating the anxiolytic response to 
exogenously applied neurosteroids. Plus maze and light-dark box tests were 
repeated, using mice pre-injected with the neurosteroid THDOC, at doses 
previously known to be anxiolytic in both tests (Wieland et al., 1991; Rodgers & 
Johnson, 1998). 
 
In the elevated plus maze, both doses of THDOC (10 mg/kg and 20 mg/kg) are 
anxiolytic in wt animals, increasing percentage time on open arms (Fig. 5.3 A) 
and percentage open arm entries (Fig. 5.3 B) relative to vehicle injected mice. 
The total number of arm entries increases at 20 mg/kg THDOC (Fig. 5.3 D), but 
there is no change in closed arm entries (Fig. 5.3 C). Although the former could 
suggest an increased locomotor activity, some investigators have suggested 
closed arm entries is a better activity measure, because it is independent of the 
(anxiety-related) number of open arm entries (Rodgers & Johnson, 1995).  
 
THDOC injection is also anxiolytic in hom mice on the elevated plus maze, but 
only at the higher (20 mg/kg) dose: at 10 mg/kg THDOC, hom animals spend 
significantly less time on and make significantly fewer entries into open arms 
than wt littermates (Fig. 5.3 A, B), and these parameters are no different to 
those for vehicle-injected homozygotes. Such a rightward shift in the anxiolytic 
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dose-response curve for α2Q241M mice is consistent with our prediction of 
reduced anxiolytic potency of neurosteroids. 
 
 
Figure 5.3 – α2Q241M influences behavioural responses to injected THDOC on the 
elevated plus maze 
A. and B. Bar charts detailing the effect of THDOC injection on percentage time spent 
on the open arms (A) and the percentage open arm entries (B) for each genotype. 
C. and D. Activity measures – closed arm entries (C) and total arm entries (D) – are 
potently reduced by THDOC in hom animals only. 
Data represent the mean (error bars, s.e.m.) of 6-7 animals per group. * - p<0.05, ** - 
p<0.01 and *** - p<0.001 for effect of THDOC vs. vehicle (veh); # - p<0.05, ## - p<0.01 
and ### - p<0.001 for effect of genotype at a given dose of THDOC. Comparisons 
were either ANOVA, with multiple comparisons corrected with Benjamini-Hochberg 
adjustment (B, C), or all pairwise Behrens-Fisher comparisons (A, D). 
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Unexpectedly, hom animals respond to THDOC with profound reductions in 
locomotion: both doses significantly decreased closed arm entries (Fig. 5.3 C) 
and total arm entries (Fig. 5.3 D) when compared to vehicle treated animals, or 
to wt animals at equivalent THDOC dose. Whilst these activity effects could cast 
doubt over the genotypic difference in anxiety measures, the percentage open 
arm entries measure inherently accounts for total arm entries made during the 
test (i.e. the reduced activity is accounted for in Fig. 5.3 B). The conclusion that 
anxiolytic potency of neurosteroids is diminished in α2Q241M mice therefore still 
stands. However, THDOC’s ataxic effects pose some serious problems with the 
light-dark box approach, as will be discussed below. The mechanism underlying 
these activity effects is explored in Section 5.2.5. 
 
In the light-dark box procedure, as with the elevated plus maze, injections of 
THDOC have classical anxiolytic effects in wt animals. The 20 mg/kg dose 
increases time to first exit the light zone compared to vehicle-treated animals 
(Fig. 5.4 A), consistent with an abated active avoidance response to the 
aversive light zone. This dose of THDOC also releases inhibition on exploratory 
activity in the wt mice, leading to increased transitions between the two zones 
(Fig. 5.4 B) and increased line crossings within each zone (Fig. 5.4 D). 
However, THDOC’s anxiolytic effects are not manifest in an increased time 
spent in the light zone (Fig. 5.4 C). 
 
Surprisingly, THDOC injection into hom mice has apparent anxiogenic effects in 
the light dark box, including significant reductions in transitions between zones 
(Fig. 5.4 B) and time spent in the light zone (Fig. 5.4 C). THDOC also tends to 
reduce exploratory activity in both zones; although the effect only reaches 
significance in the dark zone at 20 mg/kg vs. vehicle, activity is significantly 
lower than for wt animals at both doses of THDOC (Fig. 5.4 D). Given the 
potent ataxic effects of THDOC in hom animals within the elevated plus maze, 
however, it is difficult to determine whether these are truly anxiogenic effects, or 
an artefact of altered motor activity. For example, decreased time in the light 
zone may represent mice sleeping/resting in the dark zone, rather than avoiding 
the light zone. 
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Figure 5.4 – α2Q241M alters response to THDOC injection in the light-dark box 
Bar charts detailing the effect of intraperitoneally-injected THDOC on time to exit the 
light zone (A), the number of transitions between the two zones (B), time spent in the 
light zone (C) and the exploratory activity within each zone (D).  
Data represent the mean (error bars, s.e.m.) of 6-9 animals per group. * - p<0.05, ** - 
p<0.01 and *** - p<0.001 for effects of THDOC vs. vehicle (veh); + - p<0.05 for effect of 
20 mg/kg vs. 10 mg/kg THDOC; # - p<0.05, ## - p<0.01 and ### - p<0.001 for effect of 
genotype at a given dose of THDOC. Comparisons were by ANOVA, with multiple 
comparisons corrected with Benjamini-Hochberg adjustment, except dark zone 
exploratory activity, which was subject to all pairwise Behrens-Fisher comparisons. 
 
Unlike in the elevated plus maze, there is no easy means to correct for 
THDOC’s activity effects in the light-dark box. Interestingly, THDOC-treated 
hom mice still exit the light zone very quickly (Fig. 5.4 A). Apparently, the initial 
need to escape from the aversive light zone is sufficient motivation for active 
avoidance, despite the drug’s activity-reducing effect. Time to exit the light zone 
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at 20 mg/kg THDOC is no different to that for vehicle treated mice – consistent 
with a lack of anxiolytic effect of the drug in hom animals. Therefore, light-dark 
box results may well concur with those from the elevated plus maze. 
 
Scoring for the light-dark box test was performed in two minute bins, allowing 
any time-dependent effects to be probed. Habituation of mice to the new 
environment of the box manifests in a tendency for reduced exploratory activity, 
in either zone, with increasing time. Habituation of wt and hom animals occurs 
at similar rates following vehicle injection (Fig. 5.5 A), but the effects of THDOC 
treatment on activity timecourses diverge between genotypes. THDOC 
counteracts habituation in wt mice (Fig. 5.5 B), and at the higher dose actually 
increases activity over time (compare bins 2/3 with bin 1). Conversely, THDOC 
accelerates habituation of hom mice (Fig. 5.5 C), with significant activity 
reductions occuring at earlier time bins than vehicle-treated controls. 
 
Interestingly, THDOC does not significantly affect activity of either genotype in 
the first scoring bin (0-2 min timepoint of test, effects of dose: wt, p = 0.20; hom, 
p = 0.22). The time spent in each zone during this time bin may therefore be 
used as an anxiety measure without confound from activity effects (Fig. 5.5 D). 
A trend consistent with THDOC-mediated anxiolysis (increased time in light 
zone / decreased time in dark zone) is seen in wt animals, although this does 
not quite reach significance. Conversely, THDOC appears anxiogenic in hom 
animals (less time in light zone / more time in dark zone) with significant effects 
of 20 mg/kg THDOC vs. vehicle-treated homs and vs. 20 mg/kg THDOC-treated 
wt mice. When the same analysis is applied to data from uninjected animals 
(Fig. 5.5 E), hom mice still tend toward an anxious phenotype, although the 
difference between genotypes is not quite significant (p = 0.09, t-test). Data in 
Fig. 5.5 D therefore seem consistent with elevated plus maze findings – the 
α2Q241M mutation has disrupted the anxiolytic response to injected neurosteroid. 
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Figure 5.5 – Timecourse analysis of light-dark box results 
A – C. Time courses for activity (grid lines crossed) in both zones of the light-dark box for 
mice injected with 2-hydroxypropyl-β-cyclodextrin vehicle (A) show a trend to decrease. 
This decrease is prevented by THDOC in wt animals (B), and accelerated by THDOC in 
hom animals (C). Activity within the first two minutes of the test (bin 1) is not significantly 
affected by THDOC in either genotype. Presented data represent the mean (error bars, 
s.e.m.) of 6-9 animals per group. * - p<0.05 and ** - p<0.01 (repeated measures ANOVA 
with Dunnett comparisons to bin 1). 
D – F. Bar charts detail the time spent in each zone of the light-dark box in the first two 
minutes of the test for experiments with THDOC injected (D), untreated (E) and diazepam 
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injected (F) mice. Presented data represent the mean (error bars, s.e.m.) of 6-9 animals 
per group. *** - p<0.001 for effect of THDOC vs. vehicle (veh); + - p<0.05 for effect of 4 
mg/kg diazepam vs. 0.5 mg/kg and 1 mg/kg doses of diazepam; ### - p<0.001 for effect of 
genotype at 20 mg/kg THDOC. Comparisons were either by ANOVA, with multiple 
comparisons corrected with Benjamini-Hochberg adjustment (F) or non-parametric all-
pairwise Behrens-Fisher comparisons (D). 
 
 
5.2.3. Anxiolytic effects of pentobarbital and diazepam are retained in α2Q241M 
knock-in mice 
 
Results presented above indicate a disrupted anxiolytic response to 
neurosteroids in α2Q241M mice. This could be a specific consequence of losing 
neurosteroid potentiation at α2-type GABAA receptors, or due to some general 
defect in their anti-anxiety circuitry. Sensitivity to pentobarbital and diazepam 
potentiation is normal for α2Q241Mβ3γ2S receptors expressed in HEK293 cells, 
and for sIPSCs recorded from brain slices of hippocampus and nucleus 
accumbens (Fig. 3.1, Fig. 4.4; Hosie et al., 2006). A normal anxiolytic response 
to diazepam or pentobarbital would therefore be expected for α2Q241M knock-in 
mice. However, refer back to Section 3.3.3 for a discussion of how endogenous 
neurosteroids may complicate behavioural approaches. In spite of these 
complications, the anxiolytic potencies of pentobarbital and diazepam have 
been assessed using the plus maze and light-dark box procedures. 
 
Pentobarbital was more potent in our mouse strain than reported elsewhere 
(Lister, 1987): in preliminary tests, 20 mg/kg pentobarbital induced loss of 
righting reflex in our strain. Lower intraperitoneal doses were therefore 
employed in this test (10 and 15 mg/kg). Although there is a significant increase 
in time spent on open arms for wt animals at 15 mg/kg (Fig. 5.6 A), this may 
well be a consequence of hyperactivity at this dose (increased total arm entries 
– Fig. 5.6 D). Using percentage open arm entries (Fig. 5.6 B) as an anxiety 
measure that is independent of altered activity, we see a trend to an increase 
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(i.e. anxiolysis) in both genotypes; however two-way ANOVA suggests the 
effect of drug is not quite significant (p = 0.06, F = 3.04, 2 d.f.). Encouragingly, 
we can be confident that there is no effect of genotype (ANOVA p = 0.32, F = 
1.02, 1 d.f.), nor an interaction effect (ANOVA p = 0.64, F = 0.45, 2 d.f.). There 
is no effect of drug or genotype on activity as assessed by closed arm entries 
(Fig. 5.6 C), although there is a tendency towards increased activity at the 
higher dose of pentobarbital. 
 
Because pentobarbital also appeared to be strongly motor impairing at the 15 
mg/kg anxiolytic dose – mice showed an uncoordinated gait, or even fell off the 
open arms of the maze – this drug was not taken forward to light-dark box 
comparisons. Overall, elevated plus maze results suggest that pentobarbital 
tends to be anxiolytic with similar potency in both genotypes. 
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Figure 5.6 – α2Q241M does not influence pentobarbital’s effect on elevated plus 
maze behaviour 
A. and B. Bar charts detailing the effect of pentobarbital injection on percentage time 
spent in the open arms (A) and the percentage open arm entries (B) for each genotype. 
C. and D. Activity measures – closed arm entries (C) and total arm entries (D) – reveal 
pentobarbital-induced hyperactivity in wt animals only. 
Data represent means (error bars, s.e.m.) for 6 animals per group. *** - p<0.001 for 
effects of drug vs. saline (all pairwise Behrens-Fisher comparisons). 
 
Diazepam’s anxiolytic effects in the elevated plus maze were seen in both wt 
and hom mice, which tend to spend more time on open arms with diazepam 
treatment (Fig. 5.7 A). For percentage time on open arms, two-way ANOVA 
finds an effect of drug (p = 0.02, F = 4.37, 2 d.f.) but no effect of genotype (p = 
0.61, F = 0.27, 1 d.f.) and no interaction effect (p = 1.0, F = 0, 2 d.f.); none of 
the individual pairwise comparisons reach significance. Anxiolytic effects of 
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diazepam are additionally seen as increased percentage entries onto open 
arms (overall Kruskal-Wallis test, p = 0.03), individual pairwise comparisons in 
this case also reveal significant effects of drug vs. vehicle (and no differences 
between genotypes at any dose – see Fig. 5.7 B). There are no statistically 
significant effects of diazepam or genotype on activity measures within the plus 
maze (Fig. 5.7 C, D). Results are therefore consistent with a retained anxiolytic 
effect of diazepam in α2Q241M mice. 
 
Figure 5.7 – α2Q241M does not influence diazepam’s effect on elevated plus maze 
behaviour 
A. and B. Bar charts detailing the effect of diazepam injection on percentage time 
spent in the open arms (A) and the percentage open arm entries (B) for each genotype. 
C. and D. Activity measures – closed arm entries (C) and total arm entries (D) – are 
not significantly affected by genotype or diazepam administration. 
Data are the mean (error bars, s.e.m.) of 6-9 animals per group. ** - p<0.01 for effects 
of diazepam vs. vehicle (veh) (all pairwise Behrens-Fisher comparisons). 
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A wider range of diazepam doses was employed in the light-dark box procedure 
to probe dose-responses in finer detail. Diazepam’s effects in wt animals closely 
mirror the pattern of effects seen by Hascoet and Bourin (1998). We see a 
biphasic effect of diazepam on activity in light and dark zones (Fig. 5.8 D): low 
doses, 0.5 and 1 mg/kg, tend to increase activity (anxiolytic effect), whilst higher 
doses, 2 and 4 mg/kg, tend to decrease activity (sedative effect). Although 
increased time to exit the light zone at 2 and 4 mg/kg (Fig. 5.8 A) could 
represent anxiolytic effects of the drug, decreased exploratory activity at these 
doses implicates a contribution of sedation. Transitions between zones (Fig. 5.8 
B) and time spent in the light zone (Fig. 5.8 C) fail to demonstrate diazepam 
anxiolysis. The former parameter only revealed sedative effects of higher 
diazepam doses, and the latter shows no significant variation with dose. 
 
Homozygous animals appear unresponsive to diazepam in the light-dark box 
test, showing no increase in time to exit light zone (Fig. 5.8 A), no change in 
transitions between zones (Fig. 5.8 B), no change in time spent in the light zone 
(Fig. 5.8 C), nor any alteration in exploratory activity in either zone (Fig. 5.8 D). 
Exploratory activity clearly depends on a mixture of anxiolysis (increases 
activity) and sedation (decreases activity). The apparent diazepam insensitivity 
of exploratory activity in hom animals could result if these mice were more 
sensitive to sedation – e.g. sedation at a dose of 1 mg/kg cancelling out the 
activity increase expected for anxiolysis. This notion is consistent with the 
apparent hom hypersensitivity to sedation with THDOC. However, transitions 
between zones and time to exit light zone results are not consistent with ‘hyper-
sedation’ by diazepam, arguing instead that hom α2Q241M mice are simply 
insensitive to diazepam in this test. Furthermore, even when focussing only on 
the first time bin of scoring (Fig. 5.5 F), an approach that helped to reduce the 
problem of THDOC’s activity effects, data still fail to demonstrate an anxiolytic 
effect of diazepam. 
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Figure 5.8 – α2Q241M alters response to diazepam in the light-dark box 
Bar charts detailing the effect of intraperitoneally-injected diazepam on time to exit the 
light zone (A), time spent in the light zone (B), the number of transitions between the 
two zones (C) and the exploratory activity within each zone (D).  
Presented data represent the mean (error bars, s.e.m.) of 7-8 animals per group. 
Statistically significant differences are highlighted: * - p<0.05 and ** - p<0.01 for effect 
of diazepam dose vs. vehicle (veh); + - p<0.05 and ++ - p<0.01 for effect of diazepam 
dose vs. 1 mg/kg diazepam; & - p<0.05 and && - p<0.01 for effect of diazepam dose 
vs. 0.5 mg/kg diazepam; # - p<0.05 and ## - p<0.01 for effect of genotype at a given 
diazepam dose. Comparisons were by ANOVA, multiple comparisons corrected by 
Benjamini-Hochberg adjustment. 
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5.2.4. Knock-in mutation α2Q241M does not confer a depression phenotype 
 
There is no effect of the knock-in mutation on the immobility time of untreated 
mice subjected to the tail suspension test (Fig. 5.9 A), which suggests that the 
α2Q241M mutation does not induce depression – at least not in the homozygous 
state. Injected THDOC has no effect on immobility time of wt mice, and tends to 
increase immobility in hom mice at both doses (Fig. 5.9 B). Two-way ANOVA 
results indicate an effect of genotype (p = 0.006, F = 8.92, 1 d.f.), no overall 
effect of THDOC treatment (p = 0.061, F = 3.08, 2 d.f.) and no interaction effect 
(p = 0.316, F = 1.2, 2 d.f.). Unadjusted LSD comparisons suggest significant 
effects of 5 mg/kg (p = 0.03) and 10 mg/kg (p=0.03) THDOC vs. vehicle for hom 
animals, and a significant difference between immobility time for wt and hom 
animals at 10 mg/kg THDOC (p = 0.01); however, none of these values survive 
correction for multiple comparisons. 
 
 
Figure 5.9 – Immobility in the tail suspension test is unaffected by mutation 
α2Q241M 
A. Baseline behavioural despair (total immobility time) in untreated animals is no 
different across genotypes (n=8 animals per genotype). 
B. THDOC does not decrease immobility time in wt animals; the trend to increased 
immobility time with THDOC dose in hom animals is consistent with ataxic effects 
observed in other tests. None of the individual pairwise comparisons reach significance 
(n=5-7 animals per group). 
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The tendency toward increased immobility in hom animals is consistent with 
above observations that THDOC reduces motor activity in these mice, and so is 
unlikely to indicate a depressive effect of THDOC injection. The lack of 
reduction in immobility in wt mice suggests that THDOC is not antidepressant 
within the tail suspension test. 
 
 
5.2.5. Ataxic effects of THDOC injection in hom mice: not a consequence of 
increased motor impairment 
 
Performance of wt and hom mice on an accelerating rotarod was used as a 
measure of motor coordination. Scoring assessed the time taken for the mice to 
fail the test by either falling off the rod, or passively rotating with it. As can be 
seen from Fig. 5.10 A, initial performance on the rod is no different between wt 
and hom mice – i.e. the α2Q241M mutation has no inherent motor-impairing 
effects. 
 
Mice were next trained to achieve a consistent and reproducible performance 
on the rotarod, as detailed in the Section 2.7.5. Performance of these mice was 
then assessed following THDOC injection, and expressed for each mouse 
relative to his performance on the preceding training day (Fig. 5.10 B). There 
was no motor impairing effect of vehicle or THDOC at a dose of 10 mg/kg. An 
approximately 20 percent decline in performance is seen for both wt and hom 
animals at 20 mg/kg THDOC. Whilst the effect of drug only reaches significance 
for hom animals, there is no difference in performance of wt and hom animals at 
any dose. In addition, 10 mg/kg THDOC, which has clear activity-reducing 
effects in hom animals in other behavioural tests, produces no motor 
impairment within the rotarod test. This would suggest that the activity effects of 
THDOC cannot be explained by an enhancement of motor impairing effects of 
this drug in hom mice. 
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Figure 5.10 – α2Q241M does not affect performance on the accelerating rotarod 
under baseline or THDOC-treated conditions 
A. Baseline performance on the rotarod (time to fail the test) is no different across 
genotypes. 
B. THDOC impairs motor performance on the rotarod (reduces time to failure) only 
when administered at a dose of 20mg/kg. This effect reaches significance in hom 
animals: * - p<0.05 for effect of 20 mg/kg THDOC vs. vehicle (veh); + - p<0.05 for 
effect of 20 mg/kg THDOC vs. 10 mg/kg THDOC; all pairwise Behrens-Fisher 
comparisons. 
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5.3. Discussion 
 
5.3.1. Neurosteroids act via α2-type GABAA receptors to modulate anxiety state 
 
Two behavioural screens for anxiety – the elevated plus maze and the light-dark 
box – both demonstrate an anxious phenotype for untreated hom α2Q241M mice 
relative to wt littermates. This result is consistent with a model in which 
endogenous neurosteroid tone in a naïve untreated mouse regulates its 
baseline anxiety state through α2-type GABAA receptors. This conclusion relies 
on a lack of compensatory changes that may provide an alternative explanation 
for these behavioural differences. In favour of this, no changes in GABAA 
receptor protein expression were detected for subunits α1-α5 (see Chapter 3). 
 
Heterozygous animals were included in the elevated plus maze paradigm, and 
interestingly appear, by trend, to have an anxiety phenotype intermediate 
between wt and hom animals. This appears incongruous with work in brain 
slices, where THDOC-mediated prolongation of sIPSC decay time is the same 
in cells from het and wt animals (Fig. 4.3, Fig. 4.4). However, het mice have 
faster decaying baseline sIPSCs than wt mice (Table 4.1), suggesting the 
α2Q241M mutation has some effect when expressed in the heterozygous state. 
As described in Section 4.3.1, a single neurosteroid potentiation site is believed 
sufficient to achieve the full potentiating effect of neurosteroid, and so only a 
quarter of the α2-containing pentamers in het animals should be neurosteroid 
insensitive. Perhaps this small deficit is sufficient to produce a phenotypic effect 
in some situations. Nevertheless, subsequent experiments focussed on 
comparing only wt and hom animals, where we can be sure that neurosteroid 
potentiation has been ablated at all α2-type GABAA receptors in the knock-in 
mice. 
 
Anxiolytic effects of injected neurosteroids are well established (Crawley et al., 
1986; Wieland et al., 1991), and the stress-induced rise in neurosteroids has 
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been purported to be a natural anxiolytic response to restore GABAergic tone 
after stress (Purdy et al., 1991; Barbaccia et al., 1998). Here we provide the first 
direct evidence for endogenous neurosteroids having an anxiolytic effect in an 
unperturbed animal, via α2-type GABAA receptors.  
 
Our suggestion that α2-type GABAA receptors may be mediators of the 
anxiolytic response to injected neurosteroid is also supported by the results of 
behavioural screening. For the elevated plus maze, a clear rightward-shift in the 
dose-response curve for percentage open arm entries indicates a defective 
anxiolytic response to THDOC in hom mice. The anxiolytic response to the 
higher dose (20 mg/kg THDOC) does not invalidate our model: α2 and α3 
isoforms appear to have overlapping roles in benzodiazepine-mediated 
anxiolysis and myorelaxation, with α2 mediating low-dose effects, and α3 
mediating high-dose effects (see Section 1.3.2). We may be observing a related 
phenomenon for THDOC-mediated anxiolysis (i.e. 10 mg/kg acts via α2 
subunits, whilst 20 mg/kg can act via α3 subunits). Future experiments to 
confirm this hypothesis would be to cross-breed α2Q241M mice with either α3 
knock-out mice (e.g. those generated by Yee et al., 2005) or neurosteroid-
insensitive α3Q266M knock-in mice. Mice resulting from such crosses would lose 
neurosteroid potentiation at both α2 and α3 isoforms of the GABAA receptor, 
and be predicted to demonstrate no anxiolytic response to injected THDOC, 
even at high doses. 
 
Modulation of non-GABAergic transmission could also account for the residual 
anxiolysis in hom α2Q241M mutants. Whilst GABAA receptors are sensitive to 
nanomolar levels of neurosteroids, micromolar levels can also modulate 
glutamate (NMDA, AMPA and kainate), glycine, serotonin, nicotinic 
acetylcholine, oxytocin, and sigma-type-1 receptors (see review by Rupprecht & 
Holsboer, 1999). It is difficult to estimate what brain concentration of THDOC 
results from our intraperitoneal injections, which will depend on a number of 
factors. Relative absorption and clearance rates will determine the 
pharmacokinetic profile, whilst a number of factors – such as propensity to 
Chapter 5: Screening anxiety and depression phenotypes of α2Q241M 
knock-ins  160 
 
 
cross the blood-brain barrier – will influence the relative distribution in the brain 
vs. other tissues. In rats, 30 min following subcutaneous injection of 8 mg/kg 
allopregnanolone, brain levels of this compound reach 400 ng per gram tissue 
(Vallee et al., 2000). If intraperitoneally injected THDOC were to act similarly in 
our mouse strain, and if the amount reaching the brain were directly 
proportional to the amount injected, a 20 mg/kg dose of THDOC might be 
expected to produce a brain level of approximately 1000 ng/g tissue (i.e. 3 
micromoles per kg tissue). Whilst this extrapolation is based on some 
oversimplifying assumptions, it would suggest that brain THDOC concentrations 
in injected mice could be in the range of the micromolar levels that modulate 
non-GABAergic transmission. 
 
THDOCs anxiolytic effects in wt mice subjected to a light-dark box test have 
been reported previously (Wieland et al., 1991). We see this effect here as an 
increased time to exit the light zone, increased activity in both zones and 
increased transitions between zones. The time spent in the light does not 
significantly increase, but as alluded to earlier (Section 5.1.2), different 
investigators report distinct patterns of drug effects on light-dark box 
parameters. For example, no effect of diazepam on this parameter has been 
observed by Hascoet and Bourin (1998), depending on mouse strain and 
precise conditions of the test. Perhaps under some testing conditions, vehicle-
injected mice are already spending maximal time in the light zone, precluding a 
further increase by an anxiolytic. 
 
Drug effects on activity measures complicate matters further. For example, not 
all investigators agree with using increased time to exit light zone as an 
indication of anxiolysis because it could also indicate sedation. Given that 20 
mg/kg THDOC increases wt exploratory activity, the increased time to exit the 
light zone probably represents anxiolysis rather than sedation. The increased wt 
activity following THDOC injection (increased transitions between zones and 
increased exploratory activity) could also represent a stimulant effect of 
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THDOC, but the lack of increase in closed arm entries on the elevated plus 
maze indicates anxiolysis is the more likely explanation. 
 
THDOC has potent ataxic effects in hom mice, precluding a standard light-dark 
box approach to studying anxiety, because it is difficult to disentangle activity 
and anxiety effects within this test. There are some indications, however, that 
α2Q241M knock-in disrupts anxiolysis. Firstly there is no increase in time to exit 
the light zone with THDOC treatment of hom mice (Fig. 5.4 A), whilst activity-
reducing and anxiolytic effects of this drug would both be expected to increase 
this duration. It would therefore seem that placement in the light zone is 
sufficiently aversive to motivate an active avoidance response in hom mice, 
despite the activity-reducing effects of THDOC. Additional support for failure of 
anxiolysis in hom mice comes from analysis of the first two minutes of the test, 
where activity effects are not significant. Using the relative time spent in light vs. 
dark zones as an anxiety measure, wt mice show an anxiolytic-like response to 
THDOC, but hom mice demonstrate anxiogenesis. Whilst anxiogenesis was not 
seen in the elevated plus maze, these data concur that α2Q241M has disrupted 
anxiolysis. 
 
The tests used in this body of work probe only one type of anxiety, relating to 
inhibition of exploratory behaviour. This anxiety can also be probed with an 
open field apparatus, but one would predict results to be very similar to those of 
the light-dark box test – and to suffer the same difficulties when trying to 
distinguish emotionality from locomotor/activity effects (Stanford, 2007). 
Alternative rodent anxiety screens include conditioned paradigms, where 
subjects learn to associate particular non-noxious environmental cues with a co-
presented foot-shock, and subsequently demonstrate fearful responses to these 
cues in the absence of foot-shock. There is a precedent for a role of GABAA 
receptor α2 subunits in this type of anxiety, because α2-/- mice show an 
anxious phenotype in a conditioned emotional response task (Dixon et al., 
2008). It would be interesting to compare α2-/- and hom α2Q241M mice in such a 
task, to investigate whether the anxious phenotype of α2-/- mice is a 
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consequence of losing neurosteroid potentiation at the α2-type GABAA 
receptors. 
 
 
5.3.2. Anxiolytic effects of pentobarbital and diazepam  
 
To ensure that the disrupted anxiolysis in hom α2Q241M mice is purely a 
consequence of lost neurosteroid potentiation at the α2-type GABAA receptors, 
and not a general inability of hom mice to respond to any anxiolytic agent, 
behavioural studies were extended to include other GABAA receptor 
potentiators. If the normal circuitry for anxiety is intact in hom mice, and there 
have been no compensatory changes in response to the α2Q241M mutation, 
sensitivity to diazepam and pentobarbital should be retained. This is certainly 
true for the electrophysiological effects of these drugs when the mutation is 
studied in HEK cells or brain slices from the transgenic mice (Fig. 3.1, Fig. 4.4; 
Hosie et al., 2006). 
 
Pentobarbital’s anxiolytic effects are not particularly potent in either genotype in 
our mouse strain. For percentage time spent in open arms, it seems that there 
is a tendency for an overall effect of drug, but no overall effect of genotype, 
which would be consistent with retained anxiolytic function of pentobarbital in 
α2Q241M mutant mice. Lister (1987) demonstrated pentobarbital anxiolysis in the 
elevated plus maze, but only at a dose of 30 mg/kg; it was not possible to try 
this dose in our mouse strain because preliminary tests with this drug found loss 
of righting reflex at 20 mg/kg. Pentobarbital was not extended to the light-dark 
box paradigm due to its effects on activity, and because, the anxiolytic dose of 
pentobarbital (15 mg/kg) appeared, anecdotally, to be motor-impairing in 
animals of both genotypes. 
 
Diazepam effects on wt animals are as one would expect for an anxiolytic drug 
in both behavioural screens, although not all parameters in the light-dark box 
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are consistent with anxiolysis. As expected exploratory activity rises at low 
doses (anxiolysis) and falls at higher doses (sedation). A lack of increase in 
time spent in the light zone might be expected, given that THDOC also fails to 
increase this parameter in wt mice. Unlike with THDOC, when examining the 
‘transitions between zones’ parameter, diazepam-treated mice also fail to show 
anxiolysis, only revealing sedative effects of higher doses. Methodological 
differences between tests using THDOC and diazepam, such as the post-
injection time at which mice are tested (15 min and 30 min, respectively), may 
account for this difference. Mice treated with diazepam-vehicle are less anxious 
than the THDOC-vehicle mice (46 ± 4 vs. 36 ± 3 transitions, respectively). A 
lower baseline anxiety level for the diazepam-dose response curve reduces 
scope for anxiolysis to be detected for this parameter (analogous to the time 
spent in the light zone). 
 
In this study, spatiotemporal anxiety measures within the elevated plus maze 
show similar anxiolytic effects for diazepam in wt and hom mice. It is unclear 
why hom mice fail to display a response to diazepam in the light-dark box. The 
latter test is more susceptible to any activity differences between groups being 
compared, and there may be some subtle genotypic differences in activity 
effects that are precluding observation of anxiolysis. One might therefore place 
more faith in the elevated plus maze paradigm, in which activity effects can be 
accounted for before making conclusions about anxiety. On that basis, it 
appears that there is no clear effect of the mutation on diazepam sensitivity, and 
the loss of THDOC sensitivity is a specific effect of the α2Q241M mutation. To 
support this conclusion, it would be sensible to repeat the diazepam dose-
response analysis on the plus maze, using the wider range of doses that was 
employed in the light-dark box test, to examine the anxiolytic dose-response 
curve in finer detail.  
 
One must also remember that responses to injected drugs are taking place on a 
background of endogenous neurosteroids. Because the response to these 
endogenous steroids is diminished in hom mice, we might also expect a 
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disrupted response to diazepam (see Section 3.3.3). Adding further complexity, 
diazepam can increase the production of these endogenous neurosteroids, via 
the ‘peripheral benzodiazepine receptor’ (now called translocator protein 18, 
TSPO (Papadopoulos & Lecanu, 2009)). Interestingly, accumulating evidence 
implicates this neurosteroid production as a mediator in the overall in vivo 
response to benzodiazepines (e.g. midazolam’s anticonvulsant effect is partly 
mediated via neurosteroid production (Dhir & Rogawski, 2012)). The lack of 
diazepam-mediated anxiolysis we observe for hom mice in the light-dark box 
may therefore be suggesting a role for endogenous neurosteroids in this 
response. To probe whether this is the case, mice could either be pre-treated 
with finasteride (to block neurosteroidogenesis), or the experiment repeated 
with a benzodiazepine that does not act on TSPO, e.g. zolpidem (Trapani et al., 
1997). The former would be more challenging to implement, as measurements 
would need to confirm that finasteride has successfully ablated production of 
endogenous neurosteroids, but would probably be preferable to the latter (since 
endogenous neurosteroids other than those produced by benzodiazepine action 
at TSPO could still account for a difference in anxiolysis by zolpidem). 
 
 
5.3.3. Depression may not involve neurosteroids acting at α2-type GABAA 
receptors 
 
Anxiety and depression are frequently co-morbid, both may be treated with 
SSRIs and probably share common underlying patho-physiological mechanisms 
(Hirschfeld, 2001; Nutt et al., 2006; Smith & Rudolph, 2012). The depressed 
phenotype of α2-/- mice (Dixon et al., 2008), and involvement of neurosteroids 
in depression (discussed in Section 1.4.2) may lead one to predict that hom 
α2Q241M mice will be depressed as well as anxious at baseline. However, this is 
not what we observe using the tail suspension test (Fig. 5.9 A). Nevertheless, a 
single test cannot discount a phenotype; for example α2-/- mice were judged 
‘depressed’ in most, but not all behavioural tests tried (Vollenweider et al., 
2011).  Furthermore, heterozygous α2 knockout (α2+/-) mice often showed a 
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phenotype that was absent in homozygous knockouts (α2-/-), possibly due to 
(undefined) compensatory changes in α2-/- mice that reduce depression which 
are not present in the α2+/- mice. Perhaps the same is true of α2Q241M knock-in 
mice; future experiments should therefore not only consider alternative tests for 
depression, but also include het mice. Alternative screens for depression 
include ‘novelty suppressed feeding’ (Dulawa & Hen, 2005), forced swim 
(Porsolt et al., 1978) and sucrose-preference (Papp et al., 1991) tests. If 
α2Q241M mice fail to show a phenotype in these tests, anxiety and depression 
may well be less tightly coupled than currently thought, with anxiety more 
closely linked with neurosteroid regulation of α2-type GABAA receptors. 
Consistent with anxiety and depression being dissociable phenomena, GABAB 
receptor knockout mice are more anxious but less depressed than wt 
counterparts (Mombereau et al., 2004; Mombereau et al., 2005). 
 
Surprisingly, THDOC does not appear to be antidepressant in wt mice in our 
study (Fig. 5.9 B). We employed a tail suspension procedure that has been 
previously validated (Can et al., 2012); nevertheless, unknown differences in 
variables between labs can affect success of behavioural tests, so future 
experiments will also include use of a known antidepressant, such as the 
tricyclic agent desipramine, as a positive control. Furthermore, antidepressant 
efficacy in the tail suspension test can vary widely with mouse strain (van der 
Heyden et al., 1987) – perhaps the α2Q241M mutation could be tried in an 
alternative background strain to C57BL/6J, in case there is some interaction of 
strain with antidepressant efficacy of THDOC. Unsurprisingly on the basis of 
results in other tests, THDOC increases immobility in hom mice in the tail 
suspension test, probably representing the ataxic effects of the drug (rather 
than an induction of behavioural despair). 
 
Interestingly, although allopregnanolone levels are reduced in depressed 
individuals, THDOC levels are increased; antidepressant SSRIs increase 
allopregnanolone and decrease THDOC (Romeo et al., 1998; Uzunova et al., 
1998; Strohle et al., 1999; Strohle et al., 2000). Furthermore, whilst 
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antidepressant effects of progesterone and allopregnanolone have been 
extensively verified in animal models (Khisti et al., 2000; e.g. Hirani et al., 2002; 
Shirayama et al., 2011), we are unaware of any references demonstrating 
antidepression with THDOC. Given that both compounds are GABAA receptor 
potentiators, it is not clear why allopregnanolone could be antidepressant whilst 
THDOC is not, but perhaps there are subtle differences in their action in vivo, 
such as differential effects on non-GABAA receptor targets, that account for this 
discrepancy. Furthermore, the sulphated neurosteroids DHEA-sulphate and 
pregnenolone-sulphate, both negative allosteric modulators of GABAA 
receptors, also demonstrate antidepressant efficacy in the tail suspension test, 
probably via actions at sigma receptors (Dhir & Kulkarni, 2008). It would 
therefore seem that antidepressant action by neurosteroids is not restricted to 
GABAA receptor potentiation. 
 
 
5.3.4. Exploring the mechanism underlying THDOC’s ataxic effects in α2Q241M 
mice 
 
Several mechanisms could account for the reduced activity of THDOC-injected 
hom mice in the plus maze, light-dark box and tail suspension tests, including 
sedation/sleeping, freezing or impaired motor performance. Freezing is a 
normal rodent fear response; however, given that 20 mg/kg THDOC was 
activity-reducing but also anxiolytic in hom mice on the elevated plus maze, 
fear-induced freezing is unlikely to explain the reduced mobility. Sedation could 
be studied in several ways, including loss-of-righting reflex tests or by screening 
changes in electro-encephalogram (EEG) on THDOC injection; the latter may 
be more relevant to this work because the marked activity reductions are 
occurring at doses below the threshold for loss-of-righting reflex. During this 
project, THDOC’s motor-impairing effects were assessed using an accelerating 
rotarod test (Jones & Roberts, 1968). The performances of untrained wt and 
hom mice were similar in this procedure (Fig. 5.10 A), suggesting the α2Q241M 
mutation has no effect on motor function. After training, mice achieve a better 
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and more consistent performance on the rod; injection of vehicle or 10 mg/kg 
THDOC did not affect performance, whilst a similar degree of impairment was 
observed for both wt and hom animals after a 20 mg/kg dose (Fig. 5.10 B). We 
cannot rule out a genotypic difference at other doses of THDOC, but our data 
suggest that differences in motor impairment do not account for the differences 
in activity effects of THDOC. 
 
There are some important differences between the rotarod test and the other 
tests described in this chapter: mice are habituated to handling during the 
course of their training (cf. other tests, where the mouse is only handled for 
routine husbandry and ear notching), and are effectively being forced to walk, in 
order to avoid falling off the rod (cf. other tests, where mice have a free choice 
over whether or not to move). It is difficult to say whether the different natures of 
these tests may affect sensitivity of test subjects to THDOC’s ataxic effects, but 
we can at least be sure that there are no issues of tolerance because all mice 
are drug naïve. Even though different tests do appear to have slight differences 
in dose-responses (e.g. significant anxiolysis for wt mice is achieved at 10 
mg/kg THDOC in the plus maze, but only at 20 mg/kg in the light-dark box), the 
activity effects in hom mice appear to be consistent across tests. If we therefore 
consider activity effects to be similarly dose-sensitive in the rotarod, then we 
have further support that motor impairment does not explain the activity effects: 
10 mg/kg THDOC does not impair hom mice on the rotarod, but significantly 
reduces activity in the light-dark box and elevated plus maze.  
 
To corroborate the above results we could employ alternative tests for motor 
impairment, such as the inverted screen test (Coughenour et al., 1977), which 
has been argued a more sensitive test to motor impairing effects of drug. 
Perhaps a wider range of doses of THDOC should be employed on both tests, 
to ensure there are no genotypic differences in motor impairment at other drug 
concentrations. 
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A further explanation for activity effects is a hypersedative effect of THDOC in 
hom mice; several possible mechanisms could account for increased sedation. 
If, for example, the α1-type GABAA receptors are involved in sedative effects of 
neurosteroids, as they are for benzodiazepines (Rudolph et al., 1999), 
increased sedation could result if there is an increased activity of these subunits 
in hom α2Q241M knock-ins. We can rule out a change in the α1 subunit at the 
level of protein expression with our Western blot and immunofluorescence work, 
but these approaches give no indication of the activity of these ion channels. 
The faster decay kinetics for control sIPSCs recorded from CA1 pyramidal cells, 
dentate gyrus granule cells and nucleus accumbens medium spiny neurons 
(Table 4.1) may well be consistent with an increased contribution of α1-type 
GABAA receptors to these sIPSCs (an increased proportion of α1 vs. α2 
subunits has been shown to reduce decay time of mIPSCs and evoked IPSCs 
(Okada et al., 2000)). We also cannot rule out a mechanism whereby hom mice 
have a greater level of neurosteroids at baseline, such that after THDOC 
injection, brain neurosteroid levels may be sufficient to pass the sedative 
threshold in hom, but not wt mice. Additional experiments are needed to 
address the validity of these proposals. 
 
Sedation, as measured by a reduced locomotor activity, is often taken as an 
indicator of hypnosis, but using EEG fingerprints, it is possible to dissociate 
hypnosis from sedation (Mohler, 2006a). Future experiments probing the 
mechanism underlying THDOC’s hyper-sedative effects will therefore utilise 
EEG studies. If the mutation has led to an enhanced sensitivity to the hypnotic 
effects of neurosteroids, one may predict a reduced sleep latency following 
neurosteroid injection and increases in sleep vs. waking time. Potentiation of 
GABAergic transmission by diazepam has also been shown to have number of 
effects on rodent EEG patterns, including a rise in theta band (6-11 Hz) power 
during rapid eye movement (REM) sleep, decreased delta band (0.75-4 Hz)  
power in non-REM sleep and a reduced theta peak frequency during waking 
(Tobler et al., 2001; Kopp et al., 2004). These investigators found that the 
sleep-state EEG changes are attenuated in benzodiazepine-insensitive α2H101R 
knock-in mice, but not in α1H101R mice, suggesting hypnotic effects may relate to 
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benzodiazepine function at α2-, rather than α1-type GABAA receptors. It would 
therefore be interesting to perform similar experiments to probe the effects of 
α2Q241M mutation on EEG patterns under basal conditions, and after injection of 
neurosteroids. 
 
 
 
5.4. Conclusions 
 
1. Endogenous neurosteroids present at baseline have tonic anxiolytic 
effects, but probably not antidepressant effects, via α2-type GABAA 
receptors. 
 
2. Anxiolytic effects of systemically-applied neurosteroids are mediated, at 
least partly via α2-type GABAA receptors. Neurosteroids targeting the α2-
type GABAA receptor may therefore represent an appropriate treatment 
strategy for anxiety disorders. 
 
3. The α2Q241M mutation does not abolish anxiolytic effects of other GABAA 
receptor potentiators, pentobarbital or diazepam. However, disrupted 
diazepam anxiolysis in the light-dark box suggest that neurosteroid 
responses on α2 subunits may also be required for benzodiazepine 
anxiolysis. 
 
4. Systemically applied THDOC is not antidepressant in the tail-suspension 
test, and therefore may have distinct roles in anxiety and depression 
compared to the related neurosteroid allopregnanolone. 
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5. The ataxic effect of injected THDOC in α2Q241M mutant mice does not 
derive from a hypersensitivity to motor impairing effects of this 
compound. 
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Chapter 6: General Discussion 
 
6.1. Endogenous neurosteroids: functions at α2-type GABAA receptors 
 
6.1.1. Anxiolysis but not anti-depression in unperturbed state 
 
Previous work has implicated signalling through α2-type GABAA receptors as 
being an important component of anxiety circuitry and anxiolysis (Low et al., 
2000; Dixon et al., 2008), and suggested that neurosteroids may act as 
endogenous anxiolytics (Crawley et al., 1986; Purdy et al., 1991; Wieland et al., 
1991; Barbaccia et al., 1998). Our work provides the first direct demonstration 
of a link between the two: that the endogenous anxiolytic function of 
neurosteroids depends on potentiation of signalling through α2-type GABAA 
receptors. Lacking this function, homozygous α2Q241M mice have a more 
anxious phenotype at baseline than their wild-type littermates. 
 
Anxiety and depression are frequently comorbid, and so these disorders may 
have common underlying mechanisms (Hirschfeld, 2001; Nutt et al., 2006). 
Indeed depression has also been associated with reduced GABAergic signalling 
(Luscher et al., 2011b; Smith & Rudolph, 2012), possibly at α2-type GABAA 
receptors (Vollenweider et al., 2011). Further, there are proposals that 
antidepressants achieve their effects by restoring a deficit in allopregnanolone 
levels (Romeo et al., 1998; Uzunova et al., 1998; Strohle et al., 1999; Strohle et 
al., 2000). One may therefore predict a depressed phenotype to be imparted by 
knocking-in the α2Q241M mutation. However, we do not observe such a 
phenotype, using just one test, the tail suspension test. It is therefore possible 
that anxiety and depression are less tightly coupled than currently thought, with 
depression less closely linked with neurosteroid regulation of α2-type GABAA 
receptors. 
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6.1.2. α2Q241M knock-in has no effect on receptor expression 
 
Fluctuating levels of endogenous neurosteroids can influence the expression of 
GABAA receptor subunits. For example, concomitant with the allopregnanolone 
level rises in the estrus cycle of mice, hippocampal expression of δ subunits 
increases and that of γ2 subunits is decreased (Maguire et al., 2005). However, 
we have found no change in expression of GABAA receptor α subunits in our 
male α2Q241M knock-ins. This would suggest that basal neurosteroid potentiation 
at α2-subunits in male mice has little influence on the expression of GABAA 
receptor subunits. 
 
 
6.1.3. Contribution of α2-type GABAA receptors to phasic and tonic transmission 
 
On the basis of the effects of the α2Q241M mutation in recombinant expression 
systems, one would predict that GABAergic neurotransmission will respond 
normally to benzodiazepines, but have an impaired response to neurosteroids 
(when currents are carried by α2-type GABAA receptors). Our recordings from 
three neuronal cell types appear entirely consistent with these predictions. 
Synaptic currents in wild-type animals respond to diazepam (500 nM) and 
THDOC (100 nM) with a similar prolongation of decay time (i.e. enhanced 
inhibitory neurotransmission). In homozygous α2Q241M mice, however, only 
IPSC prolongation by diazepam is normal, and the response to THDOC is 
diminished (CA1 PCs) or ablated (NAcc MSNs and DG GCs). We therefore 
propose that α2-type GABAA receptors contribute significantly to the synaptic 
events in these cell types, and that the residual response of CA1 PCs to 
THDOC probably represents a ~50% contribution from the unaltered α subunit 
isoforms that are also expressed in these cells (α1, α3, α4 and α5). This result 
was to be expected given that α2 subunits play a role in synaptic targeting of 
GABAA receptors (Tretter et al., 2008; Wu et al., 2012) and are strongly 
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expressed in these cells (Fig. 3.4; Sperk et al., 1997; Pirker et al., 2000; 
Sieghart & Sperk, 2002; Mohler, 2006a). 
 
The results we observe with tonic currents were perhaps less expected. 
THDOC increased the amplitude of the tonic currents recorded from DG GCs of 
wild-type animals; there was no such response in cells from homozygous 
α2Q241M mice, indicating a requirement for potentiation at the α2 subunit. We 
believe this represents the first direct support for GABAA receptors containing 
the α2 subunit playing a role in tonic currents. This is particularly interesting 
given that the α2 subunit has been proposed to mostly assemble as α2β2/3γ2 
receptors (McKernan & Whiting, 1996; Sieghart & Sperk, 2002; Mohler, 2006a), 
and the α2 subunit plays a role in directing receptors to synaptic, rather than 
extrasynaptic sites (Tretter et al., 2008; Wu et al., 2012). Such a dual role for 
α2-type GABAA receptors is not unreasonable; indeed, α5βnγ2 receptor 
combinations contribute to both synaptic and tonic currents in hippocampal 
pyramidal cells (Banks et al., 1998; Caraiscos et al., 2004; Prenosil et al., 
2006). Interestingly, however, the synaptic events – but not tonic currents – in 
our wild-type DG GC recordings show a response to diazepam. This difference 
in pharmacological profile would implicate α2βnγ2 receptors in the synaptic 
currents, and γ-subunit-lacking receptor combinations in the tonic currents 
(Pritchett et al., 1989). We therefore propose that the THDOC-sensitive tonic 
current we observe in DG GCs may instead involve receptors of combination 
α2βn or α2βnδ. 
 
 
6.2. The therapeutic potential of neurosteroids in anxiety and depression 
 
6.2.1. THDOC is not antidepressant 
 
Depression has been proposed to result from a deficiency in neurosteroids, 
because allopregnanolone levels are diminished in the plasma and CSF of 
depressed patients, and this deficit is ameliorated by treatment with a range of 
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antidepressants (Romeo et al., 1998; Uzunova et al., 1998; Strohle et al., 1999; 
Strohle et al., 2000). Indeed, selective-serotonin reuptake inhibitor (SSRI) 
antidepressants rapidly increase allopregnanolone production in rodent models 
(Uzunov et al., 1996). Consistent with neurosteroids being the mediators of 
antidepression, antidepressant effects are evident with progesterone and 
allopregnanolone in animal models (e.g. Khisti et al., 2000; Hirani et al., 2002; 
Shirayama et al., 2011). There are, however, a number of problems with this 
proposal: 
1. Humans require chronic SSRI treatment before a benefit is observed, 
whilst the antidepressant effects are immediate in rodents (see 
discussion by Cryan et al., 2005). Interestingly, chronic fluoxetine 
administration in rats actually decreases the plasma and brain 
concentrations of THDOC and allopregnanolone (Serra et al., 2002). 
2. Other non-SSRI antidepressants, such as imipramine, are clinically 
effective, but appear not to act by influencing neurosteroid metabolism 
(Uzunov et al., 1996; Griffin & Mellon, 1999). 
3. The changes in THDOC levels oppose those of allopregnanolone in 
depressed patients (in that THDOC levels increase in depression and are 
decreased by antidepressants (Romeo et al., 1998; Uzunova et al., 1998; 
Strohle et al., 1999; Strohle et al., 2000)).  
4. We were unable to demonstrate an effect of THDOC in the tail 
suspension test – i.e. THDOC appears not to act as an antidepressant. 
 
Points 3 and 4 are particularly troubling when considering the suggestions that 
the antidepressant function of neurosteroids occurs by enhancing GABAergic 
signalling (e.g. Khisti et al., 2000). Both allopregnanolone and THDOC are 
positive allosteric modulators of GABAA receptors, so it is unclear why the 
increased THDOC in depressed patients would not have an antidepressant 
effect. Perhaps there are subtle differences between the action of 
allopregnanolone and THDOC in vivo, such as differential effects on non-
GABAA receptor targets, allowing only the former to be antidepressant. 
Interestingly, sulphated steroids, which are negative allosteric modulators of 
GABAA receptors, are also antidepressant in the mouse tail-suspension test, 
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probably via actions at sigma receptors (Dhir & Kulkarni, 2008). Furthermore, 
benzodiazepines – classical potentiators of GABAergic transmission – are not 
generally antidepressant; only alprazolam has demonstrated any efficacy in 
depression (Laakmann et al., 1996). The antidepressant action of neurosteroids 
is therefore incompletely understood, and is probably not restricted to GABAA 
receptor potentiation.  
 
 
6.2.2. α2-type GABAA receptors are an appropriate target for neurosteroid 
anxiolytics 
 
The anxiolytic response to THDOC injection in both elevated plus maze and 
light-dark box tests is disrupted by the α2Q241M knock-in. These results are 
consistent with our hypothesis that α2-type GABAA receptors will be mediators 
of neurosteroid anxiolysis. We propose that, analogous to benzodiazepines, the 
sedative effects of neurosteroids will involve the α1 isoform. If this is the case, 
subunit selective neurosteroid analogues (with efficacy at α2 and no action at 
α1 subunits) would be non-sedative anxiolytics – opening an alternative avenue 
for drug design to the selective benzodiazepine approach. 
 
 
6.3. Remaining questions and future work 
 
6.3.1. Screening for compensatory changes in α2Q241M mice 
 
Our approach to screening for compensatory alterations in α2Q241M mice was to 
focus on the total protein expression levels for GABAA subunits α1-α5, as likely 
candidates for compensatory changes. Whilst our Western blot and 
immunofluorescence data allow us to conclude that the phenotypes of this 
transgenic mouse are not a result of large changes in expression of GABAA 
receptors, they do not rule out changes in the activity of their ion channels. 
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Indeed, baseline sIPSCs in knock-in mice decay faster than those of wild-type 
littermates, reducing the charge transfer per synaptic event, which may indicate 
some compensatory response to the mutation. However, there are numerous 
observations that would argue against compensatory changes. Firstly, the 
amplitude and frequency of sIPSCs is unchanged, indicating no alteration in the 
number of GABAA receptors expressed at the synaptic site, and/or a lack of 
alteration in presynaptic GABA release. Secondly, the sIPSC decay time 
prolongation by 500 nM diazepam is undiminished by the α2Q241M mutation in 
DG GCs and NAcc MSNs, further indicating an unaltered function of synaptic 
GABAA receptors. Finally, tonic current amplitudes are unchanged in knock-in 
mice, suggesting unchanged activity of extrasynaptic GABAA receptors. We 
propose that the difference in baseline sIPSC decay times can instead be 
explained by a loss of sensitivity to endogenous neurosteroids within the brain 
slice. Indeed, other investigators have supported a role for endogenous 
neurosteroids in modulating baseline IPSC decay times in brain slice recordings 
(Puia et al., 2003).  
 
It would be surprising if loss of neurosteroid function at α2-type GABAA 
receptors does not induce some sort of compensatory change in the neuronal 
network, especially since the basal inhibitory synaptic tone has been reduced in 
the knock-in mice. We therefore propose that future work should use a 
microarray or proteomic approach to screen for differences in expression 
patterns in α2Q241M vs. wild-type mice. Furthermore, other avenues for 
compensation should be considered, particularly screening for alterations in 
neurosteroid levels. Since baseline inhibitory GABAergic neurotransmission in 
the hippocampus is defective in the α2Q241M mutant mice, one may predict a 
heightened activity of the HPA axis in these animals (see Section 1.3.1). If this 
is the case, there would also be elevated production of neurosteroids and other 
steroids in the adrenal cortex. Indeed the heightened plasma and CSF levels of 
THDOC found in depressed patients may be a consequence of the HPA axis 
hyperactivity in these individuals (Shen et al., 2010). Future work will therefore 
compare the brain neurosteroid profile of α2Q241M mice with their wild-type 
counterparts. 
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6.3.2. Understanding the activity effects 
 
Several mechanisms could account for the reduced locomotor activity observed 
in knock-in mice after THDOC injection, including sedation/sleeping, freezing or 
impaired motor performance. Our rotarod data suggest that α2Q241M mice are 
not hyper-sensitive to the motor-impairing effects of THDOC. Future 
experiments probing the mechanism underlying the hyper-sedative effects will 
utilise EEG studies. 
 
 
6.3.3. Future work with α2Q241M mutant mice 
 
Would neurosteroid therapy be addictive? 
The long-term use of benzodiazepines is precluded by the development of 
tolerance and addiction (File, 1985; O'Brien, 2005). Would a neurosteroid-
based therapy suffer the same problems? Some investigators found that no 
tolerance developed to the anticonvulsant effects of pregnenolone or the 
neurosteroid analogue, ganaxolone, in rodents (Kokate et al., 1998; Reddy & 
Rogawski, 2000), and ganaxolone has been used in some epileptic patients for 
a number of years (Nohria & Giller, 2007). However, other investigators have 
argued that tolerance does develop in response to chronic rises in neurosteroid 
levels (see review by Turkmen et al., 2011). Furthermore, disorders such as 
catamenial epilepsy, post-partum depression and premenstrual dysphoric 
disorder have all been suggested to represent a withdrawal from high 
endogenous neurosteroid levels (Smith et al., 1998; Bloch et al., 2000; Beckley 
& Finn, 2007; Turkmen et al., 2011), which would suggest that withdrawal would 
develop if neurosteroid therapies were abruptly terminated. 
 
The above observations do not necessarily suggest that neurosteroid therapies 
would be addictive, and a key question is whether they would have rewarding 
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properties. The mechanisms underlying benzodiazepine reward are a subject of 
debate. Encouragingly, there have been suggestions that α1-type GABAA 
receptors in the ventral tegmental area are key to benzodiazepine addiction, 
and that α2-selective compounds will have low addiction liability (Tan et al., 
2010; Tan et al., 2011). If neurosteroids act in a similar way, then α2-targeting 
neurosteroids may prove to be non-addictive anxiolytics. However, α2 and α3-
type GABAA receptors have recently been implicated in mediating some of the 
rewarding effects of benzodiazepines (which reduce the threshold for 
intracranial self-stimulation (ICSS) in wild-type but not α2H101R or α3H126R 
(benzodiazepine-insensitive knock-in) mice (Reynolds et al., 2012)). More work 
is therefore required to further elucidate the roles of GABAergic signalling in the 
mesolimbic dopamine pathway in addiction. It would be interesting to probe 
whether neurosteroids have similar rewarding effects in an ICSS test, and 
whether this is altered in α2Q241M mice. 
  
Neurosteroids in relief of chronic pain? 
Whilst many mechanisms underlie chronic pain (see review by Zeilhofer, 2008), 
a common emerging theme involves reduced inhibitory neurotransmission in the 
spinal cord dorsal horn. Potentiating inhibition via α2 subunit-containing GABAA 
receptors may be an appropriate therapeutic strategy for chronic pain 
syndromes (Jasmin et al., 2003; Zeilhofer et al., 2012). Furthermore, in models 
of hyperalgesia, endogenously-synthesised and applied neurosteroids are 
analgesic (Winter et al., 2003; Poisbeau et al., 2005). Using our α2Q241M mice, 
we can probe whether signalling through α2-type GABAA receptors by 
neurosteroids plays a role in pain physiology, and determine if α2-selective 
neurosteroids would form an appropriate treatment strategy for neuropathic or 
inflammatory pain. 
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6.4. Concluding statement 
 
Neurosteroids, such as allopregnanolone and THDOC, are important 
endogenous modulators of GABAA receptors. They are involved in numerous 
physiological processes, and are linked to several central nervous system 
disorders, including depression and anxiety.  Their effects in animal models 
suggest they could be useful therapeutic agents, for example in anxiety, stress 
and mood disorders. We have used α2Q241M knock-in mice to demonstrate that 
neurosteroid-mediated anxiolysis occurs via potentiation at α2 subunit-
containing receptors. This not only informs us as to one of the key physiological 
functions of endogenous neurosteroids, but also identifies the α2 isoform as an 
appropriate target for generating receptor subtype-selective neurosteroid 
therapeutics for anxiety disorders. 
 
Using our knock-in strain, we have also revealed new information with regards 
to the normal physiological roles of neurosteroids and GABAA receptors. We 
propose that neurosteroid potentiation at α2-subunits has little influence on the 
expression of GABAA receptors in male mice. Our electrophysiological 
characterization demonstrated a role for α2-type GABAA receptors not only in 
synaptic transmission, but also in mediating tonic currents in the dentate gyrus. 
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